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1 INTRODUCTION 
1.1 Adenoviruses and pathogenesis 
Adenoviruses (Ads) were initially isolated as infectious agents from adenoid tissues in the early 
1950s (Hillemann and Werner, 1954; Rowe et al., 1953). The family of Adenoviridae is 
subdivided into two genera according to serological criteria, genome organization and host range: 
Mastadenovirus and Aviadenovirus. Mastadenoviruses infect mammals, Aviadenoviruses birds. 
In addition, several unassigned adenoviruses are considered to be assigned to a third genus, 
Atadenovirus (Benkö et al., 1999). The natural host range of adenoviruses is mostly confined to 
one species or to closely related species. So far, 51 different human adenovirus serotypes have 
been described, which are classified into 6 subgenera A-F based on hemagglutination properties, 
DNA homology and oncogenicity in rodents (Bailey and Mautner, 1994; Benkö et al., 1999; De 
Jong et al., 1999; Shenk T., 1996) (Tab. 1). Interestingly, the subgenus D harbors more than half 
(ca. 56%) of all described Ad serotypes. Remarkably, most Ads isolated from human 
immunodeficiency virus (HIV) infected individuals belong to subgenus D. In a recent study, 84% 
of 183 HIV-associated Ad isolates belonged to subgenus D, 3% to subgenus C, whereas only 5% 
of Ad serotypes isolated from healthy individuals belonged to subgenus D and 49% to subgenus 
C (De Jong et al., 1999). Many of these Ads are rarely or never isolated from immunocompetent 
individuals for reasons that are not understood. Eight out of the nine most recently described Ad 
serotypes (Ad43-49, 51) belong to subgenus D and were isolated from HIV-infected individuals 
(De Jong et al., 1999; Hierholzer et al., 1988; Schnurr and Dondero, 1993).  
 
Tab. 1: Human adenovirus subgenera and serotypes 
Subgenus Serotypes 
A 12, 18, 31 
B 3, 7, 11, 14, 16, 21, 34, 35, 50 
C 1, 2, 5, 6 
D 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-49, 51 
E 4 
F 40, 41 
 
Ads cause acute as well as persistent infections (Horwitz, 1996), although little is known how Ads 
establish persistence. Diseases induced by Ads are in general mild or even subclinical, but can be 
severe or even fatal, especially in immunocompromised patients (Horwitz, 1996). Ads are 
frequently isolated from patients worldwide and were responsible for ~13% (17771 cases) of 
respiratory diseases reported to the WHO from 1967 to 1976 (Wadell, 1984). In total, 
approximately 25000 Ad isolates were reported during that time period (Schmitz et al., 1983). 
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59.2% of the isolates belonged to subgenus C (mainly Ad1, Ad2 and Ad5), 33.7% to subgenus B 
(mainly Ad3 and Ad7) and only 4.1% to subgenus D, 2.4% to subgenus E and 0.6% to subgenus 
A. The prevalence of Ad specific antibodies is generally very high worldwide, although 
differences exist between different populations with regard to the prevalence of antibodies 
against specific Ad serotypes. More than 85% of adults have been exposed to common subgenus 
C Ads. Antibodies against Ad3 were found in 50% of adults in the USA, but in 90% in Japan. 
15% of Germans were found to be positive for Ad19, whereas in Zaire the number was 85%. 
Thus, Ads of all subgenera are constantly maintained and spread in the human population.  
The pattern of disease differs depending on the subgenus (Tab. 2). The molecular basis of the 
distinct pathogenesis of different Ad serotypes is poorly understood. Ads of subgenus A and F 
cause gastrointestinal diseases. Subgenus B and C Ads are mainly associated with acute 
respiratory diseases. Subgenus B Ads also induce infections of the urinary tract. Ad4, the only 
member of subgenus E, is known for its capacity to cause epidemics of an acute respiratory 
disease in military recruits.  
 
Tab. 2: Diseases associated with adenovirus infections (modified from Lukashok and Horwitz, 
1998) 
 
Disease Individuals Most at Risk Principal serotypes 
Acute febrile pharyngitis Infants, young children 1-3, 5-7 
Pharyngoconjunctival fever School-age children 3, 7, 14 
Acute respiratory disease Military recruits  3, 4, 7, 14, 21 
Pneumonia Infants, young children 1-3, 7 
Pneumonia Military recruits 4, 7 
Epidemic keratoconjunctivitis Any age group 8, 11, 19a, 37 
Pertussis-like syndrome Infants, young children 40, 41 
Acute hemorrhagic cystitis Young children 11, 21 
Gastroenteritis Infants, young children 40, 41 
Meningoencephalitis Children and immuno-
compromised hosts 
7, 12, 32 
Hepatitis Infants and children with liver 
transplants 
1, 2, 5 
Persistence of virus in the 
urinary tract 
Bone marrow transplant 
recipients, patients with 
acquired or immunodeficiency 
or other immunosuppression 
9, 11, 19, 20, 22, 23, 26, 27, 34, 
35, 43, 44, 45, 48, 49 
 
Adenoviral conjunctivitis may be caused by several Ads of subgenera B, C, D and E, but mainly 
few Ads of subgenus D, Ad8, Ad19a and Ad37, are associated with a particularly severe and 
extremely contagious form of conjunctivitis, the epidemic keratoconjunctivitis (EKC) (Lukashok 
and Horwitz, 1998). In EKC, conjunctivitis is combined with epithelial and stromal keratitis. 
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Subepithelial infiltrates of immunopathological origin are found that fade gradually over weeks or 
months but may persist for years. In general, the disease is self-limiting and does not produce 
permanent corneal damage. Symptoms are red eye, severe pain, discomfort from glare, blurry 
vision, photophobia, foreign body sensation and excessive tearing. Disease can last up to four 
weeks, but most frequently resolves after 1-3 weeks. The incubation time is 2-14 days and 
persons remain infectious for 10-14 days. Spreading often occurs by the ophthalmologist’s hand 
or contaminated instruments. So far, no efficient treatment is available. 
1.2 Adenovirus particle 
Adenoviruses (Ads) are non-enveloped viruses with a linear double-stranded (ds) DNA genome 
of 26-45 kbp flanked by inverted terminal repeats of 43-369 bp. A virus-encoded terminal protein 
(TP) is covalently attached to the 5’-end of each strand. The viral DNA associates with the highly 
basic protein VII, a small peptide termed mu and the protein V that seems to link the core of the 
virion to the capsid via interaction with protein VI. The icosahedral capsid consists of the three 
major proteins, hexon (II), penton base (III) and a knobbed fiber (IV), and of several minor 
proteins, VI, VIII, IX, IIIa and IVa2 (Fig. 1) (Russell, 2000; Shenk T., 1996). The capsid diameter 
is 70-90 nm. 
 
 
 
 
 
FIG. 1: The adenovirus particle. Schematic model of an adenovirus particle adapted from Stewart et al., 1991. 
Virion components are designated by their polypeptide numbers with exception of the terminal protein (TP). 
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1.3 Adenovirus infectious cycle 
The Ad infectious cycle is divided into the early and the late phase of infection. The early phase 
encompasses the viral entry and the expression of early genes, which modulate cellular functions 
to prepare the cell for the replication of the viral DNA and the expression of late genes in the late 
phase of infection. The duration of the early phase depends on the cell type and takes about 6-8 h 
in HeLa cells, but can last much longer, e.g. in primary cells.  
The Ad infectious cycle starts with the binding of virus particles to receptor(s) on the target cells 
via the knob portion of fiber. Ads of all subgenera with the exception of subgenus B can bind to 
the host cell via the „coxsackie adenovirus receptor“, CAR, a 46 kDa protein which is expressed 
in most tissues in vivo (Bergelson et al., 1998; Bewley et al., 1999; Nemerow, 2000; Roelvink et al., 
1998; Tomko et al., 1997). In addition, it was proposed that the Ad5 fiber knob binds with low 
affinity to the MHC class I a2 domain (Davison et al., 1999; Hong et al., 1997). The subgenus D 
Ads Ad9, Ad15 and Ad19p can also bind to CAR (Roelvink et al., 1998; Roelvink et al., 1999), 
whereas the EKC causing members Ad8, Ad19a and Ad37 seem to utilize a(2®3)-linked sialic 
acid but not CAR (Arnberg et al., 2000a; Arnberg et al., 2000b). Interestingly, Ad19a and Ad37 
have identical fiber proteins (Arnberg et al., 1997). Although it is striking that EKC-causing Ads 
seem to use sialic acid as a receptor, this fact cannot explain the distinct pathogenesis of these 
viruses, since sialic acid is expressed on virtually all cell types. The same is true for the MHC class 
I a2 moiety. Therefore, other unknown receptors, which are subgenus specific, have to be 
postulated or other events following the attachment might be decisive. Experiments with human 
airway epithelia and primary central nervous system cells substantiate the former hypothesis 
(Chillon et al., 1999; Zabner et al., 1999). With both cell types differences in viral attachment and 
infection efficiency depending on the Ad subgenus were observed. Interestingly, subgenus D Ads 
proved to be much better in the transduction of these cells than Ad2 and Ad5 of subgenus C, 
which are commonly used in gene therapy approaches. The attachment to these cells and the 
transduction efficiency could be increased by transferring the fiber of Ad17 (subgenus D) to Ad2 
(subgenus C). It is currently unknown whether this increase is solely due to the different fiber 
proteins or is also partly based on subgenus-specific processes at the postattachment level. After 
the initial receptor binding an exposed RGD motif of the penton base interacts with cellular 
aVb3 or aVb5 integrins on the host cell and triggers clathrin-mediated endocytosis involving 
dynamin (Nemerow, 2000). These initial events activate the phosphoinositide-3-OH-kinase (PI-
3K) and Rho GTPases triggering reorganization of actin cytoskeleton and the Raf/mitogen-
activated protein (MAPK) kinase pathway inducing IL-8 production (Nemerow, 2000; Russell, 
2000). The endocytosis of virus particles is accompanied by a partial disassembly assisted by the 
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viral cysteine protease (p23). The capsids penetrate by inducing acid-enhanced lysis of the 
endosomal membrane. The viruses utilize dynein to migrate along microtubules to the nuclear 
pore complex (NPC) (Leopold et al., 2000; Suomalainen et al., 1999). Ad2 particles dock to the 
NPC-filament protein CAN/Nup214 of the NPC (Trotman et al., 2001). The subsequent 
disassembly of the Ad2 particle, which is necessary to penetrate the nuclear pore with a diameter 
of <40 nm, requires histone H1 and the H1 import factors Impb and Imp7.  
In summary, the Ad capsid disassembles stepwise by processes induced by receptor interactions, 
exposure to acidic pH, re-entry into a reducing milieu and by interactions with the NPC. Finally, 
the viral DNA is imported into the nucleus, where the genome is targeted to the nuclear matrix 
via the interaction of TP with the cellular CAD (carbamoyl phosphate synthetase, aspartate 
transcarbamoylase, dihydroorotase) pyrimidine synthesis enzyme (Russell, 2000). Subsequently, 
early gene transcription starts.  
Virus infection induces an early shut-down of host DNA synthesis and later also of host RNA 
and protein synthesis. About 40 different polypeptides are encoded by the adenoviral genome. 
Almost one third of these are structural proteins. Transcription by the host RNA polymerase II 
involves both DNA strands and initiates from five early (E1A, E1B, E2, E3, E4), two 
intermediate promoters and one major late promoter (MLP) (Fig. 2). All primary transcripts are 
capped and polyadenylated. Families of adenoviral mRNAs are produced by complex splicing 
processes. VA (virus-associated) RNAs, which inhibit the antiviral interferon response, are 
transcribed by host RNA polymerase III.  
0 10 50 100
E1A: 243R, 289R
E1B: 55K, 19K
MLP
L1: IIIa
VA RNAs 1&2
L2: III, pVII, V
L3: pVI, II, Pr
L4: 100K, 33K, pVIII L5:IV
E3: 12.5K, 6.7K, 19K, 11.6K
       10.4K, 14.5K, 14.7K
E4: orfs 1-6/7
E2A: DBP
E2B: IVa2, pTP, Pol
IX
 
FIG. 2: Transcription of the adenovirus genome (subgenus C). Early transcription units are designated E, late 
transcription units L. The proteins encoded by each transcription unit are indicated by thin line characters. Most late 
mRNAs originate from the major late promoter (MLP). For details see text. 
 
In the early phase of infection, viral mRNAs are derived from the E1A, E1B, E2, E3 and E4 
regions (Fig. 2). E1A encodes two major proteins termed 289R (13S) and 243R (12S), which 
differ in the number of amino acid residues (and mRNA sedimentation coefficient). The E1A 
proteins create a favorable environment for viral DNA replication in the late phase. Numerous 
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activities of E1A proteins have been reported frequently based on in vitro studies. Most notably, 
E1A proteins can activate transcription by binding to a variety of different cellular transcription 
factors and regulatory proteins (Gallimore and Turnell, 2001; Russell, 2000). Of major 
importance is the interaction with proteins of the Rb/p130 family, which induces the release of 
the transcription factor E2F that directs the transcription of a variety of genes functionally related 
to DNA synthesis. E2F and ETF released from Rb, on the other hand, induce the p53 dependent 
pathway of apoptosis by two major mechanisms: 1) They directly induce transcription of p53. 2) 
They induce transcription of the p19arf gene and thereby synthesis of the corresponding protein 
which inhibits mdm2-mediated induction of p53 proteolysis. Thus, E1A actions stabilize p53 and 
thereby trigger apoptosis. In addition, E1A proteins induce apoptosis independently of p53 
(Putzer et al., 2000). E1A activates also the transcription of the early transcription units E1B, E2, 
E3 and E4. Two gene products of the E1B region, E1B-19K and E1B-55K, turn off the intrinsic 
apoptosis program that is triggered by E1A. E1B-19K is homologous to the cellular protein Bcl-2 
and seems to inhibit the mitochondrial pathway of apoptosis mainly by inactivating with the pro-
apoptotic proteins Bax and Bak (White, 2001). E1B-55K directly binds to p53 and represses p53-
dependent transcriptional activation. In cooperation with E4orf6, E1B-55K enforces the 
degradation of p53 (Tauber and Dobner, 2001). In addition, E1B-55K and E4orf6 seem to be 
required for the preferential export and cytoplasmic accumulation of late viral mRNAs. The E2 
region is subdivided into E2A (DNA bending protein (DBP)) and E2B (pTP and Pol). The 
corresponding gene products are required for the replication of viral DNA and transcription of 
late genes. The proteins encoded in the E3 region seem to be mainly involved in Ad subversion 
of the immune system and are discussed in detail in chapter 1.7. Gene products of the E4 region, 
termed orf 1-6/7, are involved in mRNA metabolism and transport, DNA replication and host 
shutoff (Leppard, 1997). E4orf4 and E4orf6/7 have recently been implicated in the inhibition of 
lysis of infected cells by cytotoxic T lymphocytes (CTLs) (Kaplan et al., 1999). E4orf6/7 was also 
reported to functionally compensate for E1A via induction of E2F (O'Connor and Hearing, 
2000). 
The late phase of infection starts with the onset of viral DNA replication. Thereafter, the five late 
transcription units (L1-5) are transcribed. Transcription is driven by the major late promoter 
(MLP), which is not active in the early phase of infection. The polycistronic primary transcript is 
processed by differential splicing. The late transcripts encode mainly structural components of 
virus particles or proteins involved in assembly. In addition, Ad assembly protein L4-100K has 
recently been shown to inhibit granzyme B-induced apoptosis (Andrade et al., 2001). Ad DNA 
replication occurs by strand displacement using a protein priming mechanism involving the 
terminal protein together with the virus-encoded DNA polymerase and DNA-bending protein in 
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concert with cellular factors. Virions are assembled in the nucleus. Late in this assembly process 
the L3-encoded viral cysteine proteinase cleaves several virion proteins generating mature and 
infectious Ad particles (Shenk T., 1996). Finally, permeabilization of the nuclear envelope and the 
disintegration of the plasma membrane facilitate the release of virus particles from the cell by so 
far poorly defined mechanisms. 
1.4 Adenoviruses and antiviral defense mechanism: Viral immune evasion 
Adenoviruses induce cellular and humoral immune responses. These were frequently investigated 
with recombinant Ad vectors with deletions in the viral genomes and/or with transgene 
insertions in animal, mainly mouse models, but rarely in humans. In animal models human Ads 
do not establish productive infection, and Ads with deletions, e.g. in the E3 region which 
encodes proteins with immunomodulary functions (see below), most likely differ in the elicited 
immune responses from wild type (WT) Ads. Therefore, the significance of these results for Ad 
infections of humans remains to be clarified. Immune responses against Ads include an 
immediate inflammatory response mediated predominantly by neutrophils, macrophages and 
natural killer (NK) cells followed by CD4+ and CD8+ T cell-mediated mechanisms and 
neutralizing antibodies (Molnar-Kimber et al., 1998, and references therein). Remarkably, even in 
the absence of any viral gene expression chemokine induction, interferon and an anti-adenoviral 
CTL response were detected (Kafri et al., 1998; Muruve et al., 1999; Reich et al., 1988). Data 
from investigations of preexisting immunity to Ad5 indicate that also WT Ads induce a long-
lasting humoral as well as cellular immune response in humans (Chirmule et al., 1999; Molnar-
Kimber et al., 1998). 
Two arms of the immune system, the innate and the adaptive immune response, act in concert to 
eliminate viruses from the organism. The mechanisms employed by the immune system 
frequently induce apoptosis in infected cells by extracellular stimuli. In addition, programmed cell 
death leading to apoptosis may be induced in infected cells by changes in the intracellular 
environment associated with Ad infection.  
Whereas the E1B gene products seem to target intrinsic apoptosis programs (chapter 1.3, Fig. 4), 
proteins of the E3 region appear to counteract the induction of apoptosis programs induced by 
extracellular signals (Fig. 4), such as tumor necrosis factor a (TNFa), tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL). The latter are discussed in the 
context of the other E3 functions (chapter 1.7). However, E1B-19K was also reported to inhibit 
the apoptosis pathways induced by the proapoptotic factors TNFa, TRAIL and anti-Fas 
antibody (White, 2001). 
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1.5 Adenoviruses and the innate immune defense 
An immediate inflammatory response is elicited by Ad infection mediated predominantly by 
neutrophils, macrophages, natural killer (NK) and NKT cells. The mechanisms how infected cells 
are recognized by these immune cells are only partly understood. The adenoviral E1A protein 
was shown to induce susceptibility to NK cell lysis (Cook et al., 1987; Routes and Cook, 1995). 
But no increased susceptibility was detected after Ad2/5 infection indicating a viral immune 
escape mechanism (Routes and Cook, 1989). NK cells monitor MHC class I expression on the 
cell surface and kill cells with decreased MHC class I levels (Biron et al., 1999). Such changes are 
commonly induced by viruses to reduce the presentation of viral peptides by MHC class I 
complexes in order to escape CTL recognition. Recently, also receptors triggering NK cell lysis 
have been identified (Moretta et al., 2001). Their regulation during Ad infection is unknown. 
Immune cells and infected cells secrete a number of cytokines and interferons with antiviral 
activities.  
Some of these cytokines like TNFa, FasL or TRAIL have pro-apoptotic activities. E1A also 
sensitizes cells to TNFa-, FasL- and TRAIL-induced apoptosis (White, 2001). TNFa-induced 
apoptosis is counteracted by E3/10.4K-14.5K, E3-14.7K and E1B-19K. TNFa and IFNg are 
also able to mediate non-cytopathological elimination of viruses (Guidotti and Chisari, 2001). It is 
unknown whether these mechanisms are also involved in the control of Ad infection. Other 
cytokines induce the recruitment of cells of the innate and adaptive immune response. Nuclear 
Factor kB (NFkB) is frequently induced early after viral infection by intracellular processes as 
well as by extracellular stimuli, e.g. TNFa. NFkB is a potent inducer of a number of cytokines 
and usually induces a pro-inflammatory, anti-apoptotic response. Ad E1A can inhibit NFkB 
activation (Shao et al., 1997; Shao et al., 1999). Nevertheless, TNFa induced activation of NFkB 
increases the expression of Ad E3 proteins mediated by NFkB binding sites within the E3 
promoter (Deryckere et al., 1995; Koerner et al., 1992).  
In addition, interferons and defensins counteract Ad infection. Defensins are 3-4 kDa 
antimicrobial peptides, which are released by some epithelial cells and were reported to reduce 
the Ad infection efficiency (Gropp et al., 1999). Interferons are subdivided into two main classes, 
type I (containing interferons a and b) and type II (interferon g). Type I interferons can be 
synthesized by most cell types upon infection, whereas type II interferons are produced by NK 
cells and effector T cells. Interferons are induced by Ad particles even in the absence of viral 
protein synthesis (Reich et al., 1988). Interferon receptor signaling activates the Jak/STAT 
pathway and induces the transcription of several genes such as dsRNA induced kinase (PKR) and 
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2’-5’ oligoadenylate synthetase, which have antiviral activities and block or at least impair virus 
replication (Goodbourn et al., 2000). 
Adenovirus E1A proteins interfere with interferon signaling. They decrease the levels of STAT1 
and p48, which are part of a heterotrimeric ISRE (IFN-stimulated response element) binding 
complex including STAT2. In addition, E1A sequesters the transcriptional co-activator 
CBP/p300 and directly binds STAT1 thereby disrupting transcriptional responses to IFN-a/b 
and IFN-g. Ad VA RNAs are transcribed by cellular RNA polymerase III in the late phase of 
infection and form a highly ordered secondary structure that binds to the dsRNA-binding site on 
PKR and acts as a competitive inhibitor. 
Strikingly, in experiments with a recombinant Ad5 with E1A, partial E1B and partial E3 deletions 
90% of viral DNA was cleared within 24 h most likely involving the innate immune response 
(Worgall et al., 1997). Thus, innate immunity may play an important role in the control of Ad 
infection. 
1.6 Adenoviruses and the adaptive immune defense 
1.6.1 Cellular immune response 
The cellular immune response aims to detect and eliminate virus-infected cells. CD8+ CTLs 
recognize viral peptides generated by the proteasome and presented by MHC class I complexes 
on the cell surface of infected cells. Subsequently, CTLs release lytic granules with perforin and 
granzymes or other proapoptotic factors. In addition, the interaction of FasL with Fas can induce 
the death of the infected cell (Harty et al., 2000; Trapani et al., 2000). The E1A protein was 
shown to sensitize infected cells to CTL-induced apoptosis independently of p53 (Cook et al., 
1999). Three Ad E3 proteins are known to counteract lysis by CTLs: E3/19K and E3/10.4K-
14.5K (see below). The Ad12 E1A protein interferes with the transcription of several proteins 
that are involved in antigen presentation: MHC class I complexes, the peptide transporter 
subunits TAP1 and TAP2 and LMP2 and LMP7, which are part of the immune proteasome 
(Gallimore and Turnell, 2001). Moreover, E1A was reported to regulate the 26S proteasome, 
which might have implications for the generation of viral peptides for the presentation by MHC 
class I molecules (Gallimore and Turnell, 2001). In addition, E4orf4 and E4orf6/7 have been 
implicated in the inhibition of CTL lysis (Kaplan et al., 1999) which is difficult to reconcile with 
reports that both proteins induce apoptosis (Branton and Roopchand, 2001; Yamano et al., 
1999). Recently, the Ad assembly protein L4-100K was shown to inhibit granzyme B-induced 
apoptosis (Andrade et al., 2001). 
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1.6.2 Humoral immune response 
The humoral immune response is based on the release of specific immunoglobulins of various 
classes, which bind to viral antigens and abrogate the ability of virions to infect cells. Neutralizing 
antibodies elicited upon Ad infection are mainly directed against the capsid components penton, 
fiber, hexon and core protein V (Molnar-Kimber et al., 1998). 
1.7 Adenovirus early transcription unit 3 and its role in immune evasion 
Ad proteins with immunomodulatory functions seem to be mainly encoded by the early 
transcription unit 3 (E3). Although the E3 region is not required for Ad replication in vitro, it is 
present in all human Ads and seems to encode proteins with immunomodulatory functions. This 
might be the basis for immune evasion and establishment of persistent infections (Burgert et al., 
2002; Burgert and Blusch, 2000; Mahr and Gooding, 1999; Wold et al., 1995). 
FIG. 3: Organization of E3 region in different adenovirus subgenera. Coding capacity of the E3 region of 
representative members of subgenus C (Ad2), B (Ad3), D (Ad19a), E (Ad4), A (Ad12) and F (Ad40) (adapted from 
Burgert and Blusch, 2000). The line on the top denotes the size in bp. Open reading frames (ORFs) are indicated as 
bars and drawn to scale. The size/name of common ORFs is only given once. The shading code is depicted below 
the figure. Significant overall homology (similarity > 25 %) is indicated by identical shading. Homology to a portion 
of a protein was neglected. pVIII is not an E3 protein, but part of its sequence overlaps with the E3 promoter.  
 
Interestingly, the size and composition of the E3 regions of adenoviruses show significant 
subgenus specific variations (Fig. 3). Whereas in subgenus F (Ad40/41) about 3 kb encode five 
open reading frames (ORFs), in subgenus D (e.g. Ad19a) approximately 5200 bp encode eight 
ORFs. Some genes (e.g. 10.4K, 14.5K and 14.7K) are found in all subgenera, others in many (e.g. 
19K in subgenera B-E), whereas some genes seem to be unique to a particular subgenus (Fig. 3), 
e.g. 11.6K of subgenus C or 49K of subgenus D (Burgert and Blusch, 2000). The E3, more 
precisely the E3A region (exclusive of 10.4K, 14.5K and 14.7K), is the region of the highest 
variability in the Ad genome in a comparison of different subgenera (Bailey and Mautner, 1994). 
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Therefore, it seems likely that the E3 regions of different Ads contribute to the subgenus-specific 
pathogenesis (Tab. 2), especially since differential utilization of receptors for virus adsorption 
based on the receptors identified so far cannot explain the subgenus-specific differences in 
pathogenesis (chapter 1.3). 
Studies on E3 proteins, primarily of Ad2 and Ad5 of subgenus C, revealed several molecular 
mechanisms that are employed to escape recognition and elimination of Ad-infected cells by the 
host immune system (Fig. 4). For example, E3/19K retains MHC class I molecules in the ER and 
thereby prevents the presentation of viral peptides to and lysis of infected cells by cytotoxic T-
lymphocytes (Burgert and Kvist, 1985; Burgert, 1996). The E3/14.7K protein can protect 
infected cells from TNFa-induced cell death (Burgert and Blusch, 2000; Horwitz, 2001; Mahr 
and Gooding, 1999; Wold et al., 1999). The complex of the E3 proteins 10.4K and 14.5K has 
also been implicated in conferring resistance against cytolysis mediated by TNFa and down-
regulates the epidermal growth factor receptor from the cell surface (Burgert and Blusch, 2000; 
Wold et al., 1999). In addition, these proteins dramatically reduce the expression of the apoptosis 
receptor Fas on the cell surface of infected cells by inducing its internalization and degradation in 
lysosomes (Elsing and Burgert, 1998; Shisler et al., 1997; Tollefson et al., 1998). Furthermore, 
data have been presented suggesting that the 10.4K-14.5K complex works in concert with 6.7K 
to down-regulate TRAIL receptor 1 and 2, death receptors possibly involved in the induction of 
apoptosis in infected cells mediated by immune effector cells (Benedict et al., 2001; Tollefson et 
al., 2001). 10.4K-14.5K also down-modulate the receptors for epidermal growth factor and to 
some extent insulin and insulin-like growth factor from the cell surface (Kuivinen et al., 1993). In 
addition, 14.7K was reported to inhibit TRAIL-R1-induced apoptosis (Tollefson et al., 2001) and 
was also reported to interact with FLICE/caspase 8 to inhibit FasL-induced apoptosis (Chen et 
al., 1998). The latter could not be confirmed by other studies (Elsing and Burgert, 1998; 
Tollefson et al., 1998).  
So far, no functions have been assigned to E3 proteins of Ads of other subgenera than C. Some 
of them have been characterized biochemically and were shown to be transmembrane proteins, 
which are frequently glycosylated, e.g. Ad3 16K (Hawkins et al., 1995) and 20.5K (Hawkins and 
Wold, 1995a; Hawkins and Wold, 1995b) of subgenus B and Ad4 30K of subgenus E (Li and 
Wold, 2000). Interestingly, many of them contain potential endosomal/lysosomal sorting motifs 
(YXXF or LL motifs, chapter 1.8.3.2) (Windheim et al., 2002). 
In summary, Ad E3 proteins are not required for the basic process of replication but rather for 
virus replication in vivo in the presence of an antiviral immune response that seeks to abrogate 
virus replication and spreading by inducing apoptosis or lysis of the infected host cell, mainly 
executed by CD8+ CTLs and NK cells (Biron et al., 1999; Harty et al., 2000). 
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FIG. 4: Adenoviral immune evasion mechanisms. Adenoviruses encode a variety of proteins and virus associated 
(VA) RNAs with immunomodulatory functions. Adenoviral factors (proteins and VA RNAs) are indicated by boxed 
characters. For detailed description see text. Abbreviations not explained in the text are: MF, macrophages; Abs, 
antibodies; PM, plasma membrane; G, Golgi; M, mitochondrium. 
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1.8 Intracellular trafficking and cellular sorting 
1.8.1 Overview of vesicular transport in the eukaryotic cell 
Viruses have evolved mechanisms to exploit almost every cellular function to achieve successful 
replication. Therefore, it is not surprising that Ads, like other viruses, utilize membrane-bounded 
compartments and exploit the cellular trafficking machinery of eukaryotic cells. Findings from 
other viral proteins, e.g. MCMV gp40 (m154), gp48 (m06) or HIV (e.g. nef), demonstrate the 
importance of the exploitation of the cellular sorting machinery in the virus-host interaction 
(Greenway et al., 2000; Reusch et al., 1999; Ziegler et al., 2000). In case of adenoviruses, the 
capacity to utilize membrane-bounded compartments is mainly confined to E3 proteins. The Ad 
E3 region is the only part of the Ad genome that harbors transmembrane proteins. Interestingly, 
19 out of the 22 different proteins (12.5K, 19K, 10.4K, 14.5K counted only once) in the E3 
regions of different subgenera (Fig. 3), i.e. about 86%, are predicted to be transmembrane 
proteins (Windheim et al., 2002). Although no functions have been assigned to many of these 
proteins, it seems likely that their function depends on the cellular sorting machinery. This has 
been demonstrated for E3/19K and 10.4K-14.5K and the down-regulation of MHC class I 
molecules and Fas/EGFR respectively. Therefore, in the following the intracellular trafficking 
and the cellular sorting machinery as well as sorting motifs with potential relevance for Ad 
proteins are introduced. 
Most transport processes between the membranous compartments of a eukaryotic cell involve 
vesicles. Vesicular transport connects the organelles of the secretory pathway (the endoplasmatic 
reticulum, the ER-Golgi intermediate compartment (ERGIC), the Golgi complex, the trans-
Golgi-network, secretory vesicles, plasma membrane) as well as those of the endocytic pathway 
(plasma membrane, clathrin coated vesicles, early and late endosomes, lysosomes) (Fig. 5). 
Distinct sets of coat proteins select the cargo molecules of the transport vesicles by direct or 
indirect interaction (Mellman and Warren, 2000). Intrinsic sorting signals determine whether 
proteins are actively packaged (export) or are excluded (retention) from export vesicles, or are 
randomly incorporated into export vesicles (default) (Rothman and Wieland, 1996). Resident 
proteins of a particular compartment can contain retention signals or retrieval signals which 
efficiently return proteins transported to the acceptor compartment to the donor membrane. 
Cargo proteins may be transported by export signals or by default (“bulk flow”).  
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FIG. 5: Overview of intracellular trafficking in the secretory and the endocytic pathway. Export from the ER 
to the ERGIC occurs in COPII coated vesicles. Transport from the ERGIC to the cis-Golgi, through the Golgi and 
retrograde to the ER is mediated by COPI coated vesicles. From the TGN proteins can be exported to the plasma 
membrane in secretory vesicles or to early (EE) or late (LE) endosomes, presumably, by clathrin coated vesicles 
involving the clathrin adaptor complexes AP-1, AP-3 and the GGAs. In addition, early endosomes can be reached 
via endocytosis from the plasma membrane, which involves the clathrin adaptor complex AP-2 and clathrin. Exit 
from early endosomes may occur in three different directions: 1. Recycling to the cell surface; 2. Recycling to the 
TGN most likely by clathrin-coated vesicles involving AP-1 and PACS-1; 3. Export to late endosomes by a transport 
process that seems to require COPI subunits. From late endosomes proteins are either delivered to lysosomes (Lys) 
for degradation or to fulfill their function as lysosomal residents or are recycled to the TGN. The latter pathway 
seems to be mediated by TIP47. For details and references see text. 
 
Three major types of coat complexes have been identified to play a role in vesicular transport 
processes: Clathrin, COPI and COPII (Kirchhausen, 2000b). Coats are derived from soluble, 
cytosolic precursors and are specifically recruited to organelle membranes. Small GTP binding 
proteins (Rab and Sar1p/Arf proteins) play a crucial role in the regulation of processes such as 
budding, uncoating, tethering, docking and fusion of vesicles (Takai et al., 2001). The specific 
docking to the acceptor membrane is thought to be controlled by the pairing of SNAREs 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptors), v-SNARES on vesicles 
and t-SNARES on target membranes (Chen and Scheller, 2001). In vivo, Rab proteins regulate the 
formation of SNARE complexes (Zerial and McBride, 2001). But SNARES are not the sole 
determinants of vesicle targeting. Also, the so-called tethering factors confer targeting specificity 
to vesicles and work upstream of SNARES, e.g. p115 in the intra-Golgi transport and EEA-1 in 
endosomal fusion (Pfeffer, 1999).  
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1.8.2 Sorting in the endoplasmatic reticulum and the Golgi apparatus 
To enter the secretory pathway in mammalian cells most proteins contain a N-terminal signal 
sequence that is recognized by the signal recognition particle (SRP) (Corsi and Schekman, 1996). 
Proteins are then translocated co-translationally into the ER as soluble proteins or anchored to 
the membrane by their transmembrane region. Trafficking between the ER, ERGIC and the 
Golgi/TGN complex is mainly accomplished by COPI and COPII coats (Mellman and Warren, 
2000) (Fig. 5). COP II vesicles are thought to be the main players in the anterograde transport 
between the ER and the ERGIC. Budding of COPII vesicles requires the small GTP-binding 
protein Sar1p and occurs at specific ER exit sites. In addition, COPI coated vesicles function in 
the anterograde transport of proteins from the ERGIC to the Golgi and in the retrograde 
transport from the Golgi to the ERGIC and the ER (Fig. 5). The small GTP-binding protein 
Arf1 recruits COPI to membranes and initiates the budding of COPI coated vesicles. Sorting 
motifs implicated in COPI binding and retrograde transport to the ER are C-terminal KKXX 
and KXKXX sequences, where K is lysine and X is any amino acid (Teasdale and Jackson, 1996). 
Several other mechanisms related to quality control may also mediate ER retention (Ellgaard et 
al., 1999). On the other hand, cargo proteins seem to be concentrated in COPII vesicles 
suggesting that they contain ER export signals (Gorelick and Shugrue, 2001; Hong, 1998).  
The ER-Golgi intermediate compartment (ERGIC) is supposed to be a major site for cargo 
concentration and for sorting of proteins for anterograde transport to the Golgi from those that 
must be returned to the ER (Martinez-Menarguez et al., 1999). 
From the ERGIC, proteins are delivered to the cis face of the Golgi complex. Transit through the 
Golgi complex involves the sequential passage through 3-5 stacks (cis, medial, trans). Transport of 
cargo proteins through the Golgi/TGN is supposed to follow a default pathway (“bulk flow”) 
(Mellman and Warren, 2000). In contrast to the ER, there are no soluble residents of the Golgi 
lumen, but instead all Golgi proteins are either integral membrane proteins or peripheral 
membrane proteins on the cytoplasmic side of the Golgi (Munro, 1998). Glycosyltransferases, 
SNARE proteins and some viral proteins are targeted to the Golgi by their transmembrane 
domain (TMD), which is on average five residues shorter than that of plasma membrane proteins 
(Munro, 1998).  
Sorting motifs of TGN proteins will be discussed in the following chapter because the TGN 
seems to be closely connected to the endosomal/lysosomal system and similar sorting motifs are 
utilized (Ktiskakis and Roth, 1996). 
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1.8.3 Sorting at the TGN and within the endosomal/lysosomal system 
1.8.3.1 Adaptor complexes and sorting motifs 
The TGN serves as a sorting station, where proteins destined for the different cellular 
compartments are separated (Traub and Kornfeld, 1997). The steady-state localization of TGN 
proteins like TGN38 and furin was shown to depend on YXXF motifs (see below) in their 
cytoplasmic tails, which are required for the retrieval of these proteins from the cell surface (Tab. 
3). In addition, the TGN38 TMD mediates TGN retention (Banting and Ponnambalam, 1997). 
For the TGN localization of furin an acidic cluster motif with a casein kinase II phosphorylation 
site is important (Molloy et al., 1999). In non-polarized cells trafficking from the TGN to the cell 
surface is believed to be mainly a default pathway, whereas in polarized cells proteins are targeted 
to the apical or basolateral membrane by sorting motifs which seem to be interpreted at the TGN 
(Keller et al., 2001). Also in polarized cells a default pathway exists that delivers proteins lacking a 
specific sorting motif to the apical and the basolateral membrane. In general, transport from the 
TGN to the cell surface is assumed to be mediated directly by secretory vesicles without 
involving any intermediate organelles. In few cases it was proposed that plasma membrane 
proteins take an indirect route to the cell surface via an intracellular, most likely endosomal, 
compartment (Laird and Spiess, 2000, and references therein). In non-polarized cells, coat 
proteins of secretory vesicles have not been identified yet. In polarized cells, clathrin-coated 
vesicles have been implicated in the basolateral sorting, whereas the coats for apical transport and 
default pathways are still unknown. In the formation of clathrin-coated vesicles, members of a 
class of so-called clathrin adaptor protein (AP) complexes connect cargo proteins to the clathrin 
coat. AP complexes are tetramers (two large subunits g/a/d/e and b1-4, 90-130 kDa, one 
medium subunit, m1-4, ~50 kDa, and a small subunit, s1-4, ~20 kDa) with a molecular mass of 
about 250-300 kDa and with a similar architecture (AP-1: gb1s1µ1, AP-2: ab2s2µ2, AP-3: 
db3s3µ3, AP-4: eb4s4µ4) (Boehm and Bonifacino, 2001; Kirchhausen, 1999; Robinson and 
Bonifacino, 2001). For several subunits different isoforms have been identified. AP-1 localizes to 
the TGN. AP-3 is found at the TGN and peripheral endosomal structures. Both have been 
implicated in the sorting and trafficking between the TGN and the endosomal/lysosomal system 
and to the basolateral membrane. AP-2 localizes to the plasma membrane and directs endocytosis 
(Fig. 5). AP-2 might also participate in the budding of clathrin-coated vesicles in a retrograde 
trafficking pathway out of the lysosomal compartment (Traub et al., 1996). AP-1 with its 
epithelial cell specific subunit µ1B directs basolateral targeting (Folsch et al., 1999). The function 
of AP-1 in TGN-endosome trafficking has recently been challenged, when it was shown that 
GGAs (Golgi associated, g ear containing, ARF binding proteins) bind cargo proteins (MPRs, 
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sortilin) via a sorting motif consisting of an acidic stretch and an LL motif and mediate TGN 
export (Nielsen et al., 2001; Puertollano et al., 2001a; Zhu et al., 2001). Three GGAs are 
expressed in mammals and localize to the TGN. They are supposed to be involved in TGN-
endosome trafficking and also seem to work as adaptors for clathrin-coated vesicles (Puertollano 
et al., 2001b). Different recycling pathways exist between the endosomal/lysosomal system and 
the TGN (Rohn et al., 2000). AP-1 might rather be implicated in transport processes between 
early/recycling endosomes or late endosomes and the TGN or might be implicated in another 
trafficking pathway between the TGN and endosomes in addition to that one involving GGAs 
(Black and Pelham, 2001; Meyer et al., 2000) (Fig. 5). AP-1 has been detected on endosomal 
membranes and was found to bind to immature secretory granules (Dittie et al., 1996; Futter et 
al., 1998). AP-3 seems to be involved in the transport of proteins from the TGN to lysosomes 
(Dell'Angelica et al., 1999; Le Borgne et al., 1998). For AP-1 and AP-2 the association with 
clathrin-coated vesicles was demonstrated. For AP-3 clathrin association is controversial. AP-4 
localizes to non-clathrin-coated vesicles in the area of the TGN (Hirst et al., 1999). The contact 
site between the heterotetrameric AP complexes and clathrin has been mapped to the so-called 
“clathrin-box”, a sequence of five aa, which is found in several proteins interacting with clathrin. 
This sequence is found in AP-1 b1, AP-2 b2 and AP-3 b3, but not in AP-4 b4 consistent with 
the view that AP-4 does not bind to clathrin (Kirchhausen, 2000a). AP complexes are believed to 
be recruited to specific membranes through clathrin-independent docking mechanisms. The 
small GTP-binding protein Arf-1 is essential for TGN membrane association of AP-1 and GGA-
3 (Dell'Angelica et al., 2000) as well as membrane association of AP-3 (Faundez et al., 1998; Ooi 
et al., 1998). No related small GTP binding protein has been found for AP-2 docking. The 
formation of clathrin-coated vesicles at the plasma membrane involving AP-2 is controlled by a 
number of proteins and lipids that are connected in a complex network of interactions 
(Kirchhausen, 2000a). Coated vesicle detachment from the plasma membrane requires dynamin 
(Hinshaw, 2000). 
The AP complexes seem to participate in cargo selection mediated by direct binding of their 
subunits to sorting motifs in the cytoplasmic tails of transmembrane proteins. Two major sorting 
motifs for sorting in the TGN and the endosomal/lysosomal system have been identified: 
YXXF and LL (Tab. 3) (Heilker et al., 1999), where F represents a bulky hydrophobic aa (L, V, 
I, F, M) and X can be any aa. In most LL motifs indeed a pair of leucines is found, but one 
leucine might also be substituted by another bulky hydrophobic aa (M, V, I, F). In the following 
the term LL motif is used in both cases. The YXXF motif has also been described as a YPPF 
motif, where P represents a polar residue (Kirchhausen, 1999). Interestingly, many proteins 
contain more than one motif and frequently combinations of different signals, e.g. the mannose-
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6-phosphate receptors (MPRs). The YXXF and LL motifs will be discussed in detail in the 
following chapter (see below). Several other sorting signals have been demonstrated to play a role 
in the trafficking pathways between the TGN, the plasma membrane and the 
endosomal/lysosomal system. These pathways involve proteins like TIP47 and PACS-1 (Fig. 5). 
TIP47 has recently been shown to interact with Rab9-GTP on endosomal membranes, which 
seems to play a role in the generation of transport vesicles in endosomes destined for the TGN 
(Carroll et al., 2001). PACS-1 was shown to bind to AP-1 and AP-3 but not AP-2 complexes and 
overexpression of a dominant negative PACS-1 mutant redistributed furin and cation-
independent mannose-6-phosphate receptor (CI-MPR) from the TGN to a vesicular, most likely 
endosomal compartment (Crump et al., 2001). Furthermore, COPI subunits have been 
implicated in the trafficking in the endosomal/lysosomal system (Gu and Gruenberg, 1999) and 
have been proposed to be crucial for the biogenesis of so-called endocytic carrier vesicles (ECV), 
which are thought to transport proteins from early to late endosomes (Fig. 5). 
1.8.3.2 YXXF and LL motifs 
YXXF and LL motifs are the most frequent sorting motifs found in the cytoplasmic tails of 
transmembrane proteins that direct trafficking in the TGN/endosomal/lysosomal system (Tab. 
3). YXXF motifs bind to the µ1-4 subunits of the AP complexes (Aguilar et al., 2001; Ohno et 
al., 1998). It is still a matter of debate whether the LL motifs interact with the b subunits 
(Rapoport et al., 1998) or the µ subunits (Bremnes et al., 1998; Rodionov and Bakke, 1998) of AP 
complexes. Crystal structures of the sorting motif binding domain of µ2 and a peptide containing 
the YXXF motifs of TGN38 and EGF receptor (Owen and Evans, 1998) revealed that the 
peptide was bound in an extended conformation and not in a tight turn structure as earlier 
suggested (Collawn et al., 1990).  
Strikingly, both YXXF and LL motifs in cytoplasmic tails of transmembrane proteins control 
sorting processes between the TGN and endosomes/lysosomes and the MHC class II 
compartment as well as targeting from the TGN and endosomes to the basolateral surface of 
polarized cells. In addition, YXXF and LL motifs direct the endocytosis from clathrin-coated 
pits at the plasma membrane (Tab. 3). Therefore, proteins have to contain information in 
addition to the basic YXXF and LL motifs for the fine-tuning of their specific trafficking and 
localization information. The difficulties the cellular sorting machinery has to handle are 
exemplified by the sorting at the TGN. Here, proteins with YXXF or LL motifs interacting with 
AP-1 or AP-3 for targeting to endosomal/lysosomal compartments and proteins that reach the 
plasma membrane via secretory vesicles but contain YXXF or LL motifs for AP-2 mediated 
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endocytosis have to be distinguished. An example for the latter is the transferrin receptor which 
contains a YTRF sorting signal that interacts with µ2 but not µ1 (Ohno et al., 1995). LL motifs of 
limp-II and tyrosinase bind with a higher affinity to AP-3 than AP-1 and AP-2 (Honing et al., 
1998). For the fine-tuning of YXXF and LL motifs the residues surrounding the motif might 
play an important role.  
 
Tab. 3: TGN and endosomal/lysosomal sorting motifs 
 
Sorting signal or motif Protein Destination Adaptor binding Ref. 
YXXF motifs     
GGEPLSYTRF transferrin receptor  E1     EE2        B3 AP-2 1 
KRSHAGYQTI lamp-1  E      Lys4         B AP-1,-2,-3 1 
RAGHSSYTPL HLA-DMb E      MIIC5 AP-1,-2 1 
RPKASDYQRL TGN38/46 E      TGN       B AP-1,-2 2 
LL motifs     
EAENTITYSLLKH FcRII-B2 (mouse) E                      B  3 
EGTADERAPLIRT limp-II E      Lys          B AP-3 1 
   MDDQRDLISN 
LISNNEQLPMLGR 
Invariant Chain  
 
E      MIIC       B AP-1,-2 1 
VTSEPDKHSLLVG Menkes disease protein  E      TGN  4 
Other sorting signals     
Acidic cluster e.g. HIV-1 nef, furin E      TGN PACS-1 5 
Ubiquitin e.g. EGFR E  6 
KKFF 
KRFY 
ERGIC-53 
VIP36 
E  7 
FW CI- and CD-MPR          TGN TIP47 8 
Palmitoylation CD-MPR   9 
Man-6-P Lysosomal hydrolases          Lys  10 
 
1E (endocytosis), 2EE (early endosomes), 3B (basolateral sorting), 4Lys (Lysosomes), 5MIIC (MHC II compartment). 
For other abbreviations and details see text. References: (1) (Heilker et al., 1999) (2) (Banting and Ponnambalam, 
1997) (3) (Hunziker and Fumey, 1994) (4) (Francis et al., 1999; Petris et al., 1998) (5) (Piguet et al., 2000; Voorhees et 
al., 1995) (6) (Hicke, 1999) (7) (Hauri et al., 2000) (8) (Carroll et al., 2001) (9) (Schweizer et al., 1996) (10) (Roberts et 
al., 1998) 
 
For the LL motifs a consensus motif (-)(2-4)xLL was proposed where x is usually a polar residue 
and (-) a negatively charged residue (aspartic or glutamic acid or phospho-serine) (Kirchhausen, 
1999). In part, this was confirmed by investigating the surrounding amino acids of 35 functional 
LL motifs in 31 proteins (Windheim et al., 2002). A preference for acidic residues (E, D) or 
serine was evident at position –4 and –5. In position –1 proline was found in about 23 % of all 
LL motifs. In order to investigate the sequence requirements of YXXF motifs for their 
interaction with AP complexes combinatorial peptide libraries and the yeast-two-hybrid system 
have been applied. For the interaction with µ2, a YXRL consensus motif was found in a 
combinatorial library approach (Boll et al., 1996). No preference for surrounding residues was 
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observed. In another study the yeast-two-hybrid system was applied to reveal that the interactions 
of the YXXF motif of TGN38 with µ1 and µ2 were differentially affected by mutations in the 
SDYQRL sequence (Ohno et al., 1996), demonstrating that the surrounding residues are 
important determinants of the interaction between YXXF motifs and different AP complexes. A 
combinatorial XXXYXXF library was used in the yeast-two-hybrid system to investigate the 
interactions with µ1, µ2, µ3 and µ4 and revealed similar and divergent sequence requirements 
(Aguilar et al., 2001; Ohno et al., 1998). By investigating the surrounding residues of 48 
functional YXXF motifs in 45 proteins preferences for certain aa were found, although less 
striking than in case of the LL motifs (Windheim et al., 2002). These findings indicate that, 
although similar sorting motifs are recognized by the different AP complexes, there are 
differences in the sequences they recognize, which are possibly the basis for different trafficking 
pathways of proteins containing YXXF and LL motifs. 
In accord with this concept, some studies show that sorting motifs that specify different sorting 
events, e.g. for internalization and basolateral localization, overlap but are not identical (Lin et al., 
1997; Matter et al., 1994; Odorizzi and Trowbridge, 1997).  
Moreover, the recognition of some YXXF and LL motifs seems to be regulated by 
phosphorylation. Interestingly, recognition of LL motifs seems to be positively regulated by 
serine phosphorylation, e.g. CD4 (Shin et al., 1991), CD3g (Dietrich et al., 1994), whereas YXXF 
motifs are inactivated by tyrosine phosphorylation, e.g. CTLA-4 (Bradshaw et al., 1997; Shiratori 
et al., 1997), TGN38 (Stephens and Banting, 1997).  
The distance of functionally active YXXF and LL motifs to the putative transmembrane domain 
in the primary sequence varies, although these motifs tend to be localized in relative proximity to 
the TMD and are frequently found in proteins with very short cytoplasmic tails. Both type I 
transmembrane proteins as well as type II proteins (e.g. transferrin receptor, ASGP receptor, 
invariant chain and IRAP), contain such motifs. In case of the YTRF motif of transferrin 
receptor (type II) at least 7 aa between the F and the transmembrane domain were required for 
function (Collawn et al., 1990) but rather large deletions in the cytoplasmic tail moving the motif 
closer to the TMD were tolerated without affecting the internalization rate (Girones et al., 1991). 
In contrast, for the YQTI of lamp-1 7 aa acid spacing as in WT was obligatory and changing that 
distance to 6 or 12 aa changed the internalization rate and even more dramatically the lysosomal 
targeting (Rohrer et al., 1996). For the function of the phosphorylation-dependent LL motif 
(SDKQTLL) of CD3g at least 7 aa spacing from the TMD was required, whereas for the 
phosphorylation-independent LL motif (DKQTLL) at least 6 aa were obligatory (Geisler et al., 
1998). Thus, there seems to be a minimal distance between a sorting motif and the membrane, 
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which might depend on the motif itself and the protein. Changes in the distance between the 
motif and the plasma membrane seem to be differentially tolerated by different proteins. Notably, 
also artificial YXXF motifs mediating endocytosis could be introduced to hemagglutinin (HA) 
and glycophorin A by site directed mutagenesis (Ktistakis et al., 1990; Lazarovits and Roth, 1988; 
Zwart et al., 1996). In summary, sequence and positional requirements exist for the function of 
YXXF and LL motifs in different trafficking pathways. 
1.9 Adenovirus E3 proteins and cellular sorting 
Most proteins encoded by Ad E3 regions are transmembrane proteins. Strikingly, many of them 
contain potential sorting motifs in their cytoplasmic tails (Windheim et al., 2002). For some of 
them functionality has been demonstrated: The E3/19K protein contains a KKXX or KXKXX 
motif in the cytoplasmic tail depending on the subgenus. This motif interacts with COPI and is 
important for the retrieval of E3/19K from the cis-Golgi/ERGIC to the ER and thereby 
contributes to the ER localization of E3/19K (Windheim et al., 2002). Interestingly, in addition 
to the retrieval signal, E3/19K contains a retention signal that is localized in the transmembrane 
region of the protein (Sester et al., in preparation). Therefore, cellular retrieval and retention 
motifs seem to cooperate to mediate ER localization of E3/19K. The specific interaction of 
E3/19K with MHC class I complexes results in their retention in the ER, whereby the 
recognition of infected cells by CTLs through MHC class I-mediated presentation of viral 
peptides is impaired. 
The 10.4K and 14.5K proteins contain LL and YXXF motifs, respectively. Both motifs were 
demonstrated to be crucial for the down-modulation of Fas from the cell surface by the 10.4K-
14.5K complex (Hilgendorf et al., in preparation; Windheim et al., 2000).  
About most other E3 proteins little, if any data about trafficking as well as function have been 
gained. Most E3 proteins are postulated to be transmembrane proteins and many of them 
contain potential sorting motifs, particularly YXXF and LL motifs in their cytoplasmic domains 
(Windheim et al., 2002). The functionality of these motifs remains to be demonstrated and also 
the functions of these proteins have to be addressed to get insight into the role of Ad 
exploitation of the host sorting machinery in immune evasion. 
1.10 The Ad19a E3/49K protein of subgenus D adenoviruses 
A novel E3 gene, E3/49K, was identified recently in the genome of Ad19a, an adenovirus of 
subgenus D causing epidemic keratoconjunctivitis (EKC) (Deryckere and Burgert, 1996). 
Subsequently, it was shown that the E3/49K ORF is present in all subgenus D Ads tested, but 
not in Ads of other subgenera (Fig. 3) (Blusch et al., 2002). In addition, it could be shown that 
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the corresponding E3/49K protein is expressed by all subgenus D Ads examined. Thus, E3/49K 
may be implicated in illnesses characteristically caused by subgenus D Ads, which exhibit a 
tropism for the eye. The sequence predicts a type I transmembrane protein with an N-terminal 
signal sequence (Fig. 6). The ORF encodes a protein of the calculated molecular weight of 48,984 
(46,915 without signal peptide). The short cytoplasmic tail contains two motifs, YXXF and LL, 
that are known to be implicated in endosomal/lysosomal targeting (chapter 1.8.3.2). Both motifs 
are conserved among 49K proteins of all subgenus D Ad serotypes (Blusch et al., 2002). 
Remarkably, the E3/49K sequence predicts 14 potential N-glycosylation sites and three potential 
O-glycosylation sites. 
 
FIG. 6: Primary sequence and structural model of E3/49K. (A) Amino acid sequence of the Ad19a E3/49K 
protein. The putative signal sequence, the transmembrane region, the predicted N-glycosylation sites (*), O-
glycosylation sites (n; (Hansen et al., 1998)) and cysteine residues possibly involved in disulfide bonds (¯) are 
indicated. (B) Structural model of the Ad19a E3/49K protein. The luminal part is suggested to contain three 
domains with one disulfide bond each. The previously noted repeat structures R1-R3 with the respective amino acid 
positions in brackets are marked as black bars (Deryckere and Burgert, 1996). Predicted N- and O-glycosylation sites 
are indicated as grey and black circles, respectively. Proposed disulfide bonded loops are shown as open circles. 
 
The extracellular domain contains three regions with internal homology (R1-3, Fig. 6, 7), which 
show limited similarity (<25%) to the 20.1K and 20.5K proteins of Ad3 of subgenus B (Fig. 7A) 
(Deryckere and Burgert, 1996). Each region encompasses ~80 amino acids and contains two 
cysteine residues, which may be involved in disulfide bonding (Fig. 6). The R3 domain was found 
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to show some similarity to immunoglobulin-like domains (Fig. 7C). Based on the similarities 
between R1, R2 and R3, a similar fold might be postulated for all three domains. Also, the 
cytoplasmic tails of Ad19a 49K and Ad3 20.1K and 20.5K show some homologies (Fig. 7B). 
Interestingly, the LL motif is found in all of these proteins.  
 
FIG. 7: Homologies between repeat regions (R1-R3) and the cytoplasmic tail of Ad19a E3/49K with Ad3 
20.1K and 20.5K and immunoglobulin-like domains. All alignments were performed with DNAMAN 4.20 
(Lynnan BioSoft). (A) Alignment of 49K repeat regions R1-R3 with Ad3 20.5K (22-99) and 20.1K (22-101). 
Different degrees of homology are indicated by different shadings (100% black, >75% dark grey, >50% grey). (B) 
Alignment of the cytoplasmic tails of 49K and Ad3 20.1K and 20.5K. Shadings are as described above. (C) 
Alignment of 49K R3 region with immunoglobulin-like domain consensus sequence smart00409 (Schultz et al., 
2000). 
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1.11 Aim of this study 
The Ad E3 region most likely contributes to subgenus-specific pathogenesis (chapter 1.1, 1.3, 
1.7). However, most studies so far concentrated on subgenus C Ad E3 proteins, and no 
functional data of Ad E3 proteins not present in subgenus C have been gained. However, such 
investigations are required to understand the mechanisms that determine subgenus-specific 
pathogenesis. Subgenus D Ads have the tendency to cause diseases of the eye. The E3/49K 
protein, which is unique to subgenus D Ads, might play a role in this respect. Few subgenus D 
Ads, Ad19a, Ad37 and Ad8, cause a severe eye disease, the epidemic keratoconjunctivitis. 49K 
proteins of different subgenus D Ads may have differential activities that are relevant for 
serotype-specific pathogenesis, e.g. for the disease pattern characteristic to the epidemic 
keratoconjunctivitis. 
The aim of this work was to study the biochemistry and cell biology of the Ad19a E3/49K 
protein and to get insight into its function. First, predicted and unexpected posttranslational 
modifications were examined. Second, the intracellular trafficking of E3/49K was investigated, 
and particularly the importance of the potential endosomal/lysosomal sorting motifs was 
addressed. Third, initial data indicative of the function of E3/49K were obtained. The 
implications of these data for subgenus- or serotype-specific pathogenesis are discussed. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Equipment 
ABI PRISM System (DNA Sequencing) Perkin Elmer, Applied Biosystems Division, 
Foster City, USA 
Bacterial Shaker B.Braun, Melsungen, Germany 
Balances  Sartorius, Göttingen, Germany 
b-Counter LS6000TA Beckman, Fullerton, USA 
Centrifuge GP  Beckman, Palo Alto, USA 
Centrifuge J2-21  Beckman, Palo Alto, USA 
Centrifuge Varifuge 3.0R  Heraeus, Hanau, Germany 
Centrifuge, refrigerated and non-refrigerated  Heraeus, Hanau, Germany 
Chromatography column C10/10 Amersham-Pharmacia, Freiburg, Germany 
Confocal laser scanning microscope Leitz DM IRB Wetzlar, Germany 
Confocal laser scanner Leica TCS NT, Heerbrugg, Switzlerland  
Eagle eye Stratagene, Amsterdam, The Netherlands 
FACSCalibur Becton Dickinson, Heidelberg, Germany 
Film developing machine Optimax Typ TR MS Laborgeräte, Heidelberg, Germany 
Fluorescence-/light microscope Axiovert 35  Zeiss, Oberkochen, Germany 
Fridge (4°C) Liebherr, Ochsenhausen, Germany 
Freezer (-20°C) Liebherr, Ochsenhausen, Germany 
Freezer (-80°C) Forma Scientific, Inc., Marietta, Ohio, USA 
Cryo 1°C Freezing Container Nalgene Nunc, Wiesbaden, Germany 
g-Counter (COBRA, Auto-Gamma) Packard, Groningen, The Netherlands 
Gel dryer Bio-Rad, Munich, Germany 
GelAir drying system  Bio-Rad, Munich, Germany 
Gradient former Gibco BRL, Karlsruhe, Germany 
Incubators for cell culture (37°C) Heraeus, Hanau, Germany 
Inverted microscope Axiovert 25 Zeiss, Oberkochen, Germany 
Laminar Flow Hood Lamin Air  BDK, Sonnenbühl-Genkingen, Germany 
Magnetic stirrer with heating block  Janke & Kunkel, Staufen, Germany 
Microwave  AEG, Berlin, Germany 
Multichannel pipette   ICN Flow, Costa Mesa, USA 
Optimax Typ TR X-Ray film processor  MS Laborgeräte, Heidelberg, Germany 
PCR Thermal Cycler 480  Perkin Elmer, Weiterstadt, Germany 
Peristaltic pump P-1  Amersham-Pharmacia, Freiburg, Germany  
pH-Meter  WTW, Weilheim, Germany 
Phosphorimager (Storm 860 Molecular Imager) Molecular Dynamics, Sunnyvale, USA 
Phosphorimager screens  Molecular Dynamics, Sunnyvale, USA 
Photometer Gene Quant II  Pharmacia/LKB, Freiburg, Germany 
Pipettes   Gilson, Villies Le Bel, France; 
   Eppendorf, Hamburg, Germany 
Pipetting aid   Technomara, Zürich, Switzerland 
Pipette stepper    Eppendorf, Hamburg, Germany 
Electrophoresis Power supply EPS600  Amersham-Pharmacia, Freiburg, Germany 
Overhead mixer   Heidolph, Schwabach, Germany 
Sonifier 450   Branson Ultrasonics Corp., Danbury, USA  
Speed vac concentrator   Savant, Farmingdale, USA 
Thermomixer  Eppendorf, Hamburg, Germany 
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Tissue homogenizer (S)  B.Braun, Melsungen, Germany 
Trans-Blot SD Semidry Transfer Cell  Bio-Rad, Munich, Germany 
UV-transilluminator (366 nm)  Vetter, Wiesloch, Germany 
 (254 nm)  Konrad Benda, Wiesloch, Germany 
Vortex mixer  Janke & Kunkel, Staufen, Germany 
Water bath   Köttermann, Hängsingen, Germany 
2.1.2 Chemicals 
Acetic Acid  Roth, Karlsruhe, Germany  
Acrylamide/Bisacrylamide 29:1 (Protogel)  National Diagnostics, Atlanta, USA 
Agar for plates  Gibco BRL, Karlsruhe, Germany 
Agarose (low melting point, SeaPlaque)  Biozym, Hess. Oldendorf, Germany 
Agarose type I  Sigma, Munich, Germany 
Ammonium chloride  Merck, Darmstadt, Germany 
Ammonium persulfate (APS)  Sigma, Munich, Germany 
Ampicillin  Roche Diagnostics, Mannheim, Germany 
Bacto yeast extract  Gibco BRL, Karlsruhe, Germany 
Bacto trypton  Difco Lab., Detroit, USA 
Bafilomycin A1  Sigma, Munich, Germany 
Bestatin   Calbiochem, Bad Soden, Germany 
b-mercaptoethanol  Merck, Darmstadt, Germany  
Blue Dextran/ EDTA  Perkin Elmer, Applied Biosystems Division, 
Foster City, USA 
Boric acid   Roth, Karlsruhe, Germany 
Brefeldin A  Sigma, Munich, Germany 
Bromophenol blue  Serva, Heidelberg, Germany 
BSA (bovine serum albumin)  Sigma, Munich, Germany 
Calcium chloride  Merck, Darmstadt, Germany 
Chloroform  Merck, Darmstadt, Germany 
Chloroquine  Sigma, Munich, Germany 
Coomassie brilliant blue R-250  Bio-Rad, Munich, Germany 
Cycloheximide  Calbiochem, Bad Soden, Germany  
Dimethylpimelimidate  Amersham-Pharmacia, Freiburg, Germany 
Dimethylsulfoxid (DMSO)  Merck, Darmstadt, Germany  
Dithiothreitol (DTT)  Roth, Karlsruhe, Germany 
dNTPs  Amersham-Pharmacia, Freiburg, Germany 
Dulbecco’s modified Eagle’s medium (DMEM) Gibco BRL, Karlsruhe, Germany 
Ethanol (EtOH)  Riedel-de Haën, Seelze, Germany 
Ethidium bromide  Sigma, Munich, Germany 
Ethylendiamintetraacetate disodium salt  Roth, Karlsruhe, Germany 
(EDTA)  
Fetal calf serum (FCS)  Roche Diagnostics, Mannheim, Germany 
Ficoll (type 400)  Amersham-Pharmacia, Freiburg, Germany 
Formamide  Sigma, Munich, Germany 
Geneticin disulfate salt (G418)  Sigma, Munich, Germany 
Glucose  Merck, Darmstadt, Germany 
Glycerol  Roth, Karlsruhe, Germany 
Glycine  Serva, Heidelberg, Germany 
Guanidine hydrochloride  Sigma, Munich, Germany 
Histogel  Linaris, Wertheim-Bettingen, Germany 
Hydrochloric acid (HCl)  Merck, Darmstadt, Germany 
Igepal CA-630  Sigma, Munich, Germany 
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Imidazole   Fluka, Seelze, Germany 
Iodacetamide  Sigma, Munich, Germany 
Isopropanol  Riedel-de Haën, Seelze, Germany 
Isopropylthio-b-D-galactosid (IPTG)  Roth, Karlsruhe, Germany 
Kanamycin  Serva, Heidelberg, Germany 
Leupeptin  Sigma, Munich, Germany 
L-glutamine  Gibco BRL, Karlsruhe, Germany 
L-glutathione (reduced)  Merck, Darmstadt, Germany 
L-glutathione (oxidized)  Fluka, Seelze, Germany 
Magnesium chloride  Merck, Darmstadt, Germany 
Magnesium sulfate  Merck, Darmstadt, Germany 
Methanol  Merck, Darmstadt, Germany 
Eagle’s minimal essential medium (MEM)   Gibco BRL, Karlsruhe, Germany  
Eagle’s minimal essential medium (MEM)   Gibco BRL, Karlsruhe, Germany  
without methionine 
Paraformaldehyde  J.T.Baker B.V., Deventer, Holland 
Pefabloc   Roche Diagnostics, Mannheim, Germany 
Penicillin-Streptomycin  Gibco BRL, Karlsruhe, Germany 
Pepstatin A  Calbiochem, Bad Soden, Germany 
Phenol/ chloroform  Roth, Karlsruhe, Germany  
Phenylmethylsulfonfluoride (PMSF)  Roche Diagnostics, Mannheim, Germany  
Phosphate buffered saline (PBS) Dulbecco’s  Gibco BRL, Karlsruhe, Germany  
(liquid) 
Phosphate buffered saline (powder)  Biochrom KG, Berlin, Germany  
Ponceau S   Sigma, Munich, Germany 
Potassium acetate  Riedel-de Haën, Seelze, Germany 
Potassium chloride  Merck, Darmstadt, Germany 
Potassium phosphate salts  Merck, Darmstadt, Germany 
Protein A Sepharose CL-4B  Amersham-Pharmacia, Freiburg, Germany 
Protein G Sepharose Fast Flow  Amersham-Pharmacia, Freiburg, Germany 
RPMI1640  Gibco BRL, Karlsruhe, Germany 
RPMI1640 w/o Cys/Met  Gibco BRL, Karlsruhe, Germany  
Saponin   Calbiochem, Bad Soden, Germany 
Scintillator cocktail (Aquasafe 300 plus)  Zinsser, Frankfurt, Germany 
[35S]-cysteine/methionine (Promix)  Amersham-Pharmacia, Freiburg, Germany 
[35S]-methionine  Amersham-Pharmacia, Freiburg, Germany 
SeaPlaque agarose  FMC bioproducts, Rockland, Maine, USA 
Skim milk powder     Merck, Darmstadt, Germany 
Sodium acetate  Riedel-de Haën, Seelze, Germany 
Sodium azide  Serva, Heidelberg, Germany 
Sodium borate  Merck, Darmstadt, Germany 
Sodium chloride  Riedel-de Haën, Seelze, Germany 
Sodium thiosulfate Merck, Darmstadt, Germany 
Sodium dodecylsulfat (SDS)  Merck, Darmstadt, Germany 
Sodium carbonate  Merck, Darmstadt, Germany 
Sodium hydroxid  J.T.Baker B.V., Deventer, Holland 
Sodium phospate salts  Merck, Darmstadt, Germany 
Sucrose  Sigma, Munich, Germany 
Tetramethylethylendiamin (TEMED)   Amersham-Pharmacia, Freiburg, Germany 
Thimerosal (Merthiolate) USB, Cleveland, USA 
Trichloracetic acid  Sigma, Munich, Germany 
Triton X-100  Serva, Heidelberg, Germany 
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Trypsin  Gibco BRL, Karlsruhe, Germany 
Trypsin inhibitor  Sigma, Munich, Germany 
Tunicamycin   Sigma, Munich, Germany 
Tween 20  Merck, Darmstadt, Germany 
Urea  Roth, Karlsruhe, Germany 
Xylene cyanol FF Fluka, Seelze, Germany 
2.1.3 Additional materials 
Autoradiography films BIOMAX-MR  Eastman-Kodak, Rochester, USA 
Cell culture plastic ware Greiner, Nürtingen, Germany 
 Nunc, Wiesbaden, Germany 
Falcon/Becton Dickinson, Heidelberg, 
Germany 
Filter paper (3 mm)  Whatman Ltd., Maidstone, England 
Glass plates (round, 12 mm Æ)  Roth, Karlsruhe, Germany 
Glass slides for IF  Marienfeld, Bad Mergentheim, Germany 
Hybond ECL Nitrocellulose membranes    Amersham-Pharmacia, Freiburg,Germany 
Sterile filter units  Millipore 
2.1.4 Cell lines 
A549 human lung epithelial carcinoma (American Type Culture Collection 
(ATCC): CCL-185) 
293    human embryonal kidney cell line (ATCC: CRL-1573) 
SeBu  primary foreskin fibroblasts (Elsing and Burgert, 1998) 
LoVo human colorectal adenocarcinoma (ATCC: CCL-229) 
Jurkat J77 (clone SVT35) T cell leukemia (Ting et al., 1996) 
Jurkat E6.1 T cell leukemia (ATCC: TIB-152) 
NKL human natural killer cell leukemia (Robertson et al., 1996), kindly 
provided by Christine Falk, GSF, Munich, Germany 
B.3 NK kindly provided by Christine Falk, GSF, Munich, Germany (Falk et 
al., 2000) 
CD4+ CTL (234) kindly provided by Christine Falk, GSF, Munich, Germany (Besser 
and Wank, 1999) 
B.3 CD4 kindly provided by Christine Falk, GSF, Munich, Germany (Falk et 
al., 2000) 
DS LCL EBV-transformed B lymphocyte cell line, kindly provided by 
Christine Falk, GSF, Munich, Germany 
BW LCL EBV-transformed B lymphocyte cell line, kindly provided by 
Christine Falk, GSF, Munich, Germany 
L721.221 Variant of the EBV-transformed human lymphoblastoid cell line 
L721 (Shimizu and DeMars, 1989), kindly provided by Christine Falk, 
GSF, Munich, Germany  
L721.112 Variant of the EBV-transformed human lymphoblastoid cell line 
L721 (Shimizu and DeMars, 1989), kindly provided by Christine Falk, 
GSF, Munich, Germany  
Daudi Burkitt’s lymphoma (B lymphoblast, ATCC: CCL-213) 
K562 erythroleukemia (ATCC: CCL-243) 
HeLa human cervix carcinoma (ATCC :CCL-2) 
2.1.5 Viruses 
Ad19a kind gift of Göran Wadell, Department of Virology, University of 
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Umea, Sweden 
Ad19a-49K(-) kindly provided by Zsolt Ruzsics, Max-von-Pettenkofer Institute, 
Gene center, Munich 
2.1.6 Bacterial strains 
DH5a Gibco BRL, Karlsruhe, Germany 
XL1-blue Stratagene, Amsterdam, The Netherlands 
M15 [pREP4] Qiagen, Hilden, Germany 
2.1.7 Plasmids 
pSG5   Stratagene, Amsterdam, The Netherlands 
pSG5-E3/49K  kindly provided by Jürgen Blusch und Kerstin Siedler 
pQE-60  Qiagen, Hilden, Germany 
pSV2-neor  (Koerner et al., 1992) 
pQE-60-N49K  this study 
pSG5-E3/49K-YA/LLAA  this study 
pSG5-E3/49K-LLAA  this study 
pSG5-E3/49K-YA  this study 
pSG5-E3/49K-DCT  this study 
2.1.8 Oligonucleotides    
template name orienta-
tion 
Restriction 
site 
sequence (5’®3’) 
E3/49K 49K5’NCO sense NcoI gagcgccatgggatttcatactatcaatgctac 
E3/49K 49K3’BAM antisense BamHI cgcgggatccgggaatttttgaatcataatttc 
E3/49K 49KdelCT antisense BglII gtccagatctggatccgtcttaacgcttgcggcagcagatgtagc 
E3/49K 49KYLLAAA antisense BglII gtccagatctggatccgtcttagtaagagaagctggctgctgggt
ctaccatatgattggctgccctgggacgctt 
E3/49K 49KYA antisense BglII gtccagatctggatccgtcttagtaagagaagctgagtagtg 
ggtctaccatatgattggctgccctgggacgctt 
E3/49K 49KLLAA antisense BglII gtccagatctggatccgtcttagtaagagaagctggctgctgggt 
ctaccata 
pSG5 pSG549K2497rev antisense BglII ggacaaaccacaactagaatgcag 
E3/49K 49K1000rev antisense BglII gtaccatagtaagttccctcataatc 
E3/49K 49K1000sense sense BglII ttatgagggaacttactatggtac 
E3/49K 49K340rev antisense BglII ggttttacagtagcaggaggaggtgg 
E3/49K 49KUSER546 sense  ggtacaatcatcaaggaacccagag 
E3/49K 19.20 antisense  tgttcacatggatcaa 
E3/49K 19.21 sense  ttgatccatgtgaaca 
E3/49K 19.24 antisense  atagtgtgttctctg 
E3/49K 21 sense  ggttggacctaaagcagaagg 
E3/49K 22 antisense  Ccttctgctttaggtccaacc 
 
The oligonucleotides were obtained from metabion (Martinsried, Germany). 
2.1.9 Molecular weight markers 
DNA Molecular Weight Marker X (0.07-12.2 kbp)   Roche Diagnostics, Mannheim, Germany 
Protein marker Dalton VII-L (14000-70000) Sigma, Munich, German 
[14C] methylated protein marker (14300-220000) Amersham-Pharmacia, Freiburg, Germany 
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2.1.10 Kits 
BigDye RR Terminator Amplitaq FS Kit Perkin Elmer, Applied Biosystems Division, 
Foster City, USA 
BCA Protein Assay Pierce, Rockford, USA 
ECL western blotting detection system   Amersham-Pharmacia, Freiburg, Germany 
Nucleobond Kit    Macherey-Nagel, Düren, Germany 
Pharmacia GFX Micro Plasmid Kit   Amersham-Pharmacia, Freiburg, Germany 
Protein Assay  Bio-Rad, Munich, Germany 
QIAex II Agarose Gel Extraction Kit   Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit   Qiagen, Hilden, Germany 
Qiagen Plasmid Maxi Kit   Qiagen, Hilden, Germany 
2.1.11 Antibodies 
2.1.11.1 Primary antibodies 
anti-Ad19a E3/49K (C-terminus)  R25050, R25044, polyclonal rabbit antisera raised 
against the C-terminal 15 amino acids of E3/49K, a 
cysteine was added to the N-terminus for directed 
coupling to KLH or ovalbumin (Blusch et al., 2002) 
anti-Ad19a E3/19K  polyclonal rabbit antisera (Deryckere and Burgert, 
1996) 
anti- Ad2 hexon mouse mAb, 2Hx-2, ATCC HB-8117 
anti-TGN46  sheep and rabbit serum, kindly provided by S. 
Ponnambalam, University of Dundee, Scotland 
anti-b1®4-Galactosyltransferase  mouse mAb, GTL2, (Kawano et al., 1994) 
anti-GM130  mouse mAb, clone 35, Transduction Laboratories, 
Lexington, USA 
anti-lamp-2  2D5, mouse mAb (Diettrich et al., 1996) 
anti-lamp-1  polyclonal rabbit serum, 931-A, kindly provided by S. 
Carlson, University of Umea, Sweden 
anti-lysobisphosphatidic acid  6C4, mouse mAb (Kobayashi et al., 1998) 
anti-transferrin receptor  mouse mAb, clone number L01.1, Becton Dickinson, 
Heidelberg, Germany, and 5E9C11, ATCC HB-21 
anti-EEA1  mouse mAb, clone 14, Transduction Laboratories, 
Lexington, USA 
anti-CD46  mouse mAb, J4-48, Dianova, Hamburg, Germany  
anti-AP1  mouse mAb, 100/3, Sigma, Munich, Germany  
anti-HLA-A, -B, and -C  mouse mAb, W6/32, ATCC HB95 
anti-E1B 19K rat mAb, Oncogene Science, Manhasset, NY, USA 
anti-E1B 55K rat mAb, Oncogene Science, Manhasset, NY, USA 
anti-Ad19a E3/49K (N-terminus) polyclonal rabbit antiserum directed against the N-
terminal part of 49K: R48-1B to R48-8B, R47-1B to 
R47-10B; this study 
anti-Ad19a E3/49K (N-terminus) rat mAb, directed against the N-terminal part of 49K: 
4D1, 1E6, 1F4, 1H8, 5A7, 5D3, 6C12, 6C9, 7H10, 
10A11; this study 
2.1.11.2 Secondary antibodies 
Fluoresceine (FITC)- conjugated: 
Goat anti-Mouse IgG (Cat.No. F2012) Sigma, Munich, Germany 
Goat anti-Mouse IgG (Cat.No. 115-095-146) Dianova, Hamburg, Germany 
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Rabbit anti-Rat IgG (Cat.No. FI-4000) Vector Laboratories, Burlingame, CA, 
USA 
Goat anti-Rabbit IgG (Cat.No. 111-095-144) Dianova, Hamburg, Germany 
Donkey anti-Rabbit IgG (Cat.No. 711-095-152) Dianova, Hamburg, Germany 
Donkey anti-Mouse IgG (Cat.No. 715-095-151) Dianova, Hamburg, Germany 
 
Rhodamine-, Cy3 or Texas-Red-conjugated: 
Goat anti-Mouse IgG (Cat.No. 115-165-068) Dianova, Hamburg, Germany 
Goat anti-Rat IgG (Cat.No. 112-295-143) Dianova, Hamburg, Germany 
Goat anti-Rabbit IgG (Cat.No. 111-295-045) Dianova, Hamburg, Germany 
Donkey anti-Sheep IgG (Cat.No. 713-295-147)   Dianova, Hamburg, Germany 
Donkey anti-Rat IgG (Cat.No. 712-075-153) Dianova, Hamburg, Germany 
 
Peroxidase conjugated: 
Goat anti-Rat IgG (Cat.No. 112-035-062) Dianova, Hamburg, Germany 
Goat anti-Rabbit IgG (Cat.No. 111-035-144) Dianova, Hamburg, Germany 
 
Not modified: 
Anti-rat IgG (Cat.No. R3756) Sigma, Munich, Germany 
Anti-mouse IgG (Cat.No. M7023) Sigma, Munich, Germany 
2.1.12 Enzymes 
Lysozyme Roche Diagnostics, Mannheim, Germany 
T4 DNA Ligase   MBI Fermentas, St. Leon-Rot, Germany 
Phosphatase, alkaline, shrimp (SAP) Roche Diagnostics, Mannheim, Germany 
Proteinase K Sigma, Munich, Germany 
Pwo DNA Polymerase  Roche Diagnostics, Mannheim, Germany 
Restriction Endonucleases   MBI Fermentas, St. Leon-Rot, Germany 
Roche Diagnostics, Mannheim, Germany 
New England Biolabs, Beverly, USA 
N-glycosidase F (PNGase F) Roche Diagnostics, Mannheim, Germany 
Neuraminidase (Arthrobacter ureafaciens) Roche Diagnostics, Mannheim, Germany 
Endoglycosidase H (Streptomyces plicatus) Roche Diagnostics, Mannheim, Germany 
O-glycosidase (Diplococcus pneumoniae) Roche Diagnostics, Mannheim, Germany 
 
2.2 Methods 
2.2.1 Bacterial cell culture 
2.2.1.1 Cultivation and conservation of bacteria 
E. coli bacteria were grown in LB medium or on LB agar plates. Incubation was performed at 
37°C with constant shaking. For conservation 500 µl aliquots of a bacterial culture in the 
exponential growth phase obtained after inoculation from single colonies were mixed with 500 µl 
of LB/30% glycerol, frozen in liquid nitrogen and stored at –70°C. 
 
LB medium (1 l):            10 g Bacto tryptone 
    5 g Bacto yeast extract  
5 g NaCl 
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LB agar:   LB medium with 1.5-2 % agar 
Selection medium:   LB medium with 100 µg/ml ampicillin and/or 25 µg/ml 
kanamycin 
2.2.1.2 Preparation of competent bacteria 
For preparation of competent bacteria a single clone DH5a was picked and grown o/n in 5 ml 
LB at 37°C. 1 ml of the bacterial culture was then transferred to 100 ml LB and incubated 3 h at 
37°C until the OD600nm was 0.35-0.49. The following incubations were all performed at 4°C or on 
ice. The bacteria were distributed to two 50 ml tubes and centrifuged 5 min at 3500 rpm (Heraeus 
Varifuge 3.0R). The supernatants were discarded and the pellets were resuspended in 15 ml ice-
cold TfB I. After 40-50 min incubation on ice, the bacteria were centrifuged 10 min at 2500 rpm 
(Heraeus Varifuge 3.0R). The supernatants were discarded and the pellets were resuspended in 4 
ml ice-cold TfB II. Aliquots of 0.2 ml were added to precilled 1.5 ml reaction tubes and stored at 
–80°C. 
 
TfB I:    TfB II: 
100 mM RbCl2    10 mM MOPS pH 7.0 
50 mM MnCl2    10 mM RbCl2 
30 mM KAc    75 mM CaCl2 
10 mM CaCl          15% (v/v) glycerol 
15% (v/v) glycerol 
pH adjusted to 5.8 with 0.2 M HAc 
both buffers sterilized by filtration (Æ0.2 µm) and stored at 4°C 
2.2.1.3 Transformation 
Different volumes of the ligation reaction mixture (2, 5, 10 µl) were added to 100 µl competent 
bacteria and incubated 30 min on ice. After the heat shock, 2 min 42°C, 1 ml LB medium was 
added and bacteria were cultivated for 1 h at 37°C. Then 100 µl were taken and plated on LB agar 
plates with antibiotic(s). The residual bacteria were centrifuged (4000 g, 5 min), resuspended and 
plated the same way. The plates were incubated o/n at 37°C. 
2.2.2 DNA techniques 
2.2.2.1 Purification of plasmid DNA 
Plasmid DNA was purified with the Pharmacia GFX Micro Plasmid Kit in small scale and the 
Qiagen Plasmid Maxi Kit or the Nucleobond Kit in large scale according to the manufacturer’s 
instructions. 
2.2.2.2 Determination of DNA concentration 
The concentration and purity of the purified DNA was determined by measuring the UV 
absorbance at 260 and 280 nm. The DNA concentration was calculated with the OD260nm           
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(1 OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was estimated with the 
OD260nm/OD280nm ratio, with a ratio of ca. 1.8 indicating a low degree of protein contamination. 
2.2.2.3 Restriction endonuclease digestion 
Restriction endonuclease reactions were performed according to the manufacturer’s 
recommendations. In general, 1 µg DNA was digested for 1 h at 37°C with 1-3 U enzyme. 
Efficacy of the cleavage reaction was controlled by agarose gel electrophoresis. 
2.2.2.4 5’-Dephosphorylation reaction 
5’-dephosphorylation reaction of plasmid vector DNA after restriction endonuclease cleavage 
was performed with the shrimp alkaline phosphatase (SAP). 2 U SAP were added to about 2 µg 
restriction enzyme digested plasmid DNA. After 30 min incubation at 37 °C the phosphatase was 
inactivated by heating to 65°C for 15 min and the DNA was isolated by phenol/chloroform 
extraction and ethanol precipitation (see below). 
2.2.2.5 Polymerase chain reaction (PCR) 
Polymerase Chain Reaction (PCR) was performed with the Pwo DNA polymerase from Pyrococcus 
woesei with a 3’®5’ exonuclease proofreading activity.  
 
The reaction mixture contained: 
 
10 µl 10x PCR Puffer (100 mM Tris-HCl pH 8.85, 250 mM KCl, 50 mM (NH4)2SO4, 20 mM 
MgSO4) 
2 µl 10 mM dNTPs (200 µM each) 
2 µl 10 µM sense primer (200 nM) 
2 µl 10 µM antisense primer (200 nM) 
0.5 µl Pwo (2.5U) 
83.5 µl H2O 
+ 0.1 µg template DNA 
 
The following cycles were performed: 
 
a) Amplification of the region encoding the N-terminal part of E3/49K for the cloning of the  
   His-Tag-fusion construct: 
 
1. 94°C 5 min 
2. 94°C 1 min 
3. 55° C 1 min         25x 
4. 72°C 2 min 
5. 72°C 10 min 
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b) Amplification of the region encoding the C-terminal part of E3/49K and site-directed   
    mutagenesis: 
 
1. 94°C 5 min 
2. 94 °C 1 min 
3. 62°C 2 min          12x with a decrease of 1°C per cycle down to 50°C (touchdown), then 15x 
4. 72°C 2 min 
5. 72°C min 10 min 
2.2.2.6 Isolation of DNA fragments 
DNA fragments were separated by agarose gel electrophoresis, stained with ethidium bromide 
and detected with UV light (366 nm). The gel slice containing the DNA fragments was cut out 
and the DNA was isolated using the QIAex II Agarose Gel Extraction Kit according to the 
manufacturer’s instructions. Alternatively, DNA fragments from PCR reactions were purified 
using the QIAquick PCR Purification Kit according to the manufacturer’s instructions. 
2.2.2.7 Phenol/chloroform extraction and ethanol precipitation 
Proteins were removed from DNA preparations by extracting twice with 1x volume 
phenol/chloroform and once with 1x volume chloroform. After vigorous vortexing for 10 s the 
solution was centrifuged at 14000 rpm (microcentrifuge) for 1 min and the upper DNA 
containing phase was recovered. Then 0.1x volume 3 M NaAc pH 5.2 and 3x volume 100% 
EtOH (cold) were added, and incubation at –20°C was performed for 1-12 h. The precipitated 
DNA was centrifuged down at 14000 rpm for 30 min (4°C). Then the pellet was washed once 
with 70% EtOH (cold). After another centrifugation step (14000 rpm, 15 min, 4°C, 
microcentrifuge) the EtOH was carefully removed, the pellet air-dried at RT and finally 
resuspended in H2O or 10 mM Tris pH 8.0.  
2.2.2.8 Ligation 
For ligation about 100-200 ng vector DNA was used with a molar ration of vector/insert of 
about 1:1. The reaction was performed in a total volume of 20 µl 1x reaction buffer (MBI 
Fermentas) with 2 U T4 DNA Ligase (MBI Fermentas). 
In the first step vector and insert were mixed in reaction buffer and incubated 5 min at 45°C and 
put on ice. Then the ligase was added. After incubation at 1 h 22°C the ligase was inactivated by 
heating 10 min at 65 °C. 
2.2.2.9 DNA sequencing 
2.2.2.9.1 PCR 
DNA sequencing was performed using the BigDye RR Terminator Amplitaq FS Kit. The 
reaction mixture contained 8 µl Premix, 1 µg dsDNA template and 10 pmol primer in a total 
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volume of 20 µl.  
Then the PCR was performed: 
 
96°C 10 s 
50°C 5 s             25x 
60°C 4 min 
 
The product was precipitated by adding 30 µl H2O, 5 µl 3 M NaAc pH 5.2 and 135 µl EtOH 
(RT). After 15 min centrifugation at 15000 rpm the pellet was washed with 280 µl 70% EtOH 
(RT). Then it was centrifuged for 10 min at 14000 rpm (microcentrifuge), the EtOH was 
removed and the pellet air-dried. 
2.2.2.9.2 Polyacrylamide gel electrophoresis 
A 5% polyacrylamide gel (8 M urea, 200 x 560 x 0.3 mm) was prepared as follows: 
30 g urea                         
10 ml 30% acrylamide/bisacrylamide (29:1)   
6 ml 10x TBE buffer    
22 ml H2O 
 
10x TBE buffer (1l):  108 g Tris base 
   55 g Boric acid 
   7.4 g EDTA 
 
The solution was incubated at 37°C until the urea was dissolved. Then the solution was filtered 
with a 0.2 µm filter and degassed for 10 min. 20 µl TEMED and 350 µl 10% APS solution were 
added and the gel was poured and polymerized horizontally for 4 h.  
The precipitated DNA from the PCR reaction was resuspended in 2 µl Blue Dextran/EDTA (50 
mg/ml Blue Dextran, 25 mM EDTA pH 8) and 8 µl formamide and heated for 10 min at 95°C. 
Then the samples were put on ice for 5 min. After 1 min centrifugation at 14000 rpm 
(microcentrifuge) 4 µl of the solution was loaded on the gel. The gel run was performed with 1x 
TBE buffer at 37 Watt for 18 h (prerun 30 min). Sequencing data were analyzed using the ABI 
PRISM software. 
2.2.2.10 Agarose gel electrophoresis 
Analysis of DNA fragments and plasmids was performed by agarose gel electrophoresis in 1x 
TAE. In general, agarose concentration was between 1 and 2 % in 1x TAE. The agarose was 
solubilized by heating in a microwave oven. Ethidium bromide was added to a final 
concentration of 0.1 µg/ml (1 µl stock to 100 ml) just before pouring the gel. Probes were mixed 
with 0.17x volume loading buffer. Gels (6.5 x 9.5 cm) were run horizontally at 80-120 V. DNA 
was detected with UV light, l=254 nm or l=366 nm to cut out specific fragments. 
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Loading buffer (6x in water):  0.25% bromophenol blue 
     0.25% xylene cyanol FF 
     15% Ficoll (type 400) 
 
20x TAE:     800 mM Tris 
     400 mM NaAc 
     40 mM EDTA 
     adjusted to pH 7.8 with acetic acid 
 
Ethidium bromide (stock):   10 mg/ml 
 
2.2.3 Tissue culture 
2.2.3.1 Cultivation and cryoconservation 
A549, 293, SeBu and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 10% fetal calf 
serum at 37°C and 5% CO2. Jurkat J77 (SVT 35) cells were maintained in RPMI medium 
supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 10% fetal calf serum. 
For cryoconservation cells were detached with trypsin and centrifuged at 300 g for 5 min at 4°C. 
Then the cells were resuspended in 1 ml 25% FCS/10% DMSO/65% DMEM (4°C) with a final 
concentration of 0.5-1x107 cells/ml and transferred to cryovials which were cooled to –70°C in a 
“Cryo 1°C Freezing Container”. From there the vials were transferred to liquid nitrogen for long-
term storage. Frozen aliquots were quickly thawed at 37°C in a waterbath, 1x volume DMEM 
was added and the suspension was carefully pipetted onto a FCS cushion. After centrifugation at 
300 g for 5 min the supernatant was removed, cells were resuspended in complete medium and 
transferred to cell culture dishes. 
2.2.3.2 Calcium phosphate transfection 
For transient transfection cells were grown on 6 cm Æ dishes to 60-70% confluency. 4 h prior to 
the transfection the medium was changed. 250 µl of 2x HBS pH 7.05 was added to a 1.5 ml 
reaction tube. In another tube 6-8 µg DNA was combined with H2O to a total volume of 225 µl, 
followed by the addition of 25 µl 2.5 M CaCl2. The tube with the 2x HBS was vortexed with 800 
rpm while the DNA/CaCl2 solution was added dropwise. The solution was incubated at RT for 
15-20 min to allow the formation of the Calcium-DNA precipitate. Subsequently, the suspension 
was added directly to the medium of the cells. The next day, the medium was changed and 36-
48h later protein expression was assessed by immunofluorescence. To generate transfectants 
stably expressing the E3/49K protein cells were transfected with 20 µg pSG5-E3/49K and 2 µg 
pSV2-neor, the latter conferring G418 resistance, per 10 cm Æ dishes. After two days cells were 
split 1:4 or 1:8 and cultivated in medium containing 200 µg/ml (293) or 1 mg/ml G418 (A549). 
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After 10-14 days clones were trypsinized using cloning cylinders and transferred to 3 cm Æ 
dishes. Usually, 20-30 clones were obtained per 10 cm Æ dish. 
 
2x HBS pH 7.05:   50 mM HEPES 
1.5 mM Na2HPO4x 2 H2O 
280 mM NaCl 
12 mM glucose 
2.2.3.3 Adenovirus infection 
Cells were grown to 80-90% confluency and washed once with DMEM without FCS. In general, 
5-10 plaque forming units (pfu) were applied per cell in 1 ml DMEM without FCS. Dishes were 
incubated for 1-1.5 h in the incubator and were shaken every 10-15 min. Then the virus 
containing medium was removed, and DMEM with 2.5% FCS was added. This time point was 
defined as the start of infection. Virus containing solutions were inactivated by disposing them in 
solutions with >1% SDS. 
2.2.3.4 Preparation of adenovirus stocks 
To prepare virus stocks A549 cells were grown in T175-flasks to 80-90% confluency. The cells 
were washed 1x with 30 ml DMEM without FCS. Then 8 ml DMEM without FCS containing 1-
4x107 PFUs virus were added and incubated 3 h in the incubator with shaking every 10 min. 
Then the medium was removed, 35 ml DMEM/1.5% FCS were added and cells were incubated 
until the cytopathic effect (CPE) reached 100%, which generally took 4-5 days. If necessary 
additional 15 ml DMEM/1.5% FCS were added after 3 days. Infected cells were detached by 
shaking the flasks heavily. Then the cells were transferred to 50 ml plastic tubes and centrifuged 
10 min at 300 g and 4°C. Infected cells were resuspended in 2 ml PBS (per flask) and viruses 
were released by 3-4 freeze/thaw cycles: Cells were frozen at –70°C (>30 min) and thawed at 
37°C in a water bath. Finally, the samples were centrifuged 10 min at 3500 rpm (Heraeus 
Varifuge 3.0R) to remove cell debris and the supernatant was split into aliquots of 0.5-1 ml and 
stored at –70°C. Usually 7-10 T175 flasks were harvested for one virus stock. 
2.2.3.5 Plaque assay 
Ad19a virus stocks were quantified by plaque assays (Mittereder et al., 1996). Virus stocks were 
diluted 1:109, 108, 107, 106 in DMEM without FCS. A549 cells were grown to 95% confluency and 
washed once with DMEM without FCS. Then 1 ml DMEM containing different virus dilutions 
was added and incubated 1.5 h in the incubator shaking every 10 min. 2% sterile low melting 
point agarose (SeaPlaque, in H2O) was solubilized in the microwave and a sufficient volume was 
kept at 37°C together with 2x DMEM. At the end of the adsorption time the DMEM containing 
virus was removed. 2% low melting point agarose was mixed 1:1 with 2x DMEM and 5 ml was 
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added to each dish. The dishes were left 10 min at RT (lids partly off) until the agarose hardened. 
Then the dishes were transferred to the incubator. Cells metabolize approximately 1 ml medium 
per day. When the medium became yellow, i.e. acidic, indicating depletion of nutrition 3 ml 
DMEM/1% agarose was added. At around 15-17 days plaques appeared and were counted every 
day. The final PFU was determined when the PFU count was constant for 2-3 days. 
2.2.3.6 Immunofluorescence 
Subconfluent layers of A549 or SeBu cells were grown on sterile glass coverslips. Cells were 
rinsed with PBS and fixed with 3% (w/v) paraformaldehyde in PBS for 20 min. After quenching 
aldehyde groups with 50 mM NH4Cl and 20 mM glycine in PBS for 10 min, cells were 
permeabilized with 0.2% saponin in PBS with 5% FCS to block non-specific binding for 10 min. 
The cells were incubated with the primary antibody diluted in 0.2% saponin/ 5% FCS in PBS for 
1 h, washed four times with 1 ml 0.2% saponin in PBS and incubated with the secondary 
antibody (fluorescein- or rhodamine-conjugated goat or donkey anti-mouse, anti-rabbit or anti-
sheep IgG, respectively, dilution 1:50) for 1 h. After four washing steps with 1 ml 0.2% saponin 
in PBS, the coverslips were mounted on glass slides with Histogel. The mounted cells were 
analyzed with a laser scanning confocal microscope. 
 
Antibody  dilution 
rabbit anti-49K Carboxy-terminus (R25050) 1:300 
rabbit anti-49K N-terminal domain (R48-7/8B) 1:300 
rat mAb anti-49K N-terminal domain (supernatant) undiluted 
mouse mAb anti-lamp-2 (2D5, supernatant) 1:10 
mouse mAb anti-Calnexin (AF8) 1:100 
mouse mAb anti-Galactosyltransferase (GTL2) 1:200 
mouse mAb anti-LBPA (6C4) 1:100 
mouse mAb anti-g-adaptin 1:50 
mouse mAb anti-EEA1 1:50 
mouse mAb anti-transferrin-receptor (5E9C11, supernatant) undiluted 
mouse mAb anti-GM130 1:100 
sheep anti-TGN46 1:100 
rabbit anti-TGN46 1:100 
 
2.2.3.7 Flow cytometry analysis 
For flow cytometry analysis cells were washed once with PBS and detached with 1 mM EDTA in 
PBS. Cells were centrifuged (300 g, 5 min) and resuspended in FACS (fluorescence activated cell 
sorter) buffer. 30 µl with 300000-500000 cells were added to 70 µl FACS buffer containing the 
first antibody (ca. 1 µg purified antibody or undiluted hybridoma supernatant) in a well of a 96-
well plate. In the negative control no or isotype control antibody was added. After incubation for 
45 min at 4°C, cells were washed 3x with 190 µl FACS buffer and 50 µl of secondary antibody 
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solution (Sigma 1:50, Vector 1:300) was added. Subsequently, it was incubated for 40 min at 4°C 
in the dark. After three washing steps with 190 µl FACS buffer the cells were resuspended in 100 
µl FACS buffer and transferred to plastic tubes with 400 µl FACS buffer and 5000 cells were 
analyzed in a FACSCalibur flow cytometer. 
 
FACS buffer for cell surface staining: 
3% (v/v) FCS 
0.02% (w/v) NaN3 
in PBS 
 
FACS buffer for intracellular staining: 
0.1% (w/v) saponin  
3% (v/v) FCS 
0.02% (w/v) NaN3 
in PBS 
2.2.3.8 Flow-cytometry-based 49K binding assay 
For the investigation of 49K binding to the cell surface of different cell lines a modified flow 
cytometry protocol was applied. In variation from the standard protocol as described, cells were 
incubated 1 h with ca. 200 ng purified secreted 49K at 4°C prior to the incubation with the anti-
49K antibody (4D1, supernatant, undiluted). In the following, flow cytometry analysis was 
performed as described. 
2.2.3.9 NK cell-mediated lysis 
NK cell-mediated lysis was quantified in a standard chromium-51 assay as described (Schendel et 
al., 1979). Spontaneous release was determined by incubating target cells alone in complete 
medium. Total release was determined by directly counting an aliquot of labeled cells. The 
percent cytotoxicity was calculated according to the formula: lysis [%] = (experimental cpm -
spontaneous cpm/total cpm – spontaneous cpm) x 100. Total volume was 100 µl. Purified 
secreted 49K and controls were diluted and 25 µl were combined with Killer cells (NKL, clone 
234) in total volume of 50 µl. Preincubation, 30 min at RT to allow binding to receptor(s), was 
followed by addition of chromium-51 labeled target cells in 50 µl and a standard chromium-51 
assay. 
2.2.4 Protein techniques 
2.2.4.1 Metabolic labeling and immunoprecipitation   
A549 or 293 cells were grown on 6 cm Æ culture dishes to 80-90% confluency. After washing 
once with 5 ml MEM without methionine (and cysteine), cells were incubated with 2 ml MEM 
without methionine (and cysteine) for 1 h to deplete the intracellular levels of methionine (and 
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cysteine).  Then cells were metabolically labeled with 100 or 200 µCi [35S]-methionine or a 
mixture of [35S]-methionine and [35S]-cysteine for different time periods. In pulse/chase 
experiments, subsequently, the cells were washed with DMEM containing unlabeled methionine 
(and cysteine) and chased for different times with the same medium. Finally, the cells were 
washed once with cold DMEM and once with cold PBS. The cells were lysed with 1 ml IP-lysis 
buffer containing freshly added protease inhibitors at 4°C for 10 min. The supernatant was 
transferred to 1.5 ml tubes. After 15 min centrifugation at 14000 rpm (4°C, cooled 
microcentrifuge) the supernatants were transferred to new 1.5 ml tubes. To monitor the 
incorporation of radioactive label 5 µl lysate were added to 1 ml scintillation cocktail and the 
amount of radioactivity was measured with a b-counter. All further incubations were performed 
at 4°C. After adding 5 µl preserum (rabbit) to the rest of the lysate, it was incubated for 45 min 
rotating in an overhead mixer. Preequilibrated protein A-Sepharose was washed 3x with buffer B 
and a 50% slurry was prepared. 50 µl of the 50% slurry was added to each sample, followed by 
another incubation for 45 min rotating in an overhead mixer. The protein A-Sepharose beads 
were centrifuged for 30 s at 14000 rpm (microcentrifuge). The lysate was transferred to 5 µl 
specific serum (rabbit) in a new 1.5 ml tube and incubated for 45 min rotating in an overhead 
mixer. 50 µl of a 50% protein A-Sepharose slurry was added followed by another incubation for 
45 min rotating in an overhead mixer. The protein A-Sepharose beads were centrifuged for 30 s 
at 14000 rpm (microcentrifuge). The pellet was washed 3x with 1 ml buffer B, 2x with 1 ml 
buffer C and 1x with 1 ml 10 mM Tris pH 8. Finally, the pellet was centrifuged for 2 min at 
14000 rpm (microcentrifuge). The supernatant was completely removed and the samples were 
either directly resuspended in SDS sample buffer and analyzed by SDS-PAGE or were stored at 
–70°C.  
 
Redivue™ L-[35S]-methionine: 10 mCi/ml, specific activity >1000 Ci/mmol 
Promix™: 70% L-[35S]-methionine,  30% [35S]-cysteine, 14.3 mCi/ml, specific activity >1000 
Ci/mmol 
 
IP-lysis buffer:  1% Triton X-100  Buffer B: 0.2% Triton X-100 
   140 mM NaCl     150 mM NaCl pH 8.0 
   5 mM MgCl2     2 mM EDTA  
20 mM Tris pH 7.6    10 mM Tris pH 7.6 
 
added freshly       Buffer C: 0.2% Triton X-100 
from stock:  8 µg/ml PMSF    500 mM NaCl 
   10 µg/ml trypsin inhibitor   2 mM EDTA pH 8.0 
0.5 µg/ml leupeptin    10 mM Tris pH 7.6 
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Equilibration of protein A-Sepharose: 
1.5 g protein A-Sepharose CL-4B was washed 3x with 5 ml 100 mM Tris pH 8.0, 2x with 5 ml 50 
mM Tris pH 8.0, 1x with 5 ml 10 mM Tris pH 8.0. Finally, the protein A-Sepharose was 
resuspended in 10 mM Tris pH 8.0 to obtain a 50% slurry. 
2.2.4.2 Glycosidase digestions 
For endoglycosidase H (Endo H) treatment the protein A-Sepharose pellet with the 
immunoprecipitated protein was resuspended in 50 µl reaction buffer (0.1 M sodium citrate pH 
5.5) and incubated for 24 h at 37°C with 5 mU of Endo H from Streptomyces plicatus. The mock 
treated samples were incubated under the same conditions without Endo H. In the partial 
digestion experiment (Fig. 17) only 2 mU Endo H were used for each reaction and the incubation 
time was shortened to the times indicated. Treatment with neuraminidase, O-glycosidase and 
peptide-N-glycosidase F (PNGase F) was carried out sequentially: The protein A-Sepharose pellet 
with the immunoprecipitated protein was first resuspended in 50 µl reaction buffer (50 mM 
sodium phosphate pH 7.2) and incubated for 6 h at 37°C with 20 mU neuraminidase from 
Arthrobacter ureafaciens and/or 2 mU O-glycosidase from Diplococcus pneumoniae. Subsequently, the 
pellets were washed once with 1 ml 10 mM Tris pH 8.0 and resuspended in 12.5 µl 0.1 M b-
mercaptoethanol/0.5% SDS and incubated at 95°C for 5 min. 12.5 µl buffer including 1 U 
PNGase F of Flavobacterium meningosepticum was added to give final concentrations of 0.2 M Tris 
pH 8, 0.02 M EDTA, 2% IGEPAL and the sample was incubated for 20 h at 37°C. The mock 
treated samples were incubated under the same conditions without PNGase F. 
2.2.4.3 SDS PAGE 
2.2.4.3.1 Maxigel 
Gel electrophoresis was performed using 11.5 % or 7.5 % to 13.5 % gradient gels (200 x 300 x 1 
mm) (Laemmli, 1970). The two solutions for generating the separation gel were mixed in a 
gradient former and after pouring the gel, it was overlaid with isopropanol. After polymerization 
the isopropanol was removed by washing with H2O. The stacking gel solution was poured on top 
of the separation gel and a comb (20 wells, 0.8 cm wide) was fixed. After polymerization the glass 
plates containing the gel were assembled in the gel electrophoresis apparatus. Samples or pellets 
from immunoprecipitation were resuspended in 25 µl sample buffer and heated for 5 min to 
95°C. After cooling to RT 5 µl 0.5 M iodacetamide was added and samples were incubated for 15 
min at RT. Then the samples were centrifuged for 2 min at 14000 rpm (microcentrifuge) and 
loaded on the gel. 14C-methylated proteins were used as molecular weight markers. Separation 
was performed at 18-25 mA constant current for 12-18 h. Then the gel was fixed in fixing 
solution for 45 min, transferred to Whatman paper, covered with plastic foil and dried for 2 h at 
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80°C under vaccum in a gel dryer. Dried gels were exposed to BioMaxMR films at –70° C or 
phosphorimager screens at RT. Radioactive bands were quantified using a Storm 860 Molecular 
Imager. Films were developed using an automatic film developing machine. 
 
Separation gel :   7.5% 11.5% 13.5% 
Acrylamide/Bisacrylamide (29 :1) 10 ml 15.3 ml 18 ml 
2 M Tris pH 8.8   8.4 ml 8.4 ml 8.4 ml 
20 % SDS    0.2 ml 0.2 ml 0.2 ml 
H2O     21.4 ml 16.1 ml 3.4 ml 
60% sucrose    - - 10 ml 
10 % APS    120 µl 120 µl 120 µl 
TEMED    20 µl 20 µl  20 µl 
 
Stacking gel:              5%      
Acrylamide/Bisacrylamide (29:1) 5 ml 
0.5 M Tris pH 6.8   4 ml   
20 % SDS    0.15 ml 
H2O     14 ml 
60% sucrose    7 ml 
10 % APS    150 µl 
TEMED    15 µl 
 
Sample buffer (complete):  1 ml sample buffer pH 8.8 
     100 µl 0.5 M DTT (38.5 mg/500 µl) 
     200 µl 20% SDS 
Sample buffer pH 8.8 (stock):  10 ml 2 M Tris pH8.8 
     57.14 ml 60% sucrose  
     1 ml 500 mM EDTA 
     0.01 g bromophenolblue 
Fixing solution (1 l):   10% acetic acid 
     30% methanol 
Electrophoresis buffer (5 x):   0.28 g/l Tris 
     150.14 g/l glycine 
     0.5% SDS (added just before use, final conc.: 0.1%) 
2.2.4.3.2 Minigel 
Gel electrophoresis with minigels was performed using the Protean II system (Bio-Rad) with 
10% gels (80 x 50 x 1 mm). In general, the samples were mixed with 15 µl sample buffer (1:1) and 
the same procedure as described for maxigels was applied.  
 
Separation Gel :    10%     
Acrylamide/ Bisacrylamide (29:1)  1.665 ml 
2 M Tris pH 8.8    1.05 ml 
20 % SDS     0.2 ml 
H2O      2.24 ml 
10 % APS     20 µl 
TEMED     2.25 µl 
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Stacking gel:                  5%       
Acrylamide/ Bisacrylamide (29:1)  1.35 ml 
0.5 M Tris pH 6.8    0.7 ml   
20 % SDS     25 µl 
H2O      14 ml 
10 % APS     25 µl 
TEMED        5 µl 
 
Electrophoresis buffer (10 x):    30.28 g/l Tris 
      150.14 g/l glycine 
      1% SDS (added just before use, final conc.: 0.1%) 
2.2.4.4 Western blotting 
2.2.4.4.1 Preparation of cell lysate 
Cells were grown to 80-90% confluency in 6 cm Æ culture dishes, washed with PBS and lysed 
with 100 µl IP-lysis buffer. Cells were scraped from the dish with a rubber policemen, transferred 
to a 1.5 ml tube and incubated for 20 min on ice. After 15 min centrifugation at 14000 rpm 
(microcentrifuge) the supernatant was transferred to a new 1.5 ml tube and, if not used 
immediately, stored at –80°C. Protein concentration was determined using the Pierce BCA Kit. 
10 µg protein was loaded per lane on a minigel and SDS-PAGE analysis was performed prior to 
blotting. 
2.2.4.4.2 Protein blotting and detection 
Proteins were blotted on nitrocellulose membranes using the Trans-Blot SD Semidry Transfer 
Cell (Bio-Rad). A piece of nitrocellulose membrane and eight pieces of filter paper of the same 
size as the gel were soaked with transfer buffer. Four pieces of filter paper, the nitrocellulose 
membrane, the gel and another four pieces of filter paper were packed with the nitrocellulose 
facing the anode. Subsequently, air bubbles were removed and blotting was performed with 0.8 
mA/cm2 for 1.25 h. Proteins were detected after 2 min incubation in Ponceau staining solution. 
The position of marker proteins was labeled and the membrane was washed several times to 
remove the Ponceau staining solution. Unspecific binding sites were blocked by incubation in 
PBS, 0.05% Tween 20, 5% skim milk powder, 0.02% NaN3 o/n. Then incubation with the first 
antibody was performed in 5-10 ml PBS, 0.05% Tween 20 (used also in the following washing 
and incubation steps). After five washing steps of 15 min with ca. 200 ml buffer each incubation 
with the secondary antibody coupled to peroxidase was performed in 25 ml buffer followed by 
washing 5x 10 min and 1x 30 min in 200 ml buffer. Then the blotted proteins were detected 
using the ECL Western blotting detection system (Amersham-Pharmacia) according to the 
manufacturer’s instructions. The membrane was exposed to BIOMAX-MR autoradiography 
films for different time periods. 
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Transfer buffer (1l): Ponceau solution (100 ml): 
Tris base  5.8 g Ponceau S  0.5 g 
Glycine  2.9 g Glacial acetic acid 1 ml   
SDS 0.37 g H2O 98.5 ml 
Methanol 200 ml 
H2O to 1l 
 
Antibody dilution 
rabbit anti-49K Carboxy-terminus (R25050) 1:1000 
rabbit anti-49K N-terminal domain (R48-7/8B) 1:1000 
rat mAb anti-49K N-terminal domain (supernatant) 1:10 
rat mAb anti-E1B-19K 1:100 
rat mAb anti E1B-55K 1:100 
goat anti-rabbit peroxidase coupled 1:10000 – 1:20000 
goat anti-rat peroxidase coupled 1:5000 
 
2.2.4.5 Surface plasmon resonance 
In order test the in vitro binding of the clathrin adaptor complexes AP-1 and AP-2 an interaction 
analysis was performed by Stefan Höning, University of Göttingen, Göttingen, Germany 
(Honing et al., 1997). Peptides representing the cytoplasmic tail of 49K and with mutations of the 
potential endosomal/lysosomal sorting signal that might be crucial for the interaction with the 
adaptor complexes were coupled to a CM5 sensor chip. Interaction was analyzed using a BIAcore 
2000 (BIAcore AB). Purified AP-1 and AP-2 were used at 100 nM in buffer A and injected at a 
flow rate of 20 µl/min. Association (2 min) was followed by dissociation (2 min) during which 
buffer A was perfused. The equilibrium constant (KD) was determined as described (Honing et 
al., 1997). 
 
Analyzed peptides:     Buffer A:  20 mM HEPES pH 7.0 
WT:   CRKRPRAYNHMVDPLLSFSY   150 mM NaCl 
YA:   CRKRPRAANHMVDPLLSFSY   10 mM KCl 
LLAA:          CRKRPRAYNHMVDPAASFSY   2 mM MgCl 
YA/LLAA:  CRKRPRAANHMVDPAASFSY   0.2 mM dithiothreitol 
2.2.4.6 Purification and refolding of recombinant HisTag-fusion protein 
10 ml of an o/n culture of M15 [pREP4] containing the pQE-60-49K construct were added to 
200 ml of prewarmed selection medium (LB with 25 µg/ml kanamycin, 100 µg/ml ampicillin) 
and grown at 37°C to an OD600nm of 0.5-0.7. 1 ml medium was taken and after centrifugation the 
bacterial pellet was resuspended in 50 µl 2x Sample Buffer. 200 µl 1 M IPTG was added to the 
remaining medium followed by an 4 h incubation at 37°h. 1 ml medium was taken and after 
centrifugation the pellet was resuspended in 50 µl 2x Sample Buffer. The remaining bacteria were 
pelleted by centrifugation at 4000 g for 20 min and resuspended in 5 ml buffer ( 0.1 M sodium 
phosphate, 0.01 M Tris, pH 8 including 10 µM leupeptin, 1 µM pepstatin, 500 µM pefabloc, 10 
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µM bestatin) at 4°C. 1.5 mg lysozyme was added per g bacteria and after incubation for 30 min 
on ice bacteria were sonicated 6x for 10 s (output control level 7, 100 %) with a Branson Sonifier 
450. 0.5x volume buffer (0.1 M sodium phosphate, 0.01 M Tris, pH 8, 6% Triton X-100, 1.5 M 
NaCl) including protease inhibitors was added, and after 30 min incubation at 4°C inclusion 
bodies (IBs) were pelleted by 30 min centrifugation at 31000 g. The pellet was resuspended  in 20 
ml 0.1 M sodium phosphate, 0.01 M Tris, pH 8 including protease inhibitors with a Dounce 
tissue homogenizer and centrifuged again. Then the IB pellet was resuspended in 5 ml buffer (6 
M guanidine hydrochloride, 0.1 M sodium phosphate, 0.01 M Tris, pH 8, 5 mM b-
mercaptoethanol) using the Dounce tissue homogenizer. After incubation for 2 h at 25°C, debris 
was pelleted by centrifugation (10000 g) for 30 min at 4°C. The protein concentration was 
determined using the Bio-Rad protein assay kit (according to Bradford). 1 ml Ni-agarose beads 
slurry was mixed with 0.5-1 mg protein in 5 ml buffer (6 M guanidine hydrochloride, 0.1 M 
sodium phosphate, 0.01 M Tris pH 8, 5 mM b-mercaptoethanol) and incubated 1 h at RT. The 
suspension was transferred to a column. The beads were washed two times with 5 ml buffer (6 M 
guanidine hydrochloride, 0.1 M sodium phosphate, 0.01 M Tris, pH 7, 5 mM b-mercaptoethanol) 
and were resuspended rapidly in 30 ml degassed refolding buffer (0.1 M sodium phosphate, 0.01 
M Tris, pH 7.6, 0.3 mM GSSG, 3 mM GSH, 50 mM NaCl including protease inhibitors) and 
incubated rotating overnight at 4°C. Subsequently, the suspension was transferred to a column 
and washed twice with 5 ml buffer (0.1 M sodium phosphate, 0.01 M Tris, pH 7.6, 150 mM 
NaCl, 0.2 mM b-mercaptoethanol) after a frit had been assembled on top of the beads. Then the 
HisTag-fusion protein was eluted with 16x 0.5 ml elution buffer (0.1 M sodium phosphate, 0.01 
M Tris, pH 7.6, 150 mM NaCl, 0.2 mM b-mercaptoethanol, 250 mM imidazol). Eluted fractions 
were analyzed by SDS-PAGE. Protein concentration was determined by OD280nm. After washing 
two times with 5 ml buffer (0.1 M sodium phosphate, 0.01 M Tris, pH 7.6, 150 mM NaCl, 5 mM 
b-mercaptoethanol) and incubation for 1 h at RT in 5 ml buffer (6 M guanidine hydrochloride, 
0.1 M sodium phosphate, 0.01 M Tris, pH 8, 5 mM b-mercaptoethanol) the beads were 
regenerated by elution with 16x 0.5 ml buffer (6 M guanidine hydrochloride, 0.1 M sodium 
phosphate, 0.01 M Tris, pH 4.5, 5 mM b-mercaptoethanol) and washing with 2x 10 ml buffer 
(0.1 M sodium phosphate, 0.01 M Tris, pH 8). For SDS-PAGE analysis of fractions containing 
guanidine hydrochloride, protein was precipitated with 1x volume 10% trichloroacetic acid and 
during 20 min incubation on ice. After centrifugation at 14000 rpm (4°C, cooled microcentrifuge) 
for 15 min the pellet was washed with cold 100% EtOH followed by centrifugation for another 5 
min. Then the supernatant was carefully removed, the pellet air-dried and resuspended in sample 
buffer for analysis. 
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2.2.4.7 Production of rabbit polyclonal and rat monoclonal antibodies 
2.2.4.7.1 Rabbit polyclonal antibodies 
Rabbits were immunized with approximately 250 µg 49K-HisTag-fusion protein in 500 µl buffer 
mixed with 500 µl complete Freund’s adjuvant by subcutaneous (s.c.) injection. Boosts were 
performed in the same way ca. every 2-3 weeks but with incomplete Freund’s adjuvant replacing 
the complete Freund’s adjuvant. About 20 ml blood were recovered usually ca. 10 days after 
boosting. Serum was recovered by incubation at RT for several hours, 30 min incubation at 37°C 
and o/n at 4°C. Finally, the blood was centrifuged for 15 min at 3000 rpm (Heraeus Varifuge 
3.0R) and serum aliquots of 0.5-1 ml were prepared and stored at –70°C. 
The course of the antibody development was followed by immunoprecipitation experiments, and 
the rabbit was sacrificed when the specific activity of the antibodies remained constant. 
2.2.4.7.2 Rat monoclonal antibodies 
Rat monoclonal antibodies were generated by Elisabeth Kremmer, GSF, Munich, Germany 
(Kremmer et al., 1995). Lou/C rats were immunized 3x with 50 µg N49K-HisTag-fusion protein 
in intervals of three weeks. The first injection was done with complete Freund’s adjuvant, the 
second with incomplete Freund’s adjuvant both intraperitoneally and subcutaneously and the 
third without adjuvant intraperitoneally. Fusion of rat immune spleen cells with the myeloma cell 
line P3X63Ag8.653 was performed following the protocol of Köhler and Milstein 3 days after the 
final boost (Kohler and Milstein, 1992). Supernatants from hybridoma cells were tested for the 
presence of anti-49K antibodies by an enzyme-linked immunosorbent assay (ELISA). Microtiter 
plates were coated with approximately 0.5 µg/well N49K-Histag-fusion protein by incubation in 
0.2 M sodium carbonate buffer pH 9.5 o/n. Hybridoma supernatants were added and incubated 
30 min with constant shaking followed by 30 min incubation with peroxidase-coupled goat anti-
rat antibody. Finally, bound antibody was detected using the chromogen o-phenylenediamine in a 
peroxidase reaction. ELISA positive supernatants were tested in immunofluorescence for the 
detection of native 49K. Hybridoma cells producing antibodies recognizing native 49K (4D1, 
1E6) were subcloned at least twice by limiting dilution. The immunoglobulin-isotyps were 
determined by ELISA. 
2.2.4.8 Purification of secreted E3/49K 
2.2.4.8.1 Coupling of antibody to the protein G-Sepharose column 
5 ml 1 M Tris pH 7.4 was added to 50 ml of hybridoma supernatant containing anti-E3/49K rat 
monoclonal antibodies (4D1) in a concentration of about 40 µg/ml (total 2 mg). 1 ml protein G-
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Sepharose beads was washed three times with 10 ml 0.1 M Tris pH 7.4 and added to the 
hybridoma supernatant. After incubation for 2 h at RT and gentle mixing, the beads were washed 
three times with 0.2 M sodium borate pH 9.0 (centrifugation: 3000 g for 5 min) and then 
resuspended in 10 ml 0.2 M sodium borate. 100 µl of slurry was removed for analysis. 50 mg 
dimethyl pimelimidate (DMP) were added to give a final concentration of about 20 mM. 
Incubation was performed at RT with gentle mixing for 45 min. 100 µl of slurry was removed for 
analysis. The reaction was stopped by washing the beads once in 0.2 M ethanolamine pH 8 
followed by incubation for 2 h at RT in 0.2 M ethanolamine pH 8 with gentle mixing. Then the 
beads were washed three times with PBS and stored in PBS/0.01% merthiolate (thimerosal) at 
4°C. Efficiency of coupling was tested by SDS-PAGE with beads taken before and after the 
coupling reaction in order to evaluate the elution of antibody. 
2.2.4.8.2 Purification protocol 
Secreted E3/49K was purified from medium of cell lines stably expressing the E3/49K protein. 
In general, cells were grown in 150-175 cm2 (T175) plastic flasks to 80-90% confluency and 
washed once with DMEM without FCS. Thereafter, about 35 ml DMEM without FCS was 
added and cells were cultivated for 7-9 days. The medium was collected and contaminating cells 
were removed from the medium by centrifugation (500 g, 5 min). The medium was transferred to 
another tube and stored at 4 °C. 1/10x volume of 10x PBS and 1/100x volume 2% NaN3 were 
added as well as the protease inhibitors PMSF, trypsin inhibitor, leupeptin in the same 
concentrations as used in immunoprecipitation (chapter 2.2.4.1). To remove antibodies or other 
proteins binding to the protein G-Sepharose specifically or unspecifically the medium was 
preabsorbed on a protein G-Sepharose column with 2 ml beads: At first, the column was washed 
with 20 ml PBS. Then the medium was transferred to the column with a flow rate of 10-15 ml/h 
using a peristaltic pump. The column was washed with 20 ml PBS and 20 ml 10 mM sodium 
phosphate buffer pH 6.8. Bound protein was eluted with 10 ml glycine buffer pH 2.5 and 1 ml 
fractions were collected and neutralized with 100 µl 1 M Tris pH 8. For reconstitution, the 
protein G-Sepharose column was washed with 20 ml PBS and stored in PBS/0.01% merthiolate 
at 4°C. Prior to transferring the medium to the column with protein G-Sepharose coupled to the 
E3/49K specific antibodies, the column was washed with 20 ml PBS. The flow rate was adapted 
to approximately 5 ml/h using a peristaltic pump. After loading, the column was washed with 20 
ml PBS and 20 ml 10 mM sodium phosphate buffer pH 6.8. Then bound E3/49K was eluted 
with 8x 0.45 ml 0.1 M glycine buffer pH 3.0 and collected in tubes containing 75 µl 1 M Tris pH 
8.0. For reconstitution the column was washed with 20 ml PBS and then stored in PBS/0.01% 
merthiolate at 4°C. E3/49K in the eluted fractions was detected by Western blotting and silver 
staining.  
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2.2.4.9 Silver staining  
For silver staining (Blum et al., 1987), polyacrylamide gels were fixed in 30% methanol/10% 
acetic acid for at least 2 h and subsequently washed 3x for 30 min with 30% ethanol. Then the 
gels were transferred for 1 min to a 0.22 g Na2S2O3 x 5 H2O/l solution followed by washing with 
H2O 3x for 1 min. Subsequently, the gels were incubated with 2 g AgNO3/l, 0.025 % 
paraformaldehyde for 20-30 min, washed 3x with H2O for 1 min followed by the reduction step 
in 60 g Na2CO3/l, 0.0185 % paraformaldehyde, 4 mg Na2S2O3 x 5 H20/l for 1-10 min. 
Paraformaldehyde was added from a freshly thawed 16% stock solution stored at –20°C. Then 
the gels were washed 3x for 5 min with H2O and the reaction was stopped by a 10 min 
incubation in 30% methanol/10% acetic acid. Finally, the gels were incubated for more than 30 
min in 30% methanol and dried using Bio-Rad GelAir drying system. 
2.2.4.10 Coomassie blue staining 
For Coomassie blue staining of proteins, SDS-PAGE gels were incubated in Coomassie blue 
staining solution for 1-12 h and destained with 30% methanol/10% acetic acid by changing the 
destaining solution until the desired protein staining was visible. 
 
Coomassie blue staining solution: 0.25% Coomassie brilliant blue R-250 
     45% methanol 
     10% acetic acid 
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3 RESULTS 
3.1 Time course of Ad19a E3/49K synthesis during infection 
E3/49K was identified as a novel gene within the E3 region of the epidemic keratoconjunctivitis 
(EKC) causing Ad strain Ad19a (Deryckere and Burgert, 1996) and was recently shown to be 
specific for subgenus D Ads (Blusch et al., 2002). As E3/49K is encoded by the early 
transcription unit 3, it is supposed to be an early protein. However, some E3 proteins are only 
poorly expressed early but their expression is greatly amplified at late times (Li and Wold, 2000; 
Tollefson et al., 1992). Therefore, the expression of E3/49K during the course of infection was 
monitored in comparison to E3/19K, another early protein, and hexon, a late protein (Fig. 8).  
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FIG. 8. Time course of Ad19a E3/49K synthesis during infection. A549 cells were labeled with [35S]-methionine 
at different time points postinfection (p.i.). The start of infection was defined as the end of the 1 h adsorption 
period. The indicated times given on top of the figure correspond to the start of the 1 h labeling period. Lysates with 
equal amounts of radioactivity were used for immunoprecipitation. E3/49K (A), E3/19K (C), another early protein, 
and hexon (B), a late protein, were immunoprecipitated sequentially from the same lysates using the antibodies given 
in Materials and Methods. E3/49K is visualized by three defined bands with apparent molecular masses of 77-83 
kDa, designated b, c, and d, and a diffuse band of 87-100 kDa, designated a. E3/19K is represented by six bands 
differing in the number of N-glycans attached. 
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A549 cells were labeled for 1 h with [35S]-methionine at different time points postinfection (p.i.) 
and after immunoprecipitation, proteins were analyzed by SDS-PAGE. Several bands 
representing different forms of E3/49K could be visualized: Defined bands representing proteins 
with the apparent molecular mass of about 77-83 kDa (b-d) and a diffuse band representing 
proteins of about 87-100 kDa (a). Expression of E3/49K and E3/19K was first detected at 3 h 
p.i. and reached a maximum at 6 h p.i. In contrast to E3/19K expression that declines rapidly, 
E3/49K was still expressed late during infection. Interestingly, the glycosylation pattern of  
E3/49K seemed to change during the course of infection. The intensity of the diffuse band (a) 
decreased and concomitantly the intensity of one of the lower bands (b) increased in the late 
phase of infection. 
3.2 Carbohydrate processing of E3/49K early and late during infection 
To investigate whether this differential appearance, particularly the absence of the diffuse band 
late during infection (Fig. 8), was due to an impaired carbohydrate processing a pulse/chase 
analysis was performed early (6 h p.i., Fig. 9, lanes 1-7) and late (30 h p.i., Fig. 9, lanes 8-14) 
during infection. In the early phase of infection the E3/49K species represented by the defined 
lower bands b-d (Fig. 9, lane 1) were converted to the E3/49K forms represented by the diffuse 
upper band a (Fig. 9, lanes 2-7), presumably representing terminally glycosylated products. Late 
during infection this processing of the protein was severely impaired (Fig. 9, lanes 8-14). 
Interestingly, low molecular weight fragments were detected in the chased samples (60-240 min) 
early during infection indicating proteolytic processing (h, lanes 4-7). These were absent late 
during infection. Thus, carbohydrate as well as proteolytic processing was impaired late during 
infection. The half-life of Ad19a E3/49K was determined to be only ~2 h in the early phase of 
infection (6 h p.i.). In the late phase of infection (30 h p.i.) the half-life was significantly 
prolonged to more than 4 h. The half-life was defined by the time period after which half of the 
initial protein labeling could still be detected. 
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FIG. 9. Differential processing of E3/49K in the early and late phase of infection. A pulse/chase analysis was 
carried out 6 h p.i. (early) or 30 h p.i. (late). A549 cells were metabolically labeled for 20 min with 200 µCi/ml [35S]-
methionine/cysteine and subsequently chased with medium containing non-radioactive methionine/cysteine for the 
indicated periods of time. Ad19a E3/49K protein was immunoprecipitated (R25050) and analyzed by SDS-PAGE as 
in Fig. 8. Bands a-d represent different forms of E3/49K. In addition, during the chase low molecular weight 
fragments were detected (h). 
 
Then it was examined whether the observed processing defect of E3/49K in the late phase of 
infection is common also to host proteins by monitoring the processing of lysosome-associated 
membrane protein 1, lamp-1 (Fig. 10A), and the transferrin receptor (Fig. 10B). The 
interpretation of these data is complicated by the decreased expression of cellular proteins late 
during infection due to the host shutoff (Fig. 10C, compare lanes 10-15, 30 h p.i., with lanes 2-7, 
6 h p.i.). Nevertheless, it is obvious that lamp-1 exhibited also an impaired processing during the 
late phase of infection (Fig. 10A, compare lanes 10-15 with lanes 2-7). Early during infection 
high-mannose lamp-1 proteins were completely processed within 120 min chase (Fig. 10A, lanes 
2-5), whereas late during infection high-mannose lamp-1 forms were detected up to 240 min 
chase. Transferrin receptor on the other hand was not significantly affected (Fig. 10B, compare 
lanes 10-15 to lanes 2-7). Therefore, the inhibition of glycan processing was not a general 
phenomenon but rather seemed to affect a selective set of glycoproteins.  
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FIG. 10. Inhibition of glycan processing late during Ad19a infection is neither a 49K specific nor a general 
phenomenon. In a pulse/chase experiment as described in Fig. 9 the processing of cellular proteins lamp-1 (A) and 
transferrin receptor (B) was investigated by immunoprecipitation using antibodies described in Materials and 
Methods. High-mannose and complex glycan containing protein species are indicated. 30 h postinfection synthesis 
of cellular proteins was dramatically decreased, also shown by analysis of 5 µl of total cell lysate (C).  
 
3.3 E3/49K expression in 293 and A549 cell lines 
To investigate 49K independently of the viral context, e.g. glycan or proteolyic processing and 
localization, cell lines stably expressing 49K were established (Fig. 11). A549 and 293 cells were 
transfected with a pSG5 vector (Stratagene) containing the Ad19a gene under control of the early 
SV40 promoter with the intron II of the rabbit b–globin gene located at the 5’-end of the 49K 
gene. Clones stably expressing 49K were isolated as described in Materials and Methods. Most 
293 clones exhibited in addition to the 49K-specific bands detected in infection two bands 
representing protein(s) with a molecular mass of approximately 47 and 57 kDa (e.g. K62). Only 
few 293 clones reproduced the pattern seen in infection (e.g. K35). Data from pulse/chase 
experiments and Western blotting analysis indicated that the 57 kDa protein is a degradation 
product of 49K, whereas the 47 kDa protein coprecipitates with 49K (data not shown). These 
bands were not detected in A549 cell lines expressing 49K. Interestingly, the low molecular 
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weight fragments (h) observed in infection (Fig. 9) were also detected in 293 as well as in A549 
clones expressing 49K. Thus, the carbohydrate and proteolytic processing of 49K seen in 
infection could be reproduced in A549 and partly in 293 cell lines stably expressing 49K. In the 
following, A549 cell lines were used as a model system to investigate biochemical and functional 
features of 49K. 
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FIG. 11. Expression of E3/49K in A549 and 293 cell lines. A549 and 293 cell lines stably expressing the 49K 
protein were established using a pSG5-49K construct as described in Materials and Methods. After 2 h metabolic 
labeling 49K cells were lysed and immunoprecipitation (R25050) was followed by SDS-PAGE analysis. 
 
3.4 Expression of the N-terminal ectodomain of Ad19a E3/49K as a HisTag-fusion 
protein in E.coli 
The low molecular weight fragments detected in Ad19a-infected and 49K-transfected cells 
indicated that 49K is proteolytically processed. The antibodies utilized in these experiments 
recognized the C-terminus of 49K. Therefore, a proteolytic cleavage was postulated which 
separated the short C-terminal part that was detected in immunoprecipitation from the N-
terminal part of 49K. The fate of the large N-terminal part of the protein remained elusive. Two 
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possibilities were envisaged: Proteolytic degradation or release of the ectodomain to an 
intracellular compartment or to the extracellular space, i.e. secretion.  
To address this question the N-terminal part of the protein was expressed as a HisTag-fusion 
protein in E. coli (Fig. 12). Upon induction, a significant part of the bacterial proteins was 
constituted by the 49K-HisTag-fusion protein (Fig. 12A, compare lanes 1 and 2). The protein 
was found mainly in inclusion bodies (Fig. 12A, lanes 3 and 4) but could be purified after 
solubilization with guanidinium hydrochloride.  
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FIG. 12. Purification of the N-terminal ectodomain of 49K expressed as a HisTag-fusion protein. A) 
Expression of the 49K-HisTag-fusion protein encompassing residues 20-382 of 49K (Fig. 6) in E. coli. The DNA 
encoding the N-terminal part of 49K was PCR amplified using the primers 49K5’NCO and 49K3’BAM as described 
in Materials and Methods. This fragment was cloned into the pQE-60 expression vector (Qiagen) after restriction 
endonuclease digestion with NcoI and BamHI. The sequence was confirmed by sequencing. The 49K-HisTag-fusion 
protein was expressed as described in Materials and Methods. E. coli cell lysates from IPTG induced (A, lane 2) or 
uninduced cultures (lane 1, 100 µl out of 200 ml culture) were analyzed by SDS-PAGE as well as samples from 
supernatant (lane 4, 5 µl out of 5 ml) or the resuspended pellet including inclusion bodies (IBs) (lane 3, 1 µl out of 2 
ml) obtained after sonication. From 200 ml culture 15-20 mg of HisTag-fusion protein were obtained that was 
exclusively found in inclusion bodies. 49K-specific bands are indicated by arrows. B) Presence of disulfide bonds in 
the 49K-HisTag-fusion protein expressed in E.coli. The 49K-HisTag-fusion protein contained disulfide bonds in E. 
coli as indicated by the observed shift upon reduction with DTT (compare lanes 1 and 2, E. coli cell lysates). C) 
Elution of refolded 49K-HisTag-fusion protein. After refolding on the Ni-agarose column, 49K-HisTag-fusion 
protein was eluted as described in Materials and Methods. 500 µl fractions were recovered (designated E1-E15) 
which contained protein in a max. concentration of about 300–500 µg/ml, as measured by OD280nm. 10 µl per 
fraction were analyzed by SDS-PAGE (C, lanes 1-9). 
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Interestingly, the 49K-HisTag-fusion protein contained intramolecular disulfide bonds as 
indicated by the faster migration of 49K-HisTag-fusion protein in the absence of the reducing 
agent dithiothreitol (DTT) (Fig. 12B, compare lanes 1 and 2). These disulfide bonds could not be 
resolved by addition of b-mercaptoethanol to the solubilization buffer (data not shown). In order 
to generate a 49K-HisTag-fusion protein that adopts a rather native structure, it was attempted to 
refold 49K, while bound to the Ni-agarose column used for the purification of the HisTag-fusion 
protein, and to elute the refolded protein (Fig. 12C). The eluted proteins contained disulfide 
bonds (data not shown). The molecular weight difference (ca. 1.2 kDa) between 49K-HisTag-
fusion protein with or without disulfide bonds observed in SDS-PAGE analysis is very similar to 
that seen in WT E3/49K expressed during infection (ca. 1.1 kDa, Fig. 20).  
3.5 Production of polyclonal and monoclonal antibodies directed against the N-
terminal domain of E3/49K 
Recombinant E3/49K was utilized to generate polyclonal rabbit antibodies and monoclonal rat 
antibodies (the latter in cooperation with Elisabeth Kremmer, GSF, Munich, Germany). With 
antisera derived from immunized rabbits, 49K could be immunoprecipitated from lysates of 
Ad19a-infected A549 cells (Fig. 13). 
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Fig. 13. Production of polyclonal rabbit antiserum against 49K. Two rabbits were immunized with 
approximately 250 µg of refolded 49K-HisTag-fusion-protein (rabbit and derived sera named R48) or 250 µg 
inclusion bodies (rabbit and derived sera named R47) and boosted several times with the same amount of protein. 5 
µl rabbit antiserum (from R48), prepared as described in Materials and Methods, were tested in immunoprecipitation 
using lysates of Ad19a- (lanes 1-6) or mock- (lane 7) infected A549 cells after 1 h metabolic labeling. After eight (ten) 
boosts no further increase in the activity of the antibodies obtained from R48 (R47) in immunoprecipitation was 
detected and the rabbit was sacrificed. The antiserum obtained from rabbit R48 showed higher specific activity in 
immunoprecipitation and was used in the following studies. 
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These antisera detected 49K also in Western blots (Fig. 14, lane 2). As expected, antibodies 
directed against the N-terminus of E3/49K recognized only the high molecular weight forms of 
E3/49K, whereas antibodies directed against the C-terminus recognized in addition the low 
molecular weight fragments (Fig. 14, compare lane 2 with lane 4). These fragments appear in this 
experiment as one band due to limited separation in the minigel. This also demonstrated clearly 
that the low molecular weight fragments detected in the immunoprecipitation are 49K-derived 
and do not represent coprecipitated proteins. 
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FIG. 14. Western blotting with antibodies directed against the N- and the C-terminus of 49K. Full-length 
49K could be detected after SDS-PAGE analysis of lysates of Ad19a- (lanes 2, 4) or mock- (lanes 1, 3) infected A549 
cells 24 h p.i. (10 µg total protein/lane) with antibodies directed against the N- (R48-8B) and the C-terminus 
(R25044) in Western blotting (lanes 2, 4). Low molecular weight fragments could be detected only with antibodies 
directed against the C-terminus (lane 4). 
 
Hybridoma cell supernatants containing rat monoclonal antibodies showed differential activities 
in different immunoassays (Tab. 4, data not shown). Differences are, if not caused by different 
antibody concentrations, most likely based on the differences in the recognition of epitopes 
between the 49K-HisTag-fusion protein expressed in E. coli and the WT 49K protein expressed 
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upon Ad19a infection in eukaryotic cells. In particular, misfolding and the lack of glycosylation in 
the 49K-HisTag-fusion protein might lead to the generation of antibodies recognizing 49K-
HisTag-fusion protein epitopes that are not accessible in the WT 49K protein. As antibodies 
from clone 4D1 recognized 49K in immunofluorescence, immunoprecipitation, Western blotting 
and flow cytometry, in the following experiments these antibodies were utilized. The isotypes of 
antibodies from clone 4D1 and 1E6 were determined to be both isotype IgG2a. 
 
Tab. 4: Activity of ELISA-positive supernatants of hybridoma cell lines containing rat    
            monoclonal antibodies in different immunoassays 
 
Supernatants 
(mAb) from 
hybridoma 
clones 
IF IP Western Flow 
cytometry 
(fixed, 
internal) 
Flow 
cytometry 
(surface) 
1E6 + + + - + 
1F4 - - + - - 
1H8 - +/- ++ - - 
4D1 +++ ++ +++ + ++ 
5A7 - - - - - 
5D3 - - ++ - - 
6C9 - - - - - 
6C12 - - - - - 
7H10 - - - - - 
10A11 - - - - - 
-: No activity; +/-: Poor activity; +: Low activity; ++: Medium activity; +++: High activity 
3.6 Proteolytic processing and secretion of E3/49K 
The antibodies directed against the N-terminal part of protein made it possible to address the fate 
of the N-terminal portion of 49K. 49K was immunoprecipitated from lysates and supernatants of 
Ad19a-infected A549 cells (Fig. 15A, B) and 49K-transfected cells (Fig. 15C, D) in a pulse/chase 
experiment with antibodies directed against the C-terminal or the N-terminal part of 49K. With 
antibodies directed against the C-terminus, 49K could be precipitated from lysates but not from 
the supernatants (Fig. 15A, C). Strikingly, with antibodies against the N-terminus, 49K could be 
precipitated from lysates as well as from the supernatants demonstrating that the N-terminal 
portion of the protein is secreted (Fig. 15B, D). Low molecular weight fragments were detected 
in the chased samples intracellularly only with antibodies directed against the C-terminus (A, C) 
not with antibodies against the N-terminus (B, D). This finding confirmed that these fragments 
were derived from the C-terminus of 49K. The proteolytic processing was observed in Ad19a-
infected and 49K-transfected cells in the absence of additional viral gene products demonstrating 
that the proteolytic processing of 49K is independent of the viral context. Therefore, the 
proteolytic cleavage of 49K is executed by cellular proteases.   
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FIG. 15. Proteolytic processing and secretion of E3/49K. Ad19a-infected A549 (A, B, 16 h p.i.) and 49K-
transfected A549 cells (C, D, A549 clone K27S) were metabolically labeled for 30 min with [35S]-methionine and 
chased with medium containing non-radioactive methionine for the indicated times. Subsequently, E3/49K was 
precipitated from cell lysates and from supernatants with antibodies directed against the C-terminus (R25050, A, C) 
or N-terminus (R48-1B, B, D). 
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In the  lysate and in the supernatant of infected cells the abundant hexon protein is detected (designated with a star) 
which unspecifically coprecipitates with several antibodies. 
                                                                                                                                            Results 
 61
3.7 Fully processed E3/49K proteins contain high-mannose and/or hybrid in addition 
to complex N-glycans 
The difference between the apparent molecular mass of 80-100 kDa in SDS-PAGE and the 
calculated molecular mass of the protein backbone of 46,915 kDa (without signal sequence) 
indicated that E3/49K is highly glycosylated. The appearance of the three E3/49K species b-d in 
the pulse labeled sample (Fig. 9, lane 1) indicated that they represent the high-mannose forms of 
the protein that are further processed to the protein species represented by the diffuse upper 
band a (Fig. 9), supposedly containing complex glycans. 
To verify this idea, a pulse/chase experiment was performed and immunoprecipitated E3/49K 
from lysates and supernatants was treated with endoglycosidase H (Endo H, Fig. 16A, B). Endo 
H cleaves high-mannose and hybrid, but not complex carbohydrates. Endo H treatment of the 
pulsed lysate sample (Fig. 16A, lane 2) resulted in a decrease of the apparent molecular mass and 
the appearance of two prominent protein species of about 50 and 53 kDa (f and g), respectively 
(Fig. 16A, lane 10), demonstrating that only high-mannose and/or hybrid N-glycans were 
present. The 53 kDa species represents E3/49K with one N-linked glycan. Its appearance is due 
to incomplete Endo H digestion and was not observed after Endo H treatment under denaturing 
conditions (data not shown), Endo F treatment (Blusch et al., 2002) or PNGase F treatment (Fig. 
18A, lane 11). In parallel to the appearance of the diffuse upper band in the mock treated lysate 
samples (20’-240’ chase, Fig. 16A, lanes 3-8), E3/49K forms of 67-92 kDa were visualized in the 
Endo H treated samples (e, Fig. 16A, lanes 11-16). As these forms migrated faster than the 
heterogenous species of 87-100 kDa appearing in the untreated samples, the processed form of 
E3/49K was obviously not completely resistant to Endo H. Therefore, the processed E3/49K 
contained complex N-glycans and/or O-glycans not cleavable by Endo H but also high-mannose 
and/or hybrid N-linked sugars cleavable by Endo H. While the 87-100 kDa band of E3/49K 
disappeared gradually during the chase, small fragments of 12-13 kDa (h) were precipitated in 
increasing amounts. These fragments were not sensitive to Endo H digestion indicating that they 
are either not glycosylated or that the attached glycan(s) are Endo H resistant. Endo H treatment 
of secreted 77-90 kDa 49K species in the supernatant, which seemed to correspond to the 
heterogenous species of 87-100 kDa in the lysate, were partially Endo H sensitive indicated by 
the shift to an apparent molecular mass of 62-86 kDa (Fig. 16B). In addition, a weak 49K-related 
band corresponding to protein species of approximately 50-60 kDa was detected in the 
supernatant during the chase (Fig. 16B, lanes 6-8). 
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FIG. 16. Mature E3/49K protein remains partially Endo H sensitive. A549 cells were infected with Ad19a.  At 
6 h p.i. cells were labeled for 20 min with [35S]-methionine and then chased for the time periods indicated. Two 
culture dishes were mock-infected (lanes 1 and 9). Lysates (A) and supernatants (B) were collected. For each time 
point, two culture dishes were lysed, the lysates (supernatants) were pooled and then split into two aliquots for 
E3/49K immunoprecipitation: one sample was treated with Endo H for 24 h (lanes 9-16), the other one was mock- 
treated (lanes 1-8). A) Endo H treatment of 49K immunoprecipitated from lysates generated the protein species e-g. 
Band f corresponds to 49K molecules containing a residual oligosaccharide chain (53 kDa) that is not efficiently 
removed under the non-denaturing conditions used. When 49K immunoprecipitates were denatured prior to Endo 
H treatment or incubated with Endo F (data not shown), only the 50 kDa form with all N-linked glycans removed 
(g) and the heterogeneous species of 67-92 kDa, designated e, is visualized. B) The secreted form of 49K is still Endo 
H sensitive in a similar fashion as the mature intracellular 49K species of 87-100 kDa. 
 
3.8 Only 12-13 of the 14 predicted N-glycosylation sites of E3/49K are utilized 
To investigate how many of the 14 predicted N-glycosylation sites are actually utilized, E3/49K 
was immunoprecipitated from Ad19a-infected A549 cells after metabolic labeling for 20 min. 
During this labeling period E3/49K is supposed to contain exclusively high-mannose N-glycans. 
By incubation with Endo H for different time periods and subsequent analysis of the samples by 
SDS-PAGE, partially deglycosylated forms of E3/49K could be differentiated that differ by one 
glycan each (Fig. 17). By counting the various forms it is obvious that the E3/49K form with the 
highest apparent molecular mass contained 13 N-linked glycans, but the great majority of 
E3/49K proteins had only 12 carbohydrates attached. Therefore, not all of the 14 predicted N-
glycosylation sites were utilized.  
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FIG. 17. Not all of the predicted N-glycosylation sites are utilized. E3/49K was immunoprecipitated after 20 
min metabolic labeling of Ad19a-infected A549 cells 6 h p.i. and incubated with Endo H for the times indicated on 
top of the figure. Digested material was analyzed by SDS-PAGE, resulting in a series of 49K molecules differing by 
one oligosaccharide chain. The number of attached N-glycans for each 49K species is indicated on the right. 
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3.9 Evidence for O-glycosylation of E3/49K 
The pulse/chase analysis of E3/49K (Fig. 16) demonstrated that the protein became partially 
Endo H resistant indicating the presence of complex N-glycans and/or O-glycans. E3/49K is 
predicted to contain three O-glycosylation sites (Hansen et al., 1998) (Fig. 6). To experimentally 
substantiate this prediction, Ad19a-infected A549 cells were pulse labeled for 1 h and chased for 
1 h to generate fully processed potentially O-glycosylated E3/49K molecules. To compare the 
glycosylation of 49K in infected and 49K-transfected cells, in addition, 49K-transfected A549 
cells were labeled 2 h. Subsequently, the protein was immunoprecipitated and treated with 
various glycosidases (Fig. 18A, B). To facilitate the detection of O-linked carbohydrates, all N-
linked sugars were removed by treating immunoprecipitated E3/49K with PNGase F (Fig. 18A, 
lane 7-11; B, lane 4-7). By cleaving N-linked glycans this enzyme converts glycan-linked 
asparagine residues into aspartic acid residues, which changed the migration behavior of the 
protein due to the added negative charges (data not shown). As a reference for potential 
modifications occurring during the chase, E3/49K was immunoprecipitated from pulse labeled 
cells (A, 20 min; B, 30 min) and treated with PNGase F. This generated an E3/49K molecule (k) 
without glycan structures, but containing aspartates instead of asparagines (Fig. 18A, lane 11; B, 
lane 7). Two E3/49K species (i) with an apparent molecular mass of ~53-54 kDa could be 
differentiated after PNGase F treatment of the chased protein (Fig. 18A, lane 7; B, lane 4), that 
migrated slower than the pulsed PNGase F treated form (k) with about 50 kDa (Fig. 18A, lane 
11; B, lane 7). This indicates the presence of a posttranslational modification in addition to N-
glycosylation. The reduction of the apparent molecular mass of the PNGase F treated form upon 
neuraminidase treatment (j) to ~52 kDa (Fig. 18A, lane 9; B, lane 5) clearly demonstrates the 
presence of glycan structures containing sialic acid even after PNGase F treatment and indicates 
O-glycosylation. However, the utilized O-glycosidase from Diplococcus pneumoniae had no effect 
either used alone (Fig. 18A, lanes 3 and 8 (+PNGase F)) or in combination with neuraminidase 
that removes attached sialic acid groups potentially inhibiting O-glycosidase activity (Fig. 18A, 
lanes 4 and 10 (+PNGase F); B, lanes 1 and 6 (+PNGase F)). But the O-glycosidase decreased 
the apparent molecular mass of CD46, a highly O-glycosylated protein (Liszewski et al., 1991) 
(Fig. 18B, lanes 8 and 13, compare with lanes 9 and 12, respectively), which was used as a positive 
control for the O-glycosidase activity. Interestingly, in an experiment with a high MOI of ~10, in 
which most cells were infected with Ad19a (6 h p.i.), CD46 synthesis was decreased to 
undetectable levels (data not shown). Thus, this phenomenon seems to be Ad-induced and may 
have implications for Ad immune evasion and replication. The O-glycosidase used in these 
experiments removes the disaccharide core Galb(1-3) GalNAc of O-glycans only if no other 
carbohydrate groups, e.g. sialic acid, are attached to the core. The finding that neuraminidase 
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treatment caused a shift after all N-glycans were removed can only be explained by the presence 
of O-glycans that contained sialic acids. Thus, the lack of sensitivity for the O-glycosidase was 
either due to the presence of O-glycan core structures, which cannot be cleaved by the O-
glycosidase used, or the inaccessibility of the disaccharide core Galb(1-3)GalNAc. Interestingly, 
the low molecular weight fragments (h) were not sensitive to any of the treatments suggesting 
that they are not glycosylated (Fig. 18A, lanes 2-10, B, lanes 1-6). 
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FIG. 18. Evidence for O-glycosylation of E3/49K. Ad19a-infected (6 h p.i., A) and 49K-transfected A549 cells 
(K27S, B) were labeled for 1 h with [35S]-methionine/cysteine and chased for an additional hour with medium 
containing unlabeled methionine/cysteine (A) or were labeled for 2 h (B). To obtain a source of unprocessed 49K, 
one culture dish of cells was labeled for 20 min (A) or 30 min (B) with [35S]-methionine/cysteine (A, lane 11; B, lane 
7, 14). E3/49K and CD46 were sequentially immunoprecipitated from the same lysates and were incubated with 
different glycosidases as indicated on top of the figure and analyzed by SDS-PAGE. Endoglycosidase H cleaves only 
high-mannose and hybrid N-linked glycan structures. PNGase F removes all N-linked glycans. The O-glycosidase 
from Diplococcus pneumoniae cleaves only the unmodified disaccharide Gal(b1®3)GalNAc, one of the core structures 
of O-glycans bound to Ser/Thr. (C) To compare glycosylation of 49K in A549 and 293 cells, Ad19a-infected (lane 2-
5), 49K-transfected A549 cells (lane 6-9) and 49K-transfected 293 cells (11-14) were metabolically labeled for 2 h. 
49K was immunoprecipitated and digested with glycosidases as indicated. For tunicamycin treatment 10 µg/ml 
tunicamycin were included in the starvation medium and were present during labeling. 
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The N- and O-glycosylation patterns of E3/49K in Ad19a-infected and 49K-transfected cells are 
very similar (compare Fig. 18A and 18B). Only the molecular mass of processed 49K seems to be 
slightly higher in transfected cells (Fig. 18C, compare lane 2 with lane 6). Thus, the viral context 
has no major effect on carbohydrate processing of Ad19a E3/49K, proteolyic processing and 
secretion (Fig. 15). Therefore, the intracellular processing is an intrinsic property of the E3/49K 
protein.  
Interestingly, the glycan processing of 49K in 293 cells seems to differ partly from that in A549 
cells indicated by the higher molecular weight of the PNGase F treated 49K forms (Fig. 18C, 
compare lanes 4 and 8 with lane 13). Therefore, 49K might be more extensively O-glycosylated 
or O-glycans may contain more sugar groups in 293 cells. Another explanation would be the 
presence of additional posttranslational modifications, e.g. phosphorylation. 
3.10 Kinetics of E3/49K processing 
The overall processing kinetics of 49K in Ad19a-infected cells (Fig. 19A) and a 49K-transfected 
cell line (Fig. 19B) are very similar. In general, the processing in the cell line is slightly faster. The 
high-mannose forms of 49K, which are produced cotranslationally, are the main 49K species 
present after the pulse (0 h). They are converted to 49K proteins containing hybrid and complex 
N-glycans as well as O-glycans. The half-life of the high-mannose forms was 30-35 min in 
infected cells, 20-25 min in 49K-transfected cells. The quantity of complex and hybrid sugar 
containing mature 49K proteins reaches a maximum at ~60 min chase. This is also the first time 
point at which C-terminal low molecular weight fragments are detected intracellularly and the 
secreted N-terminal ectodomain is detected in the supernatant. Most likely only the terminally 
processed 49K proteins are proteolytically processed. During the following chase time their 
quantity decreases constantly. The half-life of the mature 49K species was 40-60 min in infected 
cells and 30-50 min in 49K transfected cells assuming a first order rate law for the elimination of 
mature 49K. The amounts of low molecular weight C-terminal fragments intracellularly and 
secreted 49K in the supernatant increase during the chase. However, after 240 min only ca. 10% 
of the initial labeling is recovered in the cytoplasmic tail fragments and only 10-15 % in the 
secreted 49K in the supernatant. The overall half-life was 120 min in infected cells, 80-100 min in 
49K-transfected cells. 
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FIG. 19. Processing kinetics of 49K in Ad19a-infected (A) and 49K-transfected (K27S, B) A549 cells. For the 
data of 49K processing in Ad19a-infected cells results of four independent experiments were analyzed, for the 49K 
processing in transfected cell lines the result of a single experiment is shown. The initial labeling after the pulse (20 
min in infection, 30 min in the 49K transfectant) was used as a reference (100%). The high-mannose forms are 
represented by the bands b-d (e.g. in Fig. 9), the complex form by the band a (e.g. in Fig. 9) and the low molecular 
weight fragments by the band h (e.g. in Fig. 9). Immunoprecipitation was performed with the antibodies directed 
against the C-terminus from cell lysates and with antibodies directed against the N-terminus from supernatants. Data 
were analyzed with SigmaPlot for Windows Version 5.00. 
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3.11 E3/49K contains intramolecular disulfide bonds 
There are six cysteine residues in the lumenal domain of E3/49K capable to form intramolecular 
disulfide bonds or S-S mediated E3/49K multimers  (Fig. 6A, B). To investigate the presence of 
disulfide bonds in E3/49K, the protein was immunoprecipitated and analyzed by SDS-PAGE in 
the presence and absence of the reducing agent dithiothreitol (Fig. 20). To evaluate the potential 
apparent molecular mass changes more easily, the experiment was also performed in the presence 
of tunicamycin, an inhibitor of N-glycosylation (Duksin and Mahoney, 1982) (Fig. 20, lanes 1, 2). 
In both cases E3/49K migrated faster without dithiothreitol demonstrating the presence of 
intramolecular disulfide bonds. The difference in the migration behavior corresponded to ~1.1 
kDa. Compared to the altered migration of the major histocompatibility complex (MHC) class I 
heavy chain containing two loops of ~60 amino acids that corresponded to about 1.2 kDa (data 
not shown), this rather small shift suggests that no large disulfide bonded loops are formed. 
Thus, it is likely that the six cysteine residues in the luminal domain form three disulfide bonds, in 
which neighboring cysteines are linked, creating loops of 13 and 9 amino acids respectively (Fig. 
6B). 
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FIG. 20. E3/49K contains intramolecular disulfide bonds. Ad19a-infected A549 cells were preincubated in 
methionine/cysteine free medium containing (lanes 1 and 2) or not containing 10 µg/ml tunicamycin (lanes 3 and 4). 
After 1 h metabolic labeling with [35S]-methionine/cysteine in the presence (lanes 1 and 2) or absence (lanes 3 and 4) 
of 10 µg/ml tunicamycin, E3/49K was immunoprecipitated. Immunoprecipitates were heated for 5 min to 95°C in 
the presence (lanes 2 and 4) or absence (lanes 1 and 3) of the reducing agent dithiothreitol (DTT) prior to SDS-
PAGE analysis. 
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3.12 Intracellular staining patterns detected with antibodies directed against the N- and 
the C-terminus of E3/49K early during infection are indistinguishable  
In order to find out how the intracellular trafficking of 49K may be connected to the proteolytic 
processing and to gain insight into a potential function of 49K, immunofluorescence studies were 
performed. Primary foreskin fibroblasts (SeBu) were utilized because intracellular compartments 
can be more readily differentiated in these cells than in immortal cell lines, e.g. A549, with a more 
condensed cytoplasm. Since 49K is proteolytically cleaved resulting in the separation of C- and 
N-terminus, it was first examined whether C- and N-terminus of 49K colocalize or may follow 
partly different trafficking pathways in Ad19a-infected SeBu cells 12-15 h p.i. This time point 
corresponds to the early phase of infection in SeBu cells. The intracellular staining patterns of 
49K detected with C- and N-terminal antibodies were indistinguishable (Fig. 21). Therefore, full-
length proteins and the C-terminal fragments generated by the proteolytic processing seem to 
follow very similar intracellular trafficking pathways. With both antibodies a perinuclear, vesicular 
and tubular compartment and numerous vesicles in the periphery of the cell were stained.  
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FIG. 21. Intracellular colocalization of the C- and the N-terminus of 49K. Primary fibroblasts (SeBu) were 
infected with Ad19a and processed for confocal laser microscopy 12-15 h p.i. as described in Materials and Methods. 
The localization of the C-terminus of 49K was analyzed with a polyclonal rabbit antiserum (R25050, green) and that 
of the N-terminus with a monoclonal rat antibody (4D1, red).  
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3.13 E3/49K localizes to the Golgi/trans-Golgi-network (TGN) and early endosomal 
vesicles early during infection 
In colocalization studies with various cellular marker proteins it was analyzed, in which 
intracellular compartments E3/49K is localized. Hardly any colocalization with the ER marker 
calnexin was found (Fig. 22A). The perinuclear structure could be identified as the Golgi/trans-
Golgi network (TGN) by colocalization with GM130, a marker for the cis-Golgi cisternae 
(Nakamura et al., 1995) (Fig. 22B), b1®4-Galactosyltransferase, a marker for trans-Golgi 
cisternae and the TGN (Nilsson et al., 1993) (Fig. 22C), AP-1 (Fig. 22D) and TGN46 (Fig. 26B), 
both markers for the TGN (Ahle et al., 1988; Ponnambalam et al., 1996). To distinguish between 
the Golgi complex and the TGN, brefeldin A (BFA) was used (data not shown), a drug reported 
to have differential effects on proteins of the Golgi complex and the TGN (Klausner et al., 
1992). Whereas proteins of the Golgi complex redistribute to the ER, the TGN collapses onto 
the microtubule-organizing center (MTOC) (Ladinsky and Howell, 1992; Reaves and Banting, 
1992). Upon BFA treatment, E3/49K staining of the perinuclear region disappeared almost 
completely and a slightly increased ER staining was detected in Ad19a-infected SeBu cells (data 
not shown). However, like TGN46, E3/49K was also detected in a perinuclear spot. This 
suggests that at steady-state E3/49K was present in the TGN as well as in the Golgi complex.  
Interestingly, the integrity of the Golgi/TGN was disturbed by the Ad19a infection. In 
uninfected cells the Golgi/TGN was represented by a number of tubules (Fig. 26A), whereas in 
infected cells the Golgi/TGN exhibited a rather vesicular appearance (Fig. 26B). Since this effect 
was already observed 12-15 h p.i., it seems to be mediated by early Ad gene products and is not 
related to late phenomena like host shutoff. Currently it is unknown whether this phenomenon is 
related to the inhibition of 49K and lamp-1 processing late during infection (Fig. 9, 10A). 
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FIG. 22. E3/49K localizes to the Golgi/trans-Golgi network. Primary fibroblasts (SeBu) were infected with 
Ad19a and processed for confocal laser microscopy 12-15 h p.i. Intracellular localization of E3/49K (green, R25050) 
was compared to that of marker proteins (red) for different cellular compartments: A) calnexin (endoplasmic 
reticulum); B) GM130 (cis-Golgi); C) GalT (trans-Golgi/TGN); D) AP-1 (TGN). The antibodies used are given in 
Materials and Methods. 
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In studies to determine the identity of the E3/49K-positive peripheral vesicles, colocalization of 
49K was observed neither with the late endosomal marker lysobisphosphatidic acid, LBPA 
(Kobayashi et al., 1998) (Fig. 23B) nor with the lysosomal marker lamp-2 (Hunziker and Geuze, 
1996) (Fig. 23C). In contrast, a substantial number of E3/49K-positive vesicles did colocalize 
with EEA1 (Fig. 23A), an early endosomal marker (Mu et al., 1995). These data suggest that 
E3/49K is targeted to early endosomal but not to late endosomal and lysosomal compartments 
early during infection.  
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FIG. 23. E3/49K localizes to early endosomes but not late endosomes or lysosomes. Primary fibroblasts 
(SeBu) were infected with Ad19a and processed for confocal laser microscopy 12-15 h p.i. Intracellular localization 
of E3/49K (green, R25050) was compared to that of marker proteins (red) for different endosomal/lysosomal 
compartments: EEA-1 (early endosomes, A), lysobisphosphatidic acid (LBPA, late endosomes, B), lamp-2 (late 
endosomes and lysosomes, C). The antibodies used are given in Materials and Methods. 
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In cells expressing very high amounts of 49K, cell surface expression of 49K was detected in 
immunofluorescence (data not shown). Cell surface expression of 49K was subsequently 
confirmed by flow cytometry analysis of cell lines stably expressing 49K (Fig. 24) and in infected 
cells (data not shown).  
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FIG. 24. E3/49K is expressed on the cell surface. Rat monoclonal antibody (4D1) directed against the N-
terminus of 49K was used to detect 49K on the cell surface of 49K-transfected A549 cells (grey) using flow 
cytometry shown in comparison to the mock-transfected parental cell line (black). 
3.14 Cytoplasmic tail fragments of E3/49K accumulate in late endosomes/lysosomes 
during the course of Ad19a infection 
No striking difference in the intracellular localization of E3/49K was found in A549 cell lines 
stably expressing E3/49K or after transient transfections (data not shown). In contrast to 49K 
localization in the early phase of infection in SeBu cells, in some cases a limited colocalization of 
49K with lamp-2 staining in peripheral vesicles was observed. Interestingly, in the late phase of 
Ad19a infection of SeBu cells, colocalization of E3/49K with lamp-2 was observed (Fig. 25). In 
general, at around 18 h p.i., E3/49K was found in few peripheral vesicles that were only weakly 
lamp-2-positive, whereas the major fraction of the lamp-2-positive vesicles remained E3/49K-
negative. At later time points (24-48 h p.i.) a major fraction of lamp-2-positive vesicles exhibited a 
profound E3/49K staining. Notably, this phenomenon was only observed with the C-terminal 
antibodies, but not with the N-terminal antibodies (36 h p.i., Fig. 25).  
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FIG. 25. Cytoplasmic tail fragments of 49K localize to the Golgi/TGN and late endosomes/lysosomes late 
during infection. Primary fibroblasts (SeBu) were infected with Ad19a and processed for confocal laser microscopy 
12 or 36 h p.i. Intracellular localization of 49K was analyzed with antibodies directed against the C- (polyclonal rabbit 
(R25050), A, B, E, F) and the N-terminus (polyclonal rabbit (R48-7B), C, D; rat mAb (4D1), E, F) and was 
compared to the localization of lamp-2 (mouse mAb, 2D5), a late endosomal/lysosomal marker.  
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Early during infection (12 h p.i.) with neither antibody a colocalization of 49K with lamp-2 was 
found (Fig. 25A, C). Late during infection (36 h p.i.) 49K was detected in lamp-2-positive vesicles 
with antibodies directed against the C-terminus (Fig. 25B) but not with antibodies directed 
against the N-terminus (Fig. 25D). Both antibodies stained a lamp-2-negative perinuclear 
structure, presumably the Golgi/TGN (Fig. 25F) that seemed to contain full-length 49K 
proteins. In addition, a more pronounced ER staining was visible late during infection (Fig. 25B, 
D, F). Only rarely vesicles were stained late during infection with antibodies directed against the 
N-terminus of 49K. This result indicates that the impaired processing observed in Ad19a-
infected A549 cells in the late phase of infection (Fig. 9) is accompanied by a transport block in 
the ER/Golgi/TGN.  
3.15 Intracellular localization of E3/49K is influenced by acidotropic agents 
One possible explanation for the finding that 49K could not be detected in late 
endosomal/lysosomal structures early during infection is that 49K localizes only transiently to 
these compartments, e.g. due to rapid degradation. Therefore, it was tested whether treatment 
with acidotropic/lysosomotropic agents, like bafilomycin A1 and chloroquine, that block 
trafficking at an early or late endosomal state, increase the pH of endosomal compartments and 
inhibit lysosomal degradation (de Duve, 1983) would allow the detection of 49K in late 
endosomes or lysosomes. These compounds were also shown to block recycling of TGN38/46 
to the TGN (Banting and Ponnambalam, 1997; Ponnambalam et al., 1996). Unexpectedly, 
overnight treatment of SeBu cells with 100 µM chloroquine resulted in changes in the ER 
morphology and in an accumulation of 49K in the ER, which was not observed in transiently or 
stably transfected A549 cells or after 3 h treatment of Ad19a-infected SeBu cells. After 3 h 
treatment no significant increase in colocalization of 49K and lamp-2 was detected (data not 
shown). However, the tubular TGN46 staining of the Golgi/TGN that was mostly perinuclear in 
untreated cells shifted dramatically to a vesicular staining in the periphery of chloroquine treated 
cells (Fig. 26B, C). Interestingly, these peripheral TGN46-positive vesicles contained also 49K. 
TGN46 is known to recycle from the cell surface to the TGN via early endosomal vesicles 
(Ghosh et al., 1998; Mallet and Maxfield, 1999). These findings indicate that the trafficking 
pathways of 49K and TGN46 overlap in early endosomal vesicles and may suggest that these 
proteins utilize similar trafficking pathways. 
Overnight treatment with acidotropic agents like chloroquine was feasible with E3/49K 
transfected A549 cells without deleterious effects on the ER. Upon treatment with chloroquine, 
49K could be detected in large swollen vesicles (Fig. 33B). These were partially lamp-2 positive 
(data not shown). Since it is a matter of debate whether acidotropic agents block trafficking at an 
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early or late endosomal state (Bayer et al., 1998; Clague et al., 1994; van Deurs et al., 1996; van 
Weert et al., 1995), it is questionable if this colocalization truly reflects targeting to and 
stabilization of 49K in a late endosomal/lysosomal compartment. Colocalization may be rather 
caused by a redistribution of lamp-2 to an early endosomal compartment. The colocalization of 
49K with TGN46 after treatment with chloroquine supports the latter interpretation. 
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FIG. 26. Colocalization of E3/49K with TGN46 in peripheral vesicles upon chloroquine treatment. Primary 
fibroblasts (SeBu) were Ad19a- (B, C) or mock- (A) infected and processed for confocal laser microscopy 12-15 h 
p.i. Intracellular structures were stained with antibodies against TGN46 and E3/49K (R25050) in mock-infected cells 
(A), mock-treated Ad19a-infected cells (B) or Ad19a-infected cells treated for 3 h with 100 µM chloroquine (C). 
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3.16 Evidence for E3/49K recycling to the TGN 
To answer the question whether the prominent Golgi/TGN staining of 49K at steady-state 
represents newly synthesized protein or 49K molecules recycled from the cell surface via early 
endosomes as demonstrated for TGN46, Ad19a-infected SeBu cells were treated for 6 h with 
cycloheximide to inhibit protein synthesis. Subsequently, the localization of 49K was determined 
using antibodies directed against the C- and the N-terminus and was compared to TGN46 
localization (Fig. 27). After 6 h cycloheximide treatment the perinuclear labeling of 49K detected 
with the antibody against the N-terminus diminished drastically (Fig. 27D, F, compare with C 
and E, respectively) and frequently disappeared entirely (data not shown), whereas the labeling 
with the antibody against the C-terminus was still present (Fig. 27B, F, compare with A and E, 
respectively), although the intensity of the staining decreased. The TGN46 staining was 
essentially unchanged (Fig. 27B, D, compare with A and C, respectively). Thus, C-terminal 
fragments of 49K were recycled to the Golgi/TGN suggesting that full-length proteins 
presumably also utilize this pathway. Therefore, the steady-state localization of 49K in the 
Golgi/TGN represents newly synthesized proteins as well as proteins recycled from the cell 
surface. At the moment it is unknown how much each fraction contributes to the Golgi/TGN 
staining of 49K. 
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FIG. 27. Newly synthesized as well as recycled 49K proteins localize to the Golgi/TGN. Primary fibroblasts 
(SeBu) were infected with Ad19a. 12 h p.i. cells were treated 6 h with 50 µg/ml cycloheximide. Subsequently, cells 
were processed for confocal laser microscopy. 49K was stained using antibodies directed against the C- (rabbit 
polyclonal Ab (R25050), A, B, E, F) and against the N-terminus (rat mAb, 4D1), C, D, E, F). To evaluate the 
Golgi/TGN localization, the TGN marker TGN46 was detected as well (sheep polyclonal Ab, A, B; rabbit 
polyclonal Ab, C, D).  
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3.17 Processing of E3/49K is influenced by agents affecting glycosylation, acidification, 
lysosomal proteases and intracellular trafficking 
The immunofluorescence studies indicated that acidotropic agents affect the intracellular 
trafficking of 49K. In order to find out how this may affect the proteolytic processing of 49K 
and to identify the compartments, where the processing of 49K occurs, Ad19a-infected A549 
cells were treated with chloroquine, ammonium chloride, bafilomycin A1 and the Na+ ionophore 
monensin, which increase the pH of acidic compartments (Fig. 28B, C). In addition, leupeptin, an 
inhibitor of lysosomal cysteine and serine proteases, tunicamycin, an inhibitor of N-glycosylation, 
and brefeldin A, an inhibitor of guanine nucleotide exchange factors (GEFs) for Arfs, which 
induces the collapse of the Golgi onto the ER and blocks transport to the cell surface, were 
applied (Fig. 28A, D). In a pulse/chase experiment the intracellular processing of 49K was 
followed with the C-terminal antibody, whereas the secretion of 49K was monitored with the N-
terminal antibody. 
In mock-treated cells the known processing was visualized (Fig. 28A, lanes 2-7). Notably, a 
distinct low molecular weight band is detected after 6 h chase (h3), indicating that C-terminal 
fragments are further trimmed after the initial cleavage(s) releasing the N-terminal ectodomain. 
This seems to occur in a different compartment than the initial cleavage, since the fragment h3 
appeared in general later during the chase (2-3 h) than the other fragments, h1 and h2 (~1 h). 
Interestingly, upon treatment with leupeptin (Fig. 28A, lanes 8-13) fragment h3 was not detected 
(compare lane 10 with lane 4). This suggests that a lysosomal cysteine or serine protease generates 
this fragment. On the other hand, the secretion of the N-terminal ectodomain is not significantly 
affected by leupeptin. Fragment h3 was also not detected after treatment with agents that elevate 
the pH of intracellular, particularly endosomal/lysosomal, compartments, like bafilomycin A1 
(Fig. 28B lanes 1-6), monensin (Fig. 28B, lanes 7-12) and chloroquine (Fig. 28C, lanes 1-6), 
substantiating the hypothesis that the cleavage producing the fragment with the lowest apparent 
molecular weight (h3) takes place in late endosomes/lysosomes in a pH-dependent manner. After 
treatment with ammonium chloride reduced amounts of the C-terminal fragment h3 were 
detected (Fig. 28C, lanes 7-12). Interestingly, the acidotropic compounds also changed the glycan 
processing of 49K: Chloroquine and to a lesser extent bafilomycin A1 prolonged the processing 
time. Ammonium chloride and monensin impaired modifications in the glycan structures 
indicated by a different molecular weight of the processed 49K. This effect was even more 
dramatic at a higher concentration (50 mM) of ammonium chloride (data not shown).  
In order to investigate the influence of these agents on the proteolytic cleavage and secretion, the 
secretion rate was determined as follows: secretion rate [%]= (radioactive label of the secreted 
49K in the supernatant after 6 h chase/ ((radioactive label of intracellular high molecular weight 
                                                                                                                                            Results 
 81
forms of 49K after the pulse; 0 h chase) – (radioactive label of intracellular high molecular weight 
forms of 49K after 6 h chase)) x 100. This procedure was required, since due to the influence of 
some agents on the glycan processing after 6 h chase still significant amounts of 49K could be 
detected, e.g. with chloroquine, whereas, e.g. in mock-treated cells, only very low amounts of 49K 
remained after 6 h chase intracellularly. Therefore, the radioactive label of 49K in the supernatant 
after 6 h chase itself was not conclusive in order to evaluate the influence of the tested agents on 
proteolytic cleavage and secretion. Labeling was performed with [35S]-methionine. 49K without 
the signal peptide contains five methionine residues, one in the cytoplasmic tail, four in the N-
terminal ectodomain (Fig. 6). Therefore, 20% of total labeling is expected to end up in 
cytoplasmic tail fragments and 80% in the N-terminal ectodomain. In these calculations potential 
differences in the affinities of the antibodies directed against the N- (supernatant) and the C-
terminus (lysate) were ignored. Other experiments indicated that slight differences exist. 
Surprisingly, chloroquine and bafilomycin A1 treatment increased the secretion rate from 25-30% 
in untreated cells to ~66% and 56%, respectively. In contrast, ammonium chloride had no 
significant effect on the secretion rate. Monensin, which has been reported to inhibit secretion of 
several proteins (Mollenhauer et al., 1990), decreased secretion only slightly to about 20% of total 
labeling. Treatment with the inhibitor of N-glycosylation, tunicamycin, and the inhibitor of ER to 
Golgi transport, brefeldin A, totally blocked the proteolytic processing of 49K as indicated by the 
absence of low molecular weight fragments in the lysates and secreted 49K in the supernatants 
(Fig. 28D). In immunofluorescence studies after treatment with tunicamycin, 49K was detected 
in the ER, which was probably due to misfolding (data not shown). This also explains the 
coprecipitation of the ER resident Ad19a E3/19K protein. Brefeldin A causes the redistribution 
of the Golgi complex into the ER. The marginal molecular weight shift indicative of limited 
glycan processing of 49K during the chase upon brefeldin A treatment is most likely caused by 
the residual activity of Golgi glycosyltransferases in the fused Golgi-ER-complex (Fig. 28D, lane 
7-9). Also after BFA treatment coprecipitation of low amounts of Ad19a E3/19K was observed. 
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FIG. 28. 49K processing in the presence of agents affecting glycosylation, intracellular trafficking or 
protease activities. Ad19a-infected cells were pulsed with [35S]-methionine for 30 min and chased with medium 
containing non-radioactive methionine for 2 h and 6 h. Several different agents were included in the starvation 
medium and were present in all other incubations: A) mock (lanes 2-7) and leupeptin (200 µM, lanes 8-13); B) 
bafilomycin A1 (0.1 µM, lanes 1-6) and monensin (10 µM, lanes 7-12); C) chloroquine (100 µM, lanes 1-6) and 
ammonium chloride (10 mM, lanes 7-12); D) tunicamycin (10 µg/ml, lanes 1-6) and brefeldin A (5 µg/ml, lanes 7-
12). 
3.18 Function of the potential endosomal/lysosomal sorting motifs in the cytoplasmic 
tail of E3/49K 
3.18.1 Surface plasmon resonance analysis 
The data presented so far demonstrated that 49K localizes mainly to the Golgi/TGN, the plasma 
membrane and early endosomes. In addition, a minor trafficking pathway to late endosomes and 
lysosomes seems to exist. The cytoplasmic tail of 49K contains potential endosomal/lysosomal 
sorting motifs, YXXF and LL, which are possibly implicated in the regulation of the intracellular 
trafficking of 49K. These motifs are known to interact with the clathrin adaptor complexes AP-1 
to AP-4 (chapter 1.8.3). At first, it was therefore examined whether peptides representing the 
cytoplasmic tail of 49K bind in vitro to purified clathrin adaptor complexes AP-1 and AP-2 (in 
collaboration with Stefan Höning, University of Göttingen, Germany). Interestingly, an 
interaction with both AP-1 and AP-2 was detected (Fig. 29). Mutating either of the putative 
sorting motifs decreased the interaction with the adaptor complexes, mutating both motifs 
abolished binding entirely. These data indicated that both motifs contribute to the binding to AP-
1 and AP-2 in vitro and may be functional in vivo. 
 
 KD (M) 
Peptides AP-1 AP-2 
CRKRPRAYNHMVDPLLSFSY (WT) 2.4 x 10-7 3.2 x 10-7 
CRKRPRAANHMVDPLLSFSY (YA) 6.4 x 10-7 5 x 10-7 
CRKRPRAYNHMVDPAASFSY (LLAA) 20 x 10-7 8 x 10-7 
CRKRPRAANHMVDPAASFSY (YA/LLAA) no binding 
detectable 
no binding 
detectable 
 
FIG. 29. Peptides representing the cytoplasmic tail of 49K interact with AP-1 and AP-2 in vitro via the 
YXXF and LL motifs. The interaction of purified adaptor complexes AP-1 and AP-2 with peptides representing 
the cytoplasmic tail of 49K as indicated was examined by surface plasmon resonance analysis as described in 
Materials and Methods. In addition, peptides with the YXXF and LL motif mutated to AXXF and AA respectively 
were tested and the equilibrium constants (KD) were determined. 
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3.18.2 Increased cell surface expression of E3/49K proteins with mutated cytoplasmic 
tails 
To test the function of the putative sorting motifs in vivo, cell lines were established that 
expressed 49K proteins with mutated motifs. The tyrosine of the YXXF and the leucines of the 
LL were replaced by alanine individually creating the YA and the LLAA mutant respectively or 
both generating the YA/LLAA double mutant. To examine the influence of the entire 
cytoplasmic tail, in addition a 49K mutant lacking the entire cytoplasmic tail was generated 
(DCT). The cell surface expression and the intracellular levels of WT and mutated 49K in the cell 
lines were determined by flow cytometry. The cell surface expression of the mutated proteins was 
not directly utilized to evaluate effects of the mutations, since the different clones exhibited 
different synthesis rates. Therefore, the ratio of 49K detected on the cell surface to intracellular 
49K was used, which was independent of the expression rate (Fig. 30).  
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FIG. 30. Internalization of 49K from the cell surface is mainly directed by the LL motif in the cytoplasmic 
tail. Constructs for the expression of mutant proteins were based on the pSG5-49K plasmid. DNA sequences 
containing mutations were generated by PCR (sense: 49KUSER546; antisense: 49KdelCT, 49KYLLAAA, 49KYA, 
49KLLAA) and cloned into pSG5-49K using BglII restriction sites. The mutated sequences were confirmed by 
sequencing. A549 cell lines stably expressing 49K WT and mutant proteins with one or both of the YXXF and LL 
motifs in the cytoplasmic tail mutated to AXXF and AA or with the entire cytoplasmic tail deleted (DCT) were 
generated as described in Materials and Methods and analyzed by flow cytometry. Cell surface and internal 49K 
levels were measured and the ratio of the mean fluorescence values of cell surface and internal expression was 
determined for several isolated clones of 49K WT and mutants as indicated. Mean values were calculated from 4-6 
independent experiments. Error bars indicate the standard error determined with SigmaPlot for Windows Version 
5.00. 
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The ratio was determined for 2-5 clones of WT and mutant 49K proteins to exclude clonal 
differences. For WT 49K this ratio was 0.24-0.29. The YA/LLAA and DCT mutants showed 
clearly enlarged ratios of 0.64-0.97 and 0.51-0.68 respectively. In the LLAA mutants the ratio was 
slightly increased to 0.36-0.53. The YA mutants exhibited ratios of 0.19-0.28, which was 
comparable to WT. Thus, YA/LLAA and DCT, and to a lesser extent also the LLAA mutant 
49K proteins were expressed in higher amounts on the cell surface than WT and YA mutant 49K 
proteins indicating impaired internalization. 
The immunoprecipitation data demonstrated that 49K is proteolytically processed. The site of 
that cleavage was unknown but it had to be considered that the cleavage might occur at the cell 
surface. In that case the proteolytic cleavage would limit the accumulation of 49K mutants 
deficient in endocytosis on the cell surface. Consistent with this hypothesis, WT and mutated 
49K proteins were rapidly lost from the cell surface, when cells were treated with brefeldin A to 
inhibit the transport of newly synthesized protein to the cell surface (Fig. 31).  
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FIG. 31. Rapid decrease of cell surface expression of 49K in cell lines expressing WT and mutated 49K 
proteins after brefeldin A treatment. Mean fluorescence of cell surface expression of 49K was determined by flow 
cytometry after mock (black bars) or 4 h brefeldin A treatment (5 µg/ml, grey bars) of cell lines expressing WT and 
mutant 49K proteins as indicated. Mean values were calculated from 4-6 independent experiments. Error bars 
indicate the standard error determined with SigmaPlot for Windows Version 5.00. 
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After 4 h BFA treatment only 4-6% WT, 3-7% YA mutant, 6-9% LLAA mutant, 15% 
YA/LLAA mutant and 9-10% DCT mutant 49K proteins remained at the cell surface. The cell 
surface expression of some cellular proteins in comparison was only slightly decreased to about 
80% of the levels of untreated cells (HLA: ca. 75%, Fas: ca. 86%, EGFR: ca. 80%). Thus, 
although the internalization of mutated 49K proteins was impaired, 49K staining at the cell 
surface is still rapidly lost during BFA treatment. One explanation for that finding is that two 
mechanisms exist that are able to remove WT 49K from the cell surface: Endocytosis and 
proteolytic cleavage. In case of the mutant 49K proteins, a deficit in endocytosis may result only 
in a limited accumulation at the cell surface (Fig. 30), since 49K can also be removed from the 
cell surface by the proteolytic processing.  
3.18.3 Increased secretion of E3/49K proteins with mutated cytoplasmic tails 
The results from the brefeldin A experiment (Fig. 31) indicated that mutations of the cytoplasmic 
tail of E3/49K do not prevent proteolytic processing. Therefore, cleavage may occur on the way 
to and/or at the cell surface. In immunoprecipitation, 49K was detected in cell lines expressing 
WT and mutant 49K proteins after 2 h labeling (Fig. 32A). Low molecular weight fragments (h) 
were detected in lysates from cell lines stably expressing mutated E3/49K proteins using 
antibodies directed against the C-terminus (except for the mutants lacking the cytoplasmic tail 
which could only be detected with antibodies against the N-terminus). This finding confirmed 
that the mutant 49K proteins were still proteolytically processed. Notably, the mutations affected 
the recognition of the cytoplasmic tail of mutated 49K proteins. The YA/LLAA32 clone for 
example expressed three- to fourfold higher levels of 49K than WT K27S as determined by 
immunoprecipitation with N-terminal antibody after pulse labeling (Fig. 32B, compare lanes 2 
and 15) but is less well precipitated by the antibody against the C-terminus (Fig. 32A, compare 
lanes 3 and 5). In addition, synthesis rates were measured by quantification of intracellular 49K 
after brefeldin A treatment by flow cytometry with similar results (data not shown). Interestingly, 
every mutation changes the migration behavior of the low molecular weight fragments in the 
polyacryamide gel (Fig. 32A).  
To investigate the processing kinetics of WT and mutated 49K, a pulse/chase experiment (30 
min pulse, 45 and 180 min chase) with individual clones with similar synthesis rates was 
performed. No significant differences in the processing kinetics between WT and mutant 49K 
proteins were observed (Fig. 32C, data not shown). Particularly, the intracellular processing of 
WT (lane 3-5) and DCT (lane 15 –17) 49K proteins was almost identical. The YA/LLAA mutant 
49K protein was difficult to precipitate intracellularly (lane 9-11) because of the already described 
decreased recognition of the mutated cytoplasmic tail with the C-terminal antibody.  
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FIG. 32. Decreased internalization of mutated 49K proteins correlates with increased secretion. A) Different 
clones expressing 49K WT and mutant proteins were metabolically labeled for 2 h and 49K was precipitated with 
antibodies directed against the C-terminus (R25050, lanes 1-12) and with antibodies directed against the N-terminus 
(R48-7B, lanes 13, 14). B) Different clones expressing 49K WT and mutant proteins were pulse labeled 30 min and 
49K was precipitated with antibodies directed against the N-terminus to determine the synthesis rate of each clone. 
C) The processing kinetics of WT and mutated 49K proteins were determined in a pulse (30 min)/ chase (45 and 180 
min) experiment, in which 49K was precipitated from WT and YA/LLAA mutant cell lysates with antibodies 
directed against the C-terminus (lanes 3-5, 9-11) and from DCT mutant cell lysates (lane 15-17) and all supernatants 
(lanes 6-8, 12-14, 18-20) with antibodies directed against the N-terminus of 49K. D) The secretion rate of 49K was 
determined in a pulse (0.5 h)/chase (4 h) experiment followed by immmunoprecipitation with antibodies directed 
against the N-terminus (48-7B) and SDS-PAGE. Bands corresponding to 49K were quantified by phosphorimager 
analysis.  
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The radioactive labeling of 49K after the pulse was defined as 100%. The cytoplasmic tail contains 20% of total [35S]-
methionine labeling. Therefore, the maximum value for secretion is expected to be 80% of total 49K labeling. Mean 
values were calculated from two independent experiments (except for values of chloroquine and bafilomycin A1 
treatment which represent results of single experiments). Error bars indicate the standard error determined with 
SigmaPlot for Windows Version 5.00. 
                                                                                                                                            Results 
 90
Also the kinetics of the secretion of 49K seemed unchanged in the mutant 49K proteins 
(compare YA/LLAA, lanes 12-14, and DCT, lanes 18-20, with WT, lanes 6-8). However, the 
quantity of the secreted 49K seemed to be increased in the YA/LLAA and in the DCT mutant 
(compare lanes 14 and 20 with lane 8). Therefore, the secretion rate of two individual clones of 
each mutant was determined in a pulse (0.5 h)/chase (4 h) experiment and compared to WT 
clones and infection (Fig. 32D). Strikingly, the secretion of the YA/LLAA and the DCT mutants 
was increased to 58-62% and 71-82%, respectively, of total labeling compared to about 16-18% 
for WT clones and 20% in infection. The secretion rate of the LLAA mutant was also clearly 
increased to 48-54%, whereas the secretion of the YA mutant was not (14-20%). Interestingly, 
the increased secretion of mutant 49K proteins correlated with the increased cell surface 
expression substantiating the hypothesis that proteolytic cleavage can occur at the cell surface 
(Fig. 30). As shown before, acidotropic agents increased the secretion rate (Fig. 22C). In this 
experimental setting secretion rates of 75% of total 49K labeling during chloroquine and of 59% 
during bafilomycin A1 treatment were measured after Ad19a infection. 
3.18.4 Decreased internalization of mutated E3/49K proteins and accumulation of 
mutated cytoplasmic tail fragments at the cell surface 
Proteolytic cleavage, occurring most likely at the cell surface, was observed with all 49K mutants. 
Some of the mutants exhibited an increased cell surface expression suggesting a deficiency in 
endocytosis. Therefore, the proteolytic processing and secretion at the cell surface may limit the 
accumulation of endocytosis deficient 49K mutants at the cell surface if 49K is detected with 
antibodies directed against the N-terminus. On the other hand mutant cytoplasmic fragments are 
supposed to remain at the cell surface after proteolytic cleavage and secretion of the N-terminal 
ectodomain if motifs required for endocytosis have been eliminated. However, the detection of 
mutated cytoplasmic tails with antibodies directed against the WT C-terminus is decreased 
compared to WT. Despite this limitation, immunofluorescence demonstrated that the 
cytoplasmic tail fragments of the YA/LLAA mutant accumulated at the cell surface (Fig. 33A, 
left panel). The LLAA mutant exhibited only very slightly increased surface levels, whereas in the 
YA mutant no difference to WT was detectable. With antibodies directed against the N-terminus 
only a slight accumulation of full-length DCT and YA/LLAA but not of YA and LLAA mutant 
49K proteins at the cell surface could be detected (Fig. 33A, middle panel). 
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FIG. 33. Decreased internalization of mutated 49K proteins results in accumulation of the cytoplasmic tail 
at the cell surface and reduced intracellular accumulation in swollen endosomal vesicles during 
chloroquine treatment. A549 cells were transiently transfected with pSG5 plasmids encoding WT and mutant 49K 
proteins as described in Materials and Methods.  
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After 36 h cells were processed for confocal laser microscopy. Staining was performed with antibodies directed 
against the N- (rat monoclonal, 4D1) and the C-terminus (rabbit polyclonal, R25050) of 49K. Cells were mock- 
treated (A) or treated with 100 µM chloroquine for 12 h (B).  
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Treatment with acidotropic agents like chloroqine blocks intracellular transport at an early or late 
endosomal state. Transport of proteins internalized from the cell surface to the Golgi/TGN or 
lysosomes can be inhibited resulting in an accumulation of proteins in early or late endosomal 
vesicles. This has been shown to be the case for WT 49K (Fig. 26, 33B).  Therefore, it was tested 
how the trafficking of 49K mutants is affected by this treatment. A549 cells were transiently 
transfected with pSG5 constructs encoding WT and mutant 49K proteins to exclude clonal 
differences of stable transfectants. WT 49K accumulated in swollen vesicles after chloroquine 
treatment (Fig. 33B) and could be detected with antibodies directed against the C- as well as the 
N-terminus. In the YA mutant no difference was evident, in the LLAA mutant the accumulation 
was still clearly detectable, although it seemed to be slightly reduced. Some swollen vesicles were 
detected with antibodies against the C-terminus of 49K in the YA/LLAA mutant, although the 
staining was much weaker than in case of WT 49K. Hardly any stained swollen vesicles were 
detected with antibodies against the N-terminus of 49K. The same result was obtained for the 
DCT mutant. These findings are consistent with the view that internalization of the YA/LLAA 
and the DCT mutant 49K proteins is indeed strongly impaired. This is particularly evident for the 
full-length 49K proteins detected with the antibodies directed against the N-terminus.  
3.19 High stability of E3/49K in the supernatant of Ad19a-infected and E3/49K-
transfected cells 
In order to address the function of 49K, it was attempted to purify the secreted form of 49K. 
Initially, the stability of the protein in the supernatant of Ad19a-infected cells (Fig. 34A) and 
49K-transfected cells (Fig. 34B) was tested in a pulse/chase experiment with chase times up to 24 
h. The levels of 49K detected in the supernatant remained constant from 4 h to 24 h chase. Thus, 
it could be concluded that the 49K protein is stably maintained in the supernatant after its 
secretion. This was confirmed by Western blotting analysis of soluble 49K in the supernatant of 
the stable transfectant (Fig. 34C), in which 49K accumulated during 9 days of incubation.  
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FIG. 34. High stability of secreted 49K. 49K was precipitated from lysates with anti-C-terminus (R25050) and 
from supernatants with anti-N-terminus (48-7B) antibodies from Ad19a-infected (A) and 49K-transfected (K27S, B) 
A549 cells after metabolic labeling with [35S]-methionine for 1 h (9 h p.i.) and a chase with medium containing 
unlabeled methionine for 4, 12, 18 and 24 h. (C) Supernatants of 49K transfected cells were collected after 1-9 days 
and 15 µl were directly analyzed by SDS-PAGE and Western blotting using antibodies directed against the N-
terminus (R48-7B). 
 
3.20 Purification of secreted E3/49K 
To purify the secreted form of 49K, rat monoclonal antibodies directed against the N-terminal 
domain of 49K (4D1) were coupled to a protein G-Sepharose column as described in Materials 
and Methods. Supernatant from a cell line stably expressing 49K was collected after 8-9 days of 
incubation. The supernatant was precleared with a protein G-Sepharose column to remove 
antibodies and proteins present in the supernatant that bind to protein G-Sepharose. Then, the 
precleared supernatant was transferred to the affinity column. Finally, 49K was eluted with 
glycine buffer (pH 3.0). The eluted fractions were analyzed by silver staining and Western 
blotting (Fig. 35). The fractions contained very pure soluble 49K, represented by the major large 
(77-90 kDa) and a minor species (50-60 kDa) which was also detected in immunoprecipitation 
experiments, e.g. Fig. 16B. 
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FIG. 35. Purification of E3/49K. Purification was performed as described in Materials and Methods. E3/49K was 
eluted from an anti-49K affinity column, in which the rat monoclonal antibody (4D1) directed against the N-
terminus was coupled to protein G-Sepharose beads. 500 µl fractions were collected. 15 µl of each fraction was 
analyzed by SDS-PAGE, silver staining (A) and Western blotting (B) with antibodies directed against the N-terminus 
of 49K (R48-7B). 
 
3.21 E3/49K is a lymphocyte binding factor 
Proteins encoded by the early transcription unit 3 of human adenoviruses are involved in 
immune evasion (chapter 1.7). Cell surface expression and secretion of 49K led to the hypothesis 
that 49K does not affect the infected cell as other E3 gene products but rather influences 
surrounding cells, most likely cells of the immune system. In this scenario, binding of 49K to a 
receptor on immune cells was postulated. Therefore, the binding of purified, secreted 49K to 
lymphocyte and other cell lines was tested (Fig. 36). Cells were incubated for 1 h with purified 
49K at 4°C prior to flow cytometry analysis using a rat monoclonal antibody directed against 
49K. In these experiments the specific binding of 49K to several human lymphocyte cell lines, 
derived from NK cells, T lymphocytes and B lymphocytes, but not to primary human fibroblasts 
(SeBu) or to other human cell lines, e.g. A549 (lung epithelial carcinoma), 293 (embryonal 
kidney), HeLa (cervix carcinoma) or K562 (erythroleukemia) cells, could be shown. Thus, 49K 
seems to bind specifically to protein(s) expressed on lymphocytes leading to the hypothesis that 
this binding affects functions of these immune cells in the antiviral immune response. 
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FIG. 36. Secreted E3/49K binds specifically to lymphocyte cell lines. Binding of secreted 49K to different cell 
lines and primary fibroblasts (SeBu) was tested in a modified flow cytometry protocol, in which secreted 49K (~200 
ng) was incubated with cells in multiwell plates for 1 h at 4°C followed by incubation with anti-N-terminus 
(monoclonal rat, 4D1) antibodies and anti-rat FITC-labeled antibodies as described in the standard protocol for flow 
cytometry analysis in Materials and Methods. 
3.22 Jurkat specific 49K-binding proteins coprecipitate with E3/49K 
In order to identify proteins interacting with 49K, it was attempted to coprecipitate proteins from 
Jurkat (T cell leukemia) cells, which were shown to bind 49K in flow cytometry analysis (Jurkat 
J77 derived clone SVT35 (Ting et al., 1996)). A549 cells, which did not bind 49K as determined 
by flow cytometry, were used as a negative control. A549 and Jurkat cells were infected with 
Ad19a or Ad19a-49K(-), a 49K-deficient Ad19a virus, or mock-infected. A549 (6 h p.i.) and 
Jurkat (18 h p.i.) cells were labeled with [35S]-methionine for 1.5 h. 49K was precipitated from the 
lysates (Fig. 37) of A549 (lanes 1-3) or Jurkat cells (lanes 7-9). Since adenoviruses do not infect 
lymphocytes very efficiently (Korner and Burgert, 1994), it was attempted to identify 
coprecipitating proteins by two different approaches. First, lysates of Ad- or mock-infected A549 
cells were mixed with lysates of mock-infected Jurkat cells (lanes 4-6). Second, purified 49K was 
used to precipitate potential interaction partners from lysates of mock-infected A549 and Jurkat 
cells (lanes 10-13).  
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FIG. 37. Specific coprecipitation of high molecular weight protein species from Jurkat cells with E3/49K. 
2x106 A549 cells were infected with Ad19a or Ad19a-49K(-), in which a frameshift mutation abolished 49K 
expression, or mock-infected, labeled 6 h p.i. for 1.5 h and lysed in 1 ml IP-lysis buffer. 4x106 Jurkat J77 (clone 
SVT35 (Ting et al., 1996)) cells were Ad19a- or Ad19a-49K(-)- or mock-infected, labeled 18 h p.i. for 1.5 h and lysed 
in 0.5 ml IP-lysis buffer. 500 µl of the different lysates were mixed with 500 µl of other lysates as indicated or with 
500 µl IP-lysis buffer. For precipitation with purified 49K, 600 ng protein was added and incubated for 1 h at 4°C 
prior to immunoprecipitation. Immunoprecipitation was performed with antibodies directed against the C-terminus 
(R25050, lanes 1-9) or with antibodies directed against the N-terminus (R48-7B, lanes 10-13) as described in 
Materials and Methods. Infections with Ad19a and Ad19a-49K(-) were performed both with an MOI of 10. Equal 
amounts of E3/19K were precipitated from cells infected with the different Ads (data not shown) suggesting no 
differences in early gene expression between Ad19a- and Ad19a-49K(-) -infected cells in addition to the abolished 
49K expression. The areas with the bands of the coprecipitated proteins are highlighted by boxes. 
 
Strikingly, high molecular weight protein species with an apparent molecular mass of 
approximately 172, 181 and 196 kDa coprecipitated specifically with 49K using Jurkat cell lysates 
(lanes 6, 9, 13). In the absence of 49K the corresponding bands were not detected (lanes 4, 5, 7, 
8, 12). In addition, from A549 cell lysates these proteins were not precipitated, neither in the 
                                                                                                                                            Results 
 99
presence (lanes 3, 11) nor in the absence of 49K (lanes 1, 2, 10). These proteins seem to be of 
cellular origin, because the additional bands were not detected after infection with Ad19a-49K(-) 
not expressing the 49K protein (lanes 5, 8). Furthermore, purified 49K alone was sufficient to 
precipitate the high molecular weight protein species from Jurkat lysates (lane 13).  
 
3.23 E3/49K inhibits NK cell-mediated lysis 
In the 49K binding assays, the NK cell line NKL exhibited the highest mean value of 
fluorescence suggesting high expression of potential 49K-binding proteins. To test whether the 
binding of 49K might interfere with NK cell functions, NK cell-mediated lysis was measured in 
the presence and in the absence of purified 49K (in collaboration with Christine Falk, GSF, 
Munich, Germany). NKL cells induce lysis of MHC class I negative K562 (erythroleukemia) cells. 
E3/49K was able to inhibit the NKL-cell mediated lysis in a dose-dependent manner and 
reduced lysis from 56% to 28% (Fig. 38). NKL cell-mediated lysis of K562 cells can be inhibited 
by transfecting these cells with expression vectors encoding for HLA-E and the signal peptide of 
HLA-A2. Binding of the HLA-E/HLA signal peptide on the cell surface of the K562 cells to its 
receptor CD94/NKG2A on NKL cells inhibits the lysis of the target cells. This mechanism was 
able to reduce NKL cell-mediated lysis of target cells to 29%, which is comparable to the 
reduction achieved with secreted 49K. In addition, the NKL mediated lysis of Daudi cells could 
be reduced from about 16% to 6% (data not shown). Preliminary data from experiments with the 
CD4+ CTL clone 234 indicate that the lysis of target cells mediated by these cells is not affected 
by 49K (data not shown). On one hand this finding makes it rather unlikely that the 49K-
mediated inhibition of NKL cell-mediated lysis was due to an unspecific effect, on the other hand 
it raises the question what effects 49K binding to the CTL cells, revealed by flow cytometry, may 
have. 49K-mediated disturbance of other aspects of lymphocyte cell biology are conceivable. 
However, in case of the NKL cells, the 49K binding to NKL cells as determined by flow 
cytometry analysis seems to result in an inhibition of NKL cell-mediated killing of target cells 
indicating an immunomodulatory function of E3/49K.  
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FIG. 38. Purified, secreted 49K inhibits NK cell-mediated target cell lysis.  NKL cell-mediated lysis of K562 
cells was determined in a standard chromium-51 assay as described in Materials and Methods. Purified secreted 49K 
and controls (A549) were diluted as indicated. 60, 30 or 15 ng purified 49K were added to the lysis reaction in a total 
volume of 100 µl. The killer/target ratio was 20:1 (40000 NKL cells: 2000 K562 target cells). 
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4 DISCUSSION 
The E3/49K protein is encoded by the early transcription unit 3 (E3) of Ad19a, an adenovirus 
causing epidemic keratoconjunctivitis (EKC). The characterization of the Ad19a E3/49K protein 
is the first study about an E3 protein specific to subgenus D adenoviruses. E3/49K may be 
implicated in subgenus-specific diseases or serotype-specific functions of the Ad19a E3/49K 
may play a role in causing EKC. 
4.1 Ad19a E3/49K expression during the time course of infection 
As expected from its position in the early transcription unit 3, expression of E3/49K was 
initiated in the early phase of infection and reached a maximum at 6 h p.i. (Fig. 8). Unlike 
E3/19K, E3/49K was also synthesized in significant amounts in the late phase of infection (30 h 
p.i.). Whereas E3/19K synthesis decreased dramatically to ~1-2% of the maximal value, E3/49K 
was still produced at a level of ~25-30% at 30 h p.i. Similar to E3/49K, the synthesis rate of 
20.5K of Ad3 (subgenus B) was also shown to be high early during infection and continued at 
lower levels throughout the infection cycle (Hawkins and Wold, 1995a). Remarkably, the 
synthesis of E3/49K seemed to reach a minimum at 18 h p.i. and increased again slightly at later 
time points. The mechanism of this regulation is unknown at present. Some E3 proteins such as 
11.6K of Ad2 (subgenus C) and 30K of Ad4 (subgenus E) were shown to be synthesized at 
higher rates late during infection (Li and Wold, 2000; Tollefson et al., 1992). In contrast to 49K, 
11.6K is scarcely synthesized during the first 12 h of infection and synthesis is greatly amplified 
(~400 fold) in the late phase (>24 h p.i. (Tollefson et al., 1992)). In the late phase of infection, Ad 
gene transcription is driven by the major late promoter (MLP) and 11.6K mRNA is spliced to the 
y leader located within the E3 region and the major late tripartite leader (Wold et al., 1995). Little 
is known about splicing of E3 transcripts of Ads other than subgenus C. However, splicing of 
the E3 RNAs of Ad35 and Ad3 (subgenus B) differs substantially (Basler and Horwitz, 1996; 
Signas et al., 1986). The presence of a typical splice acceptor site in front of the 49K gene 
suggests that 49K mRNA can be synthesized independently of E3/19K. 
4.2 Posttranslational modifications of Ad19a E3/49K: N- and O-glycosylation, disulfide 
bonds 
The sequence of the 49K protein encoded by the E3 region of Ad19a predicts a type I 
transmembrane protein with a short cytoplasmic tail containing two motifs, YXXF and LL, that 
have been implicated in endosomal/lysosomal targeting (chapter 1.8.3.2) (Heilker et al., 1999). 
Remarkably, the E3/49K sequence contains 14 potential N-glycosylation sites and three potential 
O-glycosylation sites (Fig. 6). Experimental evidence was provided that E3/49K is indeed highly 
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N-glycosylated and presumably contains also O-glycans. The abundant glycosylation resulted in 
an apparent molecular mass of ~80-100 kDa (e.g. Fig. 8, 9, 16-18). No major differences between 
49K synthesized in the early phase of Ad19a infection or in 49K-transfected A549 cells were 
detected (Fig. 18). The E3/49K protein was initially synthesized with Endo H cleavable high-
mannose oligosaccharides, migrating with an apparent molecular mass of 77-83 kDa. 
Subsequently, these 49K forms were processed to the 87-100 kDa protein species (Fig. 16). Endo 
H treatment shifted the processed E3/49K species to an apparent molecular mass of 67-92 kDa 
(Fig. 16, band e) demonstrating the presence of a mixture of high-mannose, hybrid and complex 
N- and/or O-glycans. Limiting Endo H treatment of pulsed E3/49K revealed that the majority 
of the E3/49K proteins (~65 %) contained 12, a small fraction (~17% each) 13 and 11 N-linked 
oligosaccharides (Fig. 17). Based on the molecular weight difference the average molecular mass 
of a high-mannose N-glycan of 49K was estimated to be approximately ~2.7 kDa. The glycans of 
the 49K protein species represented by the lower border of the 87-100 kDa band are most likely 
processed to a lower degree to complex glycans than 49K protein species represented by the 
upper border. Therefore, the latter are supposed to contain more Endo H resistant carbohydrates 
and the 49K protein species represented by the upper border of the 87-100 kDa band without 
treatment are most likely represented by the upper border of the 67-92 kDa band after Endo H 
treatment, 49K protein species represented by the lower border of the 87-100 kDa band are 
represented by the lower border of the 67-92 kDa band. By calculating the shift in the molecular 
weight the number of Endo H sensitive N-glycans could be estimated: Mature 49K protein 
species contain still between three and seven high-mannose and/or hybrid N-glycans. The 
majority of mature 49K proteins had still five high-mannose and/or hybrid N-glycans attached. 
In the largest fraction of E3/49K proteins one or two N-glycosylation sites are not utilized (Fig. 
17). Three rules are known to govern the usage of potential N-glycosylation sites. Firstly, 
NxS/Tx sites are rarely glycosylated if x is a proline residue (Gavel and von Heijne, 1990). This 
does not explain the incomplete glycosylation of E3/49K, since none of the potential N-
glycosylation sites of E3/49K contains proline residues in these positions (Fig. 6). Secondly, 
steric hindrance may prevent glycosylation if the potential acceptor sites are too close to each 
other. There are indeed two positions, where potential glycosylation sites are in close proximity 
(N25 and N31, and N312 and N317), which might cross-inhibit the glycosylation of the adjacent 
acceptor sites. However, it has been shown that two NxS/T acceptor sites separated by a single 
amino acid (distance between the Ns 3 aa) can still be glycosylated at both sites (Gavel and von 
Heijne, 1990). Thirdly, unglycosylated acceptor sites tend to be found more frequently towards 
the C-termini of glycoproteins (Gavel and von Heijne, 1990). Thus, it is possible that the site 
closest to the transmembrane segment (N343) may not be utilized. This is supported by the 
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observation, that the C-terminally derived fragments (h, Fig. 9, 16, 18), generated by the 
proteolytic processing discussed below (chapter 4.3), are not glycosylated (Fig. 18). Considering 
their apparent molecular mass of 12-13 kDa, the cleavage site is predicted to be N-terminal of the 
predicted N-glycosylation site at position 343. Thus, it is likely that the E3/49K form with 13 
oligosaccharides lacks a glycan at position 343 and that with 12 glycans might in addition be 
devoid of carbohydrates at position 312 or 317 (Fig. 6). It is noteworthy, that incomplete 
glycosylation was also observed for E3/19K molecules of Ad19a (Deryckere and Burgert, 1996). 
Thus, the cleavage site for the proteolytic processing is proposed to be between N317 and N343. 
Although the presence of O-glycans could not be directly demonstrated with the O-glycosidase 
from Diplococcus pneumoniae that hydrolyzes only the unmodified disaccharide core 
Galb(1®3)GalNAc from serine or threonine, the presence of O-glycans was indicated by a shift 
in the apparent molecular mass upon neuraminidase treatment of E3/49K lacking all N-glycans 
(Fig. 18). Presumably, other O-glycan core structures or modifications not cleavable by the used 
O-glycosidase were present. The apparent molecular mass difference potentially originating from 
O-glycans accounts for ~3.5 kDa (Fig. 18A). This is consistent with the proposed three O-
glycosylation sites, assuming core structures of 4-5 sugar groups each. Interestingly, two bands 
appeared after PNGase F treatment (i, Fig. 18A, lane 7, Fig. 18B, lane 4) suggesting that E3/49K 
forms exist that differ either in the number of the utilized O-glycosylation sites or in the sugar 
side chains attached to these core units. In summary, the terminally processed form of E3/49K 
contains high-mannose/hybrid as well as complex N-glycans and O-linked oligosaccharides. 
Unexpectedly, the glycosylation pattern changed in the late phase of infection, in which E3/49K 
forms with high-mannose carbohydrates represented by the defined bands of 77-83 kDa were the 
major species (b-d, Fig. 8). A pulse/chase experiment (Fig. 9) demonstrated that late during 
infection the processing of the high-mannose to the complex glycans was severely impaired. 
Presumably, the exit of 49K out of the ER is prevented or at least delayed, and the prolonged 
residence time in the ER favors the generation of 49K molecules with 13 N-linked glycans (b). 
This was neither a 49K-specific nor a generalized processing defect induced by Ad infection, e.g. 
caused by host shutoff late during infection, since the processing of the transferrin receptor was 
not significantly changed, whereas lamp-1 processing was also affected (Fig. 10A, B). This result 
suggests that only a selective set of glycoproteins seems to be affected. Lamp-1 and E3/49K are 
both heavily N-glycosylated with 18 (Hunziker and Geuze, 1996) and 11-13 (Fig. 17) N-glycans, 
respectively, whereas the transferrin receptor contains only three N-glycosylation sites (Schneider 
et al., 1982). The reason for the differential sensitivity of the glycoproteins is unclear, but they 
may utilize different transport pathways (Karlsson and Carlsson, 1998), which might be 
differentially affected late during Ad infection. Interestingly, the Golgi/TGN appeared more 
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vesicular in infected than in uninfected cells (Fig. 26). At present, it is not known whether these 
two phenotypic changes, the altered processing late during infection and the altered morphology 
of the Golgi, which is visible already in the early phase, are related. However, it is unlikely that 
E3/49K plays a direct role in these phenomena: First, transfectants stably expressing E3/49K 
exhibited a similar processing as observed in the early phase of infection (Fig. 15) and no obvious 
changes in Golgi morphology were observed. Second, the processing deficiency is established 
only late during infection, when E3/49K synthesis is already significantly decreased. Interestingly, 
full-length 49K proteins were detected late during Ad19a infection in SeBu cells mainly in the 
ER/Golgi/TGN and only rarely in peripheral vesicles as early during infection (Fig. 25). This 
finding substantiates the hypothesis that the impaired glycan processing late during infection is 
accompanied by a severely delayed transport through the ER/Golgi/TGN. Notably, a slower 
carbohydrate processing was also observed for the 20.5K protein of Ad3 (subgenus B) in the late 
phase of infection (Hawkins and Wold, 1995a), suggesting that this phenomenon is not restricted 
to subgenus D Ads. 
As another post- or co-translational modification, 49K contains intramolecular disulfide bonds 
(Fig. 20). Since only a shift of 1.1 kDa in the apparent molecular mass was determined upon 
reduction, disulfide bonds are most likely formed by adjacent cysteine residues (Fig. 6). It cannot 
be excluded that additional posttranslational modifications are present in the mature 49K protein, 
e.g. palmitoylation. The 11.6K protein of subgenus C Ads was shown to be palmitoylated at 
cysteine residues close to the transmembrane region (ICCLKR) (Hausmann et al., 1998). A 
similar sequence (ICCRKR) is found in the 49K protein. Palmitoylation of 49K may play a role in 
49K trafficking (Tab. 3). 
4.3 Posttranslational modifications of Ad19 a E3/49K: Proteolytic processing and 
secretion 
A striking observation from the initial pulse/chase experiments was the appearance of E3/49K 
derived fragments with apparent molecular masses of about 12-13 kDa starting at about 60 min 
of chase (h, Fig. 9). Similar fragments were also observed in the cell lines stably expressing Ad19a 
E3/49K (h, Fig. 11). A low molecular weight band was also detected in Western blotting analysis 
(Fig. 14, lane 4) excluding the possibility that these bands represent coprecipitated proteins. This 
suggested that E3/49K is proteolytically cleaved. In order to elucidate the fate of the N-terminal 
ectodomain of 49K, rabbit polyclonal and rat monoclonal antibodies were generated against the 
N-terminal part of 49K expressed as a HisTag-fusion protein (Fig. 12). These antibodies 
recognized 49K in all assays tested (Fig. 13, 14, 21, 24), although different activities were 
observed with different rat monoclonal antibodies (Tab. 4). With these antibodies directed 
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against the N-terminus of 49K, it could be demonstrated that the N-terminal ectodomain is 
secreted from Ad19a-infected as well as from 49K-transfected A549 (Fig. 15) and 293 cells (data 
not shown). The proteolytic processing of 49K in 49K-transfected cells demonstrates that no 
viral protein is required for the cleavage but a cellular protease.  
As four of the five methionine residues in the 49K sequence (without signal peptide) are present 
in the N-terminal ectodomain (Fig. 6), 80% of the total labeling is expected to be contained in 
that part of 49K. The labeling of the cytoplasmic tail is expected to contain 20% of total labeling 
(one methionine). Notably, only a fraction of about 20% of total initial labeling with [35S]-
methionine was secreted (Fig. 32). 20% of total labeling corresponds to 25% of the labeling of 
the N-terminal ectodomain of 49K. Thus, 75% of the initially labeled N-terminal part of 49K 
appears to be eliminated by a so far unknown degradation system. Several agents influencing 
trafficking, glycosylation, acidification of intracellular compartments (chloroquine, bafilomycin 
A1, ammonium chloride, monensin, brefeldin A, tunicamycin) and an inhibitor lysosomal 
cysteine and serine proteases (leupeptin) were applied in order to define their influence on the 
processing, secretion and intracellular degradation of 49K (Fig. 28). Tunicamycin inhibits N-
glycosylation and retained 49K in the ER, most likely due to misfolding based on the requirement 
of N-glycosylation for proper folding (Parodi, 2000). Low molecular weight fragments were not 
detected under these conditions (Fig. 28D) suggesting that their generation requires export from 
the ER. Brefeldin A induces the collapse of Golgi but not of TGN membranes onto the ER. 
This was associated with an impaired glycan and an inhibition of proteolytic processing of 49K 
(Fig. 28D). This implies that the protease cleaving 49K does not localize to the Golgi and that the 
proteolytic processing of 49K occurs in a post-Golgi compartment. 49K was detected in swollen 
endosomal vesicles during chloroquine treatment (Fig. 33B). Acidotropic agents (chloroquine, 
bafilomycin A1, ammonium chloride, monensin) and the lysosomal cysteine and serine protease 
inhibitor leupeptin did not inhibit proteolytic processing and secretion but influenced to a 
different degree the glycan processing (Fig. 28 A-C). Chloroquine and bafilomycin A1 even 
increased the secretion rate up to 75% of initially labeled 49K, which corresponds to more than 
90% of the labeled N-terminal part of 49K (Fig. 32D). Acidotropic agents disturb the 
acidification of intracellular compartments, e.g. endosomes, which can inhibit proteases if their 
activity depends on an acidic pH. On the other hand, intracellular trafficking is affected by 
acidotropic compounds. However, it is still controversial whether they block trafficking at an 
early or late endosomal state (Bayer et al., 1998; Clague et al., 1994; van Deurs et al., 1996; van 
Weert et al., 1995). The result that leupeptin, an inhibitor of lysosomal cysteine and serine 
proteases did not significantly increase the secretion rate supports the view that rather the 
influence of acidotropic agents on trafficking than the inhibition of lysosomal proteases by an 
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increased pH was responsible for the increased secretion. Acidotropic agents efficiently block 
transport from early or late endosomes to lysosomes and to the TGN, but they only delay and do 
not inhibit recycling to the cell surface (Presley et al., 1997). Blocking transport in early or late 
endosomes by acidotropic agents, allowing a slow recycling to the cell surface, increased the 49K 
secretion rate. This supports the idea that proteolytic processing leading to secretion of 49K can 
occur at the cell surface (or less likely in a pH-insensitive way in endosomes) and that degradation 
of 49K intracellularly occurs in a compartment that is reached after passing early or late 
endosomes or in a pH-sensitive way in early or late endosomes. Proteolytic processing at the cell 
surface is further supported by the analysis of 49K proteins with mutated sorting motifs in the 
cytoplasmic tail discussed below (chapter 4.4). In this scenario, 49K is internalized from the cell 
surface and targeted to early or late endosomes. The treatment with acidotropic agents blocks 
further transport to the TGN or to late endosomes and lysosomes, which most likely is required 
for the intracellular degradation of 49K. Instead, 49K is slowly recycled to the cell surface, where 
proteolytic processing resulting in secretion of the N-terminal ectodomain occurs. In sum, these 
processes induced by acidotropic agents result in an increased secretion rate. A major 
contribution of lysosomal degradation to the intracellular degradation of 49K seems unlikely 
because no stabilization is observed during leupeptin treatment, although 49K degradation by 
lysosomal proteases not sensitive to leupeptin cannot be excluded. Preliminary data suggest that 
49K processing and degradation is also not affected by the proteasome inhibitor lactacystine 
(data not shown) arguing against a major contribution of the proteasome in 49K processing or 
degradation. 
Another interesting observation from the experiments with leupeptin and acidotropic agents was 
that the proteolytic processing of the low molecular fragments was affected by these compounds. 
The generation of the fragment with the lowest molecular weight (h3), which appeared later in 
the chase (2-3 h) than the other fragments (~1 h), was inhibited by acidotropic agents and 
remarkably also by leupeptin (Fig. 28). This strongly favors the idea that the initial cleavage 
occurs in a different compartment than the subsequent processing generating the fragment with 
the lowest molecular weight (h3). The result that leupeptin inhibits the production of this 
fragment implies that this processing step is mediated by cysteine and serine proteases in late 
endosomes or lysosomes, whereas the initial cleavage seems to occur in the TGN/secretory 
vesicles and/or at the cell surface (Fig. 39).  
Proteolytic processing of precursor proteins in the secretory pathway is frequently mediated by 
members of a family of calcium-dependent serine endoproteases related to subtilisin and the 
yeast processing protease Kex2p that are called subtilisin-like proprotein convertases (SPCs) 
(Zhou et al., 1999). These proteins are either localized in dense core vesicles of the regulated 
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secretory pathway (PC2, PC1/3) or in the TGN and secretory vesicles of the constitutive 
secretory pathway (furin, PACE4, PC5/PC6, PC7/8/LPC), where they mediate proteolytic 
processing. Among their substrates are growth and blood clotting factors, prohormones but also 
viral proteins, e.g. the Ebola glycoprotein, the influenza virus hemagglutinin and the HIV 
envelope glycoprotein. These SPCs cleave proproteins usually after KR or RR sequences, but also 
amino acids in position –4 and –6 seem to be important for the cleavage. Because of similar 
cleavage sites, different SPCs may have redundant activities (Lissitzky et al., 2000). It was 
postulated that in addition to the R in position –1 at least two basic residues, K or R, in positions 
–2, -4 or -6 are required for cleavage, although the efficiency of different target sequences can 
differ significantly (Watanabe et al., 1993). In the Ad19a E3/49K sequence a weak potential SPC 
recognition site (KDEGKR) is found at position 332 in the region where 49K is assumed to be 
cleaved, i.e. N-terminal of the predicted N-glycosylation site at position 343 which is most likely 
not utilized and C-terminal of the predicted N-glycosylation site at position 317 which is 
presumably partially used. This sequence is also found in Ad37 49K that is identical to Ad19a 
49K. In Ad15 49K the K in position –6 is substituted by R, in Ad8 and Ad9 49K the R in 
position –2 is replaced by N, but instead in position –4 a K is found which would still represent a 
potential cleavage site according to the rules described above. This might indicate that an 
evolutionary advantage exists to retain a weak recognition site for SPCs. 
LoVo cells are deficient in furin and PC5/6 expression, but synthesize PACE4 and PC7 (Seidah 
et al., 1994; Seidah et al., 1996; Takahashi et al., 1995). After Ad19a infection of LoVo cells, 
secretion of 49K was clearly reduced compared to A549 cells. After 3 h metabolic labeling 49K 
was precipitated from the lysate and the supernatant, and 49K labeling was quantified. In A549 
cells ~70% of the 49K label was detected intracellularly whereas ~30% were detected in the 
supernatant. In case of the LoVo cells ~97% of the 49K labeling was intracellular and only ~3% 
in the supernatant (data not shown). This supported the view that furin or another SPC deficient 
in this cell line may play a role in 49K cleavage. The residual proteolytic cleavage may be 
explained by a redundant activity of SPCs expressed in LoVo cells or the activities of other 
cellular proteases. However, preliminary results with the furin inhibitor decanoyl-R-V-K-R 
revealed only slightly decreased secretion levels (data not shown). These results have to be 
confirmed in further experiments. In addition, the effect of the inhibitor on other SPCs than 
furin remains to be clarified. Nevertheless, based on the results from the LoVo cells a role for 
SPCs in the processing of 49K may be proposed. 
SPCs are mainly active in the TGN and secretory vesicles either of the regulated or the 
constitutive secretory pathway. But SPCs might be transported to the cell surface from which 
they are retrieved to the TGN via endosomal compartments (Molloy et al., 1999). SPCs may 
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exhibit some residual activity at the cell surface (Wolfgang Garten, Philipps-University Marburg, 
Germany, personal communication) leaving the possibility that they also participate in proteolytic 
processing at the cell surface. The cell surface is proposed to be the site where 49K is at least 
partly proteolytically processed. The process of proteolytic processing of proteins at the cell 
surface and subsequent secretion of the ectodomain is called “protein shedding”. Protein 
ectodomain shedding is a widely used mechanism to modulate the surface of eukaryotic cells 
(Blobel, 2000; Kiessling and Gordon, 1998). Proteins released by this process include EGFR 
ligands, such as heparin-binding EGF-like growth factor (HB-EGF) and transforming growth 
factor a (TGFa), cytokines, such as TNFa, cytokine receptors, adhesion molecules and other 
proteins, e.g. the amyloid precursor protein (APP). Many of these shedding processes have been 
linked to metalloproteases. Therefore, metalloproteases may be involved in the cleavage of 49K 
at the cell surface. No consensus sequence for metalloprotease-mediated cleavage at the cell 
surface has emerged so far. Preliminary results obtained with the metalloprotease inhibitor 
marimastat (BB-2516) revealed only a slight decrease in 49K secretion (data not shown). Further 
experiments and utilization of other metalloprotease inhibitors with different specificities should 
clarify their involvement in 49K processing.  
At present, the possibility that several proteases are able to cleave 49K cannot be excluded, e.g. 
SPCs in the TGN/secretory vesicles and metalloproteases at the cell surface. This may 
complicate inhibitor studies and would be consistent with the fact that a number of low 
molecular weight fragments are detected that might be generated by cleavage of 49K at different 
positions mediated by different proteases. Thus, the protease or the proteases involved in the 
proteolytic processing of Ad19a E3/49K remain to be identified. 
4.4 Intracellular trafficking and secretion of Ad19a E3/49K directed by sorting motifs 
in the cytoplasmic tail 
Several structural features of E3/49K, such as the abundant N-glycosylation, the presence of O-
linked glycans, intramolecular disulfide bonds and the short cytoplasmic tail with 
endosomal/lysosomal targeting signals, are reminiscent of the lysosome-associated membrane 
proteins (lamps) (Hunziker and Geuze, 1996). Despite these striking similarities, the intracellular 
localization of E3/49K and lamp-2 differed considerably in primary foreskin fibroblasts (SeBu) 
in the early phase of infection (12-15 h p.i., Fig. 23). At this time point the intracellular staining 
patterns revealed with antibodies directed against the C- and the N-terminus of 49K were 
indistinguishable. Thus, the trafficking pathways of full-length 49K proteins and cytoplasmic tail 
fragments seem to be very similar, and it may be proposed that the trafficking of full-length 49K 
is directed by its C-terminal cytoplasmic portion. E3/49K was localized primarily in a perinuclear 
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compartment that was identified as the Golgi/TGN 12-15 h p.i. (Fig. 22). In 
immunofluorescence studies the Golgi complex and the TGN could not be differentiated due to 
limited resolution. TGN staining was demonstrated by brefeldin A treatment that induces the 
collapse of the Golgi onto the ER, whereas TGN membranes are relocated to the MTOC 
(Klausner et al., 1992). Most of the Golgi/TGN staining in untreated cells seemed to merge into 
the ER. Nevertheless, a TGN46-positive structure was still weakly 49K-positive suggesting that 
at steady-state the Golgi as well as the TGN contain 49K (data not shown). The 49K fraction 
detected in the Golgi/TGN included newly synthesized 49K and most likely recycled full-length 
49K and C-tails from the cell surface as indicated by the finding that after 6 h treatment with 
cycloheximide cytoplasmic tail fragments but not full-length 49K proteins could be detected in 
the Golgi/TGN (Fig. 27). Nevertheless, since the intracellular trafficking pathways of full-length 
49K and C-tails seem to be very similar, both are most likely recycled to the TGN. At present, it 
is unknown whether the prominent Golgi/TGN staining can be mainly attributed to newly 
synthesized or recycled 49K proteins. The TMD of 49K encompasses approximately 22 aa, 
which is much longer than that of typical Golgi resident proteins (chapter 1.8.2). Therefore, it is 
unlikely that the TMD of 49K directs the Golgi/TGN localization. In addition to the perinuclear 
Golgi/TGN staining, numerous E3/49K-positive vesicles were detected in the perinuclear region 
and in the periphery. A significant proportion of these vesicles were shown to be early 
endosomes by colocalization with the early endosomal marker EEA-1 (Fig. 23A). In the early 
phase no colocalization with the late endosomal marker lysobisphosphatidic acid (LBPA, Fig. 
23B) and the late endosomal/lysosomal marker lamp-2 (Fig. 23C) was found. This changed in the 
late phase of infection, when colocalization of E3/49K and lamp-2 was observed (Fig. 25). 
Strikingly, only cytoplasmic tail fragments colocalized with lamp-2 in vesicular structures but not 
full-length proteins. The cytoplasmic tail fragments of E3/49K seem to accumulate in late 
endosomes/lysosomes during the course of infection resulting in the colocalization with lamp-2 
in the late phase of infection. This concept is supported by the finding that the small E3/49K 
derived fragments exhibit a longer half-life than full-length E3/49K (5-6 h vs. ~2 h; Fig. 34A/B). 
The existence of a minor trafficking pathway to late endosomes and lysosomes is also supported 
by experiments with acidotropic/lysosomotropic agents and leupeptin. Treatment of Ad19a-
infected or 49K-transfected A549 cells with various acidotropic/lysosomotropic agents, e.g. 
chloroquine, stabilized 49K in swollen endosomal vesicles in immunofluorescence studies, 
whereas the serine and cysteine protease inhibitor leupeptin exhibited no significant effect (Fig. 
33B, data not shown). The increased secretion rates obtained with some acidotropic agents are 
also indicative of 49K stabilization (Fig. 28, 32D). This stabilization may rather originate from a 
disturbed trafficking than from an inhibition of proteases dependent on low pH, since leupeptin 
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did not significantly stabilize full-length 49K proteins. Thus, lysosomal degradation of E3/49K 
most likely plays only a minor role. On the other hand, leupeptin affected the processing of the 
cytoplasmic tail fragments. It inhibited the generation of a low molecular weight fragment (h3), 
which appeared late in the chase (Fig. 28A). This leupeptin sensitive proteolytic cleavage 
therefore seems to occur in late endosomes or lysosomes (Fig. 39). Strikingly, after long chase 
times mainly the cytoplasmic tail fragment h3 is detected (Fig. 28A, Fig. 34A, B). Thus, 
predominantly h3 may be detected late during infection in immunfluorescence studies in late 
endosomes and lysosomes (Fig. 25).  
In Ad19a-infected cells expressing E3/49K at high levels a significant staining of the cell surface 
was observed with antibodies against the C-terminus in immunofluorescence studies indicating 
that E3/49K may reach the plasma membrane. Cell surface expression was unequivocally 
demonstrated by flow cytometry using an antibody directed against the N-terminal portion of the 
49K protein (Fig. 24). No significant differences in the 49K localization in 49K-transfected cells 
compared to Ad19a-infected cells were observed (data not shown). 
Thus, at steady-state E3/49K localizes to the Golgi/TGN, early endosomes and the cell surface 
in the early phase of infection. Some unidentified vesicular structures might represent secretory 
vesicles. From early endosomes 49K is recycled to the TGN and a minor pathway also leads to 
late endosomes and lysosomes. The putative sorting motifs, YXXF and LL, in the cytoplasmic 
tail of 49K may direct the intracellular localization and trafficking of 49K. These motifs are 
involved in trafficking between the TGN, the endosomal/lysosomal system and the plasma 
membrane (chapter 1.8.3.2). The finding that peptides representing the sequence of the 
cytoplasmic tail of E3/49K bind to the clathrin adaptor protein complexes AP-1 and AP-2 in vitro 
supported a functional role in vivo (Fig. 29). This was confirmed by the examination of cell lines 
stably expressing E3/49K proteins with mutations in the putative sorting motifs. In these 
mutants, 49K expression on the cell surface was increased as shown by an increased ratio of cell 
surface to intracellular 49K staining in flow cytometry analysis (Fig. 30). In addition, an 
accumulation of YA/LLAA mutant cytoplasmic tail fragments at the cell surface was detected by 
immunofluorescence (Fig. 33A), even though the mutated tails are not as well recognized as WT 
C-tails by the relevant antibodies. Therefore, accumulation of 49K C-tails with the YA/LLAA 
mutation at the cell surface is expected to be even more dramatic. Moreover, accumulation of 
49K proteins in swollen endosomal vesicles after chloroquine treatment is dramatically decreased 
in YA/LLAA and DCT mutants and slightly in LLAA mutants but not in YA mutants compared 
to WT (Fig. 33B). Since the accumulation in swollen endosomal vesicles most likely occured after 
internalization, these results imply that endocytosis from the cell surface is impaired in 
YA/LLAA and DCT and to a lesser extent in LLAA mutants. No full-length YA/LLAA and 
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DCT mutant 49K proteins were detected in swollen endosomal vesicles after chloroquine 
treatment with antibodies directed against the N-terminus (Fig. 33B). This finding is consistent 
with the view that the proteolytic processing of these mutant 49K proteins at the cell surface is 
faster than their internalization. Proteolytic cleavage at the cell surface is also supported by flow 
cytometry analysis after brefeldin A treatment, inhibiting transport of newly synthesized 49K to 
the cell surface (Fig. 31). Despite the presumed deficiency in endocytosis, 49K staining on the cell 
surface is still rapidly lost in transfected cells expressing mutated 49K proteins most likely due to 
proteolytic processing. The mutations do not inhibit proteolytic processing and secretion and do 
not significantly change the processing kinetics (Fig. 32C) but affect the secretion rate (Fig. 32D). 
Interestingly, increased cell surface expression correlates with increased secretion rates (Fig. 30, 
Fig. 32D). The DCT mutants even reached secretion rates of ~80% of total labeling, which 
corresponds to about 100% of the labeling of the N-terminal ectodomain. These results suggest 
that the intracellular degradation of WT 49K that limits the secretion rate occurs after 
endocytosis. Thus, the decreased internalization rate of the YA/LLAA and the DCT mutant 
allows a highly efficient proteolytic processing of full-length 49K proteins at the cell surface and 
disfavors internalization and subsequent intracellular degradation. Interestingly, two different 
approaches to disturb 49K trafficking, treatment with acidotropic agents as well as mutations of 
the cytoplasmic tail, increase the secretion rate, most likely by increasing the overall residence 
time of 49K proteins at the cell surface. 
An interesting cellular protein, that is cleaved and secreted similar to 49K, is the b–amyloid 
precursor protein (APP). Proteolytic processing of APP involves three proteases, a-, b-, and g–
secretases (Esler and Wolfe, 2001). The large N-terminal ectodomain of APP (APPS) can be 
secreted after a- and b-secretase cleavage. The cytoplasmic tail of APP contains two YXXF 
motifs that direct the intracellular traffic of APP. One motif (YENP) seems to mediate mainly 
endocytosis, whereas the other (YTSI) regulates basolateral targeting (Haass et al., 1995; Perez et 
al., 1999). Interestingly, as shown for 49K, mutation of the YXXF motif mediating endocytosis 
resulted in an increased secretion of APPS (Perez et al., 1999). However, in case of the Ad19a 
E3/49K protein the LL motif seems to be decisive for endocytosis, whereas the YXXF motif 
plays only a minor role. Mutation of the LL motif to AA significantly disturbed the intracellular 
trafficking of 49K resulting in an increased cell surface expression and secretion rate, whereas 
49K proteins with a mutation of the Y of the YXXF motif to A behaved like WT. However, a 
significant effect was observed after mutation of the Y of the YXXF motif in addition to the 
elimination of the LL motif (YA/LLAA compared to LLAA). This suggests that the LL motif 
dominates the YXXF motif in the WT cytoplasmic tail of 49K. Interestingly, according to a 
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statistical analysis of residues surrounding functional YXXF and LL motifs, the YXXF motif of 
49K is not flanked by particularly favored amino acids, whereas a proline in position –1 of the LL 
motif, as found in the 49K sequence, was present in 23% of functional LL motifs (Windheim et 
al., 2002). This finding supports the view that the LL motif in the cytoplasmic tail of 49K is 
functional in vivo. At present it cannot be excluded that the YXXF motif plays a role in processes 
following internalization, e.g. basolateral targeting. The possibility that the 49K sorting motifs 
may mediate targeting to the basolateral membrane in polarized cells has not been addressed so 
far (chapter 1.8.3.2).  
49K trafficking is reminiscent of that of TGN46, a protein that also localizes to the TGN at 
steady-state and is targeted to the basolateral membrane in polarized cells (Banting and 
Ponnambalam, 1997). TGN46 also contains a YXXF motif but no LL motif and is continuously 
recycled from the cell surface via early endosomes to the TGN (Tab. 3, Ghosh et al., 1998; Mallet 
and Maxfield, 1999). The trafficking pathways of E3/49K and TGN46 were shown to overlap in 
endosomes (Fig. 26). Another cellular protein with similar trafficking pathways is the protein 
encoded by the Menkes disease gene. The Menkes disease protein, a copper transporting ATPase, 
is localized in the Golgi/TGN and cycles between the TGN and the plasma membrane. For 
Menkes disease protein an LL motif was shown to be important for the steady-state Golgi/TGN 
localization (Tab. 3). Interestingly, this motif seems to be critical for internalization from the cell 
surface but it may not be sufficient for retrieval to the Golgi/TGN, because it was unable to 
target chimeric CD8 proteins to that compartment (Francis et al., 1999). It is possible that the LL 
motif of 49K is the dominant endocytosis motif, but another sorting motif, e.g. the YXXF motif, 
may direct retrieval to the TGN from endosomes or basolateral targeting. Combinations of LL 
and YXXF motifs are found in a number of proteins. These motifs can be additive in their 
activities. The cystic fibrosis transmembrane conductance regulator contains an LL and a YXXF 
motif in its cytoplasmic tail which both contribute to internalization (Hu et al., 2001). But LL and 
YXXF motifs may also have different activities. The sequence YQGVL at the C-terminus of 
CD1d contains a tyrosine-based internalization motif (YQGV) that also directs basolateral 
sorting. This YXXF motif overlaps with a leucine-based (VL) sorting motif that is also sufficient 
for basolateral sorting, but is not active in internalization (Rodionov et al., 2000). The interleukin-
6 (IL-6) receptor is composed of two different subunits, gp80 and gp130. The gp130 subunit 
contains an LL motif in its cytoplasmic tail that mediates endocytosis (Dittrich et al., 1996), 
whereas in the C-tail of the gp80 subunit two motifs, an LL and a YXXF motif, are found that 
direct basolateral sorting (Martens et al., 2000). Interestingly, in both LL motifs of the IL-6 
receptor a proline is present in position –1, as in the LL motif of 49K.  
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LL and YXXF motifs are also found in other viral transmembrane proteins. Endocytosis and 
AP-1 and AP-2 interaction of simian as well as human immunodeficiency virus envelope 
glycoproteins seems to be controlled by LL and YXXF motifs (Bowers et al., 2000; Wyss et al., 
2001). Herpes simplex virus (HSV) and varicella zoster virus (VZV) are enveloped viruses that 
have been proposed to acquire their envelope in the trans-Golgi-network. That is the reason why 
the viral envelope glycoproteins VZV-gE and HSV-gE are targeted to that compartment. 
Interestingly, this is achieved by the utilization of YXXF motifs and other signals that also direct 
the TGN localization of cellular proteins like TGN46 and furin (Alconada et al., 1996; Alconada 
et al., 1999). In analogy to the cellular TGN proteins, the viral envelope glycoproteins cycle 
between the TGN and the plasma membrane, a trafficking pathway also 49K seems to utilize. 
The Ad2/5 10.4K and 14.5K proteins, like 49K encoded by the early transcription unit 3, form a 
complex and down-regulate Fas and EGFR (chapter 1.7). Both proteins contain sorting motifs in 
their cytoplasmic tails. The YXXF motif of 14.5K mediates internalization, whereas the LL motif 
of 10.4K seems to be required for recycling of the complex from endosomes to avoid lysosomal 
degradation (Hilgendorf et al., in preparation). Thus, in this case the two motifs appear to 
function sequentially. For the E3/49K protein the function of the LL motif in internalization was 
demonstrated. A role for the YXXF motif in recycling, e.g. to the TGN, seems unlikely. In that 
case an increased intracellular degradation and a decreased secretion rate would be expected, but 
was not detected (Fig. 32D). Basolateral targeting remains a potential function of the YXXF 
motif of 49K, but the LL motif also may be functional in both internalization and basolateral 
sorting, as shown for the invariant chain (Simonsen et al., 1998) and the Fc receptor II (Hunziker 
and Fumey, 1994). Thus, a potential basolateral targeting of 49K and a potential function of the 
YXXF or the LL motif in such a sorting event remains to be clarified. 
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FIG. 39. Model of E3/49K trafficking and proteolytic processing. At steady-state, E3/49K is found in the 
Golgi/TGN, at the plasma membrane and in early endosomes. After synthesis E3/49K passes the secretory pathway 
and is extensively posttranslationally modified obtaining N- and O-glycans and intramolecular disulfide bonds. At the 
TGN, E3/49K is packaged into secretory vesicles. Proteolytic cleavage releasing the N-terminal ectodomain most 
likely occurs at the cell surface (“shedding”) (2), but cleavage in secretory vesicles (1) and/or in the TGN cannot be 
excluded at present. The cytoplasmic tail and uncleaved full-length E3/49K proteins can be endocytosed from the 
cell surface mainly by virtue of the LL motif in the C-tail involving AP-2 interaction. From early endosomes (EE) 
E3/49K can be recycled to the TGN possibly regulated by the interaction of the sorting motifs in the cytoplasmic 
tail with AP-1. Recycling from early endosomes may also occur to the cell surface. A minor pathway directs E3/49K 
and cytoplasmic tail fragments to late endosomes (LE) and finally to lysosomes (Lys), where an additional proteolytic 
processing takes place (3). For details and references see text. 
4.5 Binding of secreted 49K to lymphocyte cell lines and coprecipitation of 49K-binding 
protein(s) 
Based on the assumption that 49K has an immunomodulatory function, it was hypothesized that 
the secreted 49K may affect effector cells of the immune system. Interestingly, a SMART search 
for homologies to common domain families (Schultz et al., 2000) revealed a similarity of R3 (Fig. 
7C) with the consensus sequence for immunoglobulin (Ig) -like domains. In addition, secondary 
structure prediction suggests that the N-terminal ectodomain of 49K contains mainly b–strands 
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(Cuff et al., 1998). Notably, in R3 as well as in R1 and R2 (Fig. 6), several b–strand regions were 
predicted, which is consistent with the 7-10 b–strands characteristically found in Ig-like domains. 
Recently, the structure of the HCMV US2 protein bound to the class I molecule HLA-A2 was 
resolved (Gewurz et al., 2001b). US2 functions in HCMV immune evasion and targets MHC 
class I molecules to the proteasome for degradation. US2 shows no sequence homology to host 
proteins. Nevertheless, the crystal structure revealed that US2 adopts an Ig-like fold. US2 binds a 
structure on MHC class I molecules that is not recognized by known host proteins interacting 
with MHC class I, e.g. CD8 or T cell receptor. Thus, it seems that HCMV has evolved a novel 
protein for this purpose. However, the scaffold for the recognition, the Ig-like fold, is widely 
used by viral and host proteins. Interestingly, it was suggested that also the Ad E3/19K adopts an 
Ig-like fold (Gewurz et al., 2001a). Thus, like HCMV US2, Ad E3/19K and E3/49K proteins 
may use the scaffold of the Ig-fold to bind to their target structures on host proteins. Ig-folds are 
frequently found in proteins with functions in the immune system. Strikingly, about 54% of all 
leukocyte membrane proteins contain at least one domain with an Ig-like fold, which is mostly 
involved in protein-protein interactions (Barclay et al., 1997). Therefore, it was reasonable to 
assume that E3/49K may bind to cell surface protein(s) of leukocytes. Indeed, purified, secreted 
49K binds specifically to lymphocyte cell lines of different origin, NK, T and B cells, but not to a 
number of other cell lines of non-lymphocytic origin, like primary fibroblasts (SeBu), lung 
epithelial cells (A549) or erythroleukemia cells (K562) (Fig. 36). This supports the hypothesis that 
49K may have an immunomodulatory function and indicates the presence of lymphocyte-specific 
49K-binding protein(s). As a first attempt to identify such proteins, 49K was precipitated from 
lysates of labeled Jurkat cells (Fig. 37). Strikingly, three high molecular weight protein species of 
172-196 kDa could be coprecipitated with 49K specifically from Jurkat cell lysates. A strong 
interaction of 49K with these proteins can be postulated, since the interaction was not disrupted 
by 1% Triton-X 100 present during immunoprecipitation. 
Interestingly, a database search for similarities to the 49K repeat regions 1-3 (R1-3, Fig. 6), 
revealed homologies with HIV/SIV gp120 proteins (Fig. 40). The HIV/SIV envelope 
glycoprotein gp120 binds to the receptor CD4 and coreceptors on lymphocytes, mainly 
chemokine receptors (Loetscher et al., 2000). Interestingly, two regions implicated in gp120 
coreceptor binding, V3 and V1/V2, show similarities to 49K (Fig. 40) (Loetscher et al., 2000; 
Poignard et al., 2001). Like Ad19a 49K, HIV/SIV gp120 is also highly glycosylated and N-
glycosylation in the V3 and V1/V2 regions affects coreceptor utilization (Pollakis et al., 2001). 
Homologous sequences of 49K and HIV/SIV gp120 include potential N-glycosylation sites (two 
in C2/V3 and V1/V2, Fig. 40A, D; one in C4/V4/C5, Fig. 40C). However, the molecular masses 
of gp120 coreceptors are much lower than the 172-196 kDa of the 49K-binding proteins in 
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Jurkat cells. Gp120 is non-covalently associated with gp41 at the cell surface and can be shed into 
the supernatant of infected cells. The biological significance of soluble gp120 is largely unknown. 
The envelope glycoproteins have pleiotropic effects on various cell types of the immune system, 
directly or indirectly (Chirmule and Pahwa, 1996). Thus, it might be worthwhile to examine 
whether 49K has similar effects.  
A
B
C
D
FIG. 40: Homologies between Ad19a 49K and HIV/SIV gp120 proteins. Different regions of the 49K sequence 
exhibit similarities to HIV/SIV gp120 proteins: A) 49K sequence 46-94 (R1) with the HIV-2 gp120 C2/V3 region 
(TrEMBL entry: Q9E8H3); B) 49K sequence 129-156 (R2) with the HIV-1 gp120 C4/V4/C5 (Q97740); C) 49K 
sequence 131-166 (R2) with SIV gp120 (Q9Q069); D) 49K sequence 308-342 (R3) with the HIV-1 gp120 V1/V2 
region (O71468). Database similarity search was performed with BLAST on http://www.ncbi.nih.gov/BLAST. 
 
A number of secreted, viral proteins have been identified that may serve immunomodulatory 
functions (Alcami and Koszinowski, 2000; Tortorella et al., 2000). Most of these proteins exhibit 
sequence homologies to known host proteins. It is commonly believed that the corresponding 
genes have been captured from the host. Viral homologs of host genes involved in immune 
defense are mainly encoded by large DNA viruses (herpes- and poxviruses). These include 
homologs of proteins involved in complement activation, soluble receptors for interferon-a and 
-b, soluble cytokine receptors (viroceptors) and cytokines (virokines). Only a few secreted viral 
proteins without homology to host proteins like 49K have been identified so far. Several 
poxviruses, e.g. myxoma virus and rabbitpox virus, encode chemokine-binding proteins 
(vCkBPs) that have no cellular counterparts and interact with a broad spectrum of chemokines 
(Lalani et al., 2000). In analogy, a potential function of 49K in chemokine binding could be 
proposed. Therefore, binding of 49K to cytokines/chemokines, e.g. MIP-1a, TNF-a and IL-8, 
was tested (in collaboration with Antonio Alcami, University of Cambridge, United Kingdom), 
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but so far no interaction has been detected. In addition, no influence of 49K on the chemotaxis 
of leukocytes was found (in collaboration with Alberto Mantovani, University of Brescia, Italy).  
Similar to Ad19a E3/49K, the Ebola virus glycoprotein is found in two forms, a secreted (50-70 
kDa) and a transmembrane (120-150 kDa) form, which is incorporated into the virion. 
Production of both forms from the same gene is regulated by RNA editing introducing a frame 
shift. The first 295 aa of both proteins are identical, but the secreted glycoprotein contains 
additional 69 and the transmembrane glycoprotein another 381 aa. The secreted form seems to 
bind to CD16b, the neutrophil-specific form of the Fc g receptor III (Yang et al., 1998), whereas 
the transmembrane protein binds not to neutrophils but to endothelial cells. 49K may also 
function in the secreted as well as in the membrane-associated form. The relatively slow 
proteolytic processing of 49K allows the expression of significant amounts of 49K on the cell 
surface. However, in case of 49K it is unlikely that secreted and membrane-associated forms have 
different binding properties, since essentially the entire N-terminal ectodomain of 49K is 
released.  
In sum, the 49K-binding proteins seem to be expressed specifically by lymphocyte cell lines. 
49K-binding proteins were neither detected on the cell surface of A549 (lung epithelial 
carcinoma) cells by flow cytometry, nor intracellularly in A549 cells by coprecipitation, but in 
Jurkat J77 (T cell leukemia) cells. Although the possibility cannot be excluded that E3/49K 
affects functions of the infected cell like other Ad E3 proteins, these findings suggest that 49K 
targets infiltrating immune cells.  
Since Ad E3 proteins may be involved in subgenus-specific pathogenesis (chapter 1.1, 1.7), the 
Ad19a E3/49K protein may play a role in diseases characteristically caused by subgenus D Ads, 
particularly diseases of the eye. In addition, even though all Ads of subgenus D tested express a 
49K homolog, 49K may still contribute to the pathological features of the epidemic 
keratoconjunctivitis, in that 49K proteins of different subgenus D Ads bind to a different set of 
receptors on lymphocytes and possibly to different sets of leukocytes, which may be crucial for 
causing EKC or conjunctivitis or other diseases. Thus, potential differential activities of different 
subgenus D Ad 49K proteins remain to be addressed in future studies. 
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4.6 Inhibition of NK cell-mediated target cell lysis 
49K binding to a number of lymphocyte cell lines raised the question whether the binding has 
any functional consequences. Indeed, purified, secreted 49K inhibited target cell lysis mediated by 
the NK cell line NKL (Fig. 38). Thus, in this case binding, as measured by flow cytometry (Fig. 
36), correlated with interference with NKL function. However, the mechanism as to how 49K 
affects NK cell lysis remains unknown. 
The regulation of NK cell-mediated lysis seems to be controlled by a delicate balance between 
activating and inhibitory receptors. Consequently, 49K may trigger inhibitory NK receptors or 
suppress activating receptors. Inhibitory receptors bind to MHC class I molecules on target cells. 
In virus-infected or tumor cells the expression of MHC on the cell surface is frequently reduced 
sensitizing these cells to NK cell-mediated lysis. Three families of inhibitory MHC-specific 
receptors have been discovered, the Ly49 receptors in rodents, the killer cell immunoglobulin-like 
receptors (KIR) in primates and the CD94/NKG2 heterodimers in both primates and rodents 
(Raulet et al., 2001). Some of the activating receptors may recognize MHC class I molecules and 
belong to the same families as the inhibitory MHC-specific receptors, whereas others bind to 
non-MHC ligands, which in many cases have not been characterized yet (Moretta et al., 2001; 
Raulet et al., 2001). 
The role of NK cells in Ad infection is still elusive. Upon Ad infection an NK cell response is 
elicited, and, in case of recombinant Ads, they seem to play an important role in virus elimination 
(chapter 1.5). In addition, results were obtained indicating that Ads are able to suppress NK cell-
mediated killing of infected cells by a so far unknown mechanism (Routes and Cook, 1989; 
Routes and Cook, 1995). Some viruses express MHC class I homologs, e.g. MCMV m144, 
HCMV UL18, which have been implicated in the inhibition of NK cell-mediated lysis. The 
HCMV UL40 protein provides a peptide required for the maturation of the HLA-E molecule 
that can inhibit NK cell-mediated lysis in vitro via interaction with CD94/NKG2A on NK cells 
(Alcami and Koszinowski, 2000).  
The inhibition of NK cell-mediated lysis by 49K seems to utilize a different mechanism. Few cell 
surface markers with potential relevance for NK cell function on NKL cells are known. The 
heterodimer CD94/NKG2A is found on the cell surface of NKL cells and triggers an inhibitory 
signal upon ligation to HLA-E molecules presenting an HLA signal peptide by the target cell. In 
contrast, NKG2D is an activating receptor. NKG2D binds to the closely related MICA and 
MICB molecules (Moretta et al., 2001). In addition, 2B4 is expressed on NKL cells, which seems 
to function as a coreceptor in NK-cell mediated cytotoxicity and binds to CD48 (Moretta et al., 
2001). Interestingly, CD56, a marker for primary NK cells, is expressed only in very low amounts 
on NKL cells. In some experiments, 49K suppressed NK cell-mediated lysis even when lysis was 
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already reduced by the expression of the HLA-E/HLA signal peptide complex on the target cell 
(data not shown). This may suggest that 49K-mediated inhibition is independent of 
CD94/NKG2A. In addition, none of the proteins involved in NK cell-mediated natural 
cytotoxicity, including CD94, NKG2A, NKG2D and 2B4, displays a molecular mass of 172-196 
kDa as found for the 49K-binding proteins in Jurkat cells. The expression of a potential 49K 
receptor in different lymphocyte cell lines argues against a NK cell-specific factor. Thus, the 49K-
binding proteins involved in 49K-mediated inhibition of NK cell-mediated lysis remain to be 
identified. 
4.7 Conclusion and outlook 
In this work the Ad19a E3/49K protein was identified as a secreted lymphocyte binding factor. 
Preliminary data show that 49K has an immunomodulatory function: 49K inhibited NKL 
mediated target cell lysis in vitro. Other E3 proteins investigated so far exclusively affect the 
infected cell. Therefore, 49K seems to be the first Ad protein that directly influences 
lymphocytes, presumably in the membrane bound as well as in the secreted form. 49K 
biochemistry and cell biology is characterized by an extensive posttranslational processing 
including proteolytic cleavage and a complex intracellular trafficking. The biochemical and 
functional characterization revealed that in many ways Ad19a E3/49K exhibits unique properties 
indicating that 49K function in adenoviral immune evasion represents a novel principle.  
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5 SUMMARY 
Human adenoviruses (Ads) cause a variety of acute diseases but also establish persistent 
infections. Ads have evolved a number of mechanisms to evade the host immune response that 
seem to facilitate virus replication and transmission in vivo. Interestingly, one Ad transcription 
unit, the early transcription unit 3 (E3), appears to encode exclusively proteins with immuno-
modulatory functions. Recently, a novel open reading frame, E3/49K, was identified in the E3 
region of the epidemic keratoconjunctivitis causing serotype Ad19a. The sequence predicts a type 
I transmembrane protein with a large N-terminal domain and a short cytoplasmic tail of 19 
amino acids (aa). The N-terminal part contains three repeat regions (R1-3) of about 80 aa each 
with R3 exhibiting a significant homology to immunoglobulin-like domains. 
This study shows that 49K is a highly glycosylated protein with an apparent molecular mass of 
80-100 kDa. 12-13 out of 14 predicted N-glycosylation sites are utilized, and there is also 
evidence for O-glycosylation. 49K contains intramolecular disulfide bonds and is proteolytically 
processed. As a result of the cleavage the N-terminal ectodomain is secreted: Ad19a E3/49K is 
the first Ad protein known to be secreted.  
At steady-state, E3/49K  is detected in the Golgi/TGN, early endosomes and at the cell surface 
of Ad19a-infected as well as 49K-transfected cells. The cytoplasmic tail, which contains two 
potential endosomal/lysosomal targeting motifs, YXXF and LL, plays a major role in the 49K 
trafficking. The proteolytic processing may occur in the TGN or secretory vesicles and/or at the 
cell surface. The finding that an increased cell surface expression of 49K correlates with an 
increased secretion rate indicates proteolytic processing of 49K at the cell surface. The C-terminal 
fragments and also unprocessed 49K proteins are internalized possibly by the interaction of the 
LL motif in the cytoplasmic tail with the clathrin adaptor complex AP-2. From early endosomes 
49K proteins and C-terminal fragments recycle to the TGN potentially involving the interaction 
of the cytoplasmic tail of 49K with the clathrin adaptor complex AP-1 or to the cell surface, 
whereas a fraction is delivered to late endosomes and lysosomes. 
Remarkably, the secreted form of 49K specifically binds to various lymphocyte cell lines, 
including NK, B and T cell lines, but not to other cell types, e.g. fibroblasts, suggesting that the 
soluble and possibly also the membrane-bound 49K binds to receptor(s) on lymphocytes. Indeed, 
in Jurkat (T cell leukemia) cells, 49K-binding protein(s) with apparent molecular masses of 172-
196 kDa were identified. Moreover, purified 49K inhibited the NK cell-mediated lysis of target 
cells. Thus, upon binding to cell surface receptors, 49K may trigger an inhibitory signal or inhibit 
an activating signal. While other Ad E3 proteins affect the infected cell, 49K seems to influence 
infiltrating cells of the immune system. Therefore, 49K function appears to represent an entirely 
novel Ad immune evasion mechanism.   
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7 ABBREVIATIONS 
For amino acids the one-letter code was used. 
 
a adenine 
aa      amino acid 
Ab antibody 
Ad 
Arf 
adenovirus 
ADP-ribosylation factor 
AIDS aquired immune deficiency syndrome 
AP 
APP 
APPS      
adaptor protein complex 
b-amyloid precursor protein 
secreted form of the b-amyloid precursor protein 
APS ammonium persulfate 
ATCC      American Type Culture Collection 
ATP adenosine triphosphate 
B basolateral 
bp base pair 
c cytosine 
°C 
CAR 
degree Celsius 
coxsackie adenovirus receptor 
Ci Curie 
CD      cluster of differentation 
CD-MPR     cation-dependent mannose-6-phosphate receptor 
CI-MPR     cation-independent mannose-6-phosphate receptor 
conc. concentration 
cpm counts per minute 
CPE cytopathic effect 
CT      cytoplasmic tail 
C-tail cytoplasmic tail 
CTL      cytotoxic T lymphocytes 
d 
DBP 
deoxy 
DNA bending protein 
DMEM     Dulbecco’s modified Eagle medium 
DNA      deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
E early 
E endocytosis 
EE early endosomes 
E3      early transcription unit 3 
E. coli Escherichia coli 
EDTA ethylenediamine tetraacetic acid 
EGF epidermal growth factor 
EKC  epidemic keratoconjunctivitis 
ELISA enzyme-linked immunosorbent assay 
Endo H     endoglycosidase H 
ER      endoplasmatic reticulum 
ERGIC     ER- Golgi intermediate compartment 
EtOH      ethanol 
FACS  
FasL     
fluorescence activated cell sorter  
Fas ligand 
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FCS fetal calf serum 
FIG.  
Fig. 
figure 
figure 
FITC      fluorescein-isocyanat 
g gram 
g gravitation constant 
g guanine 
G golgi 
GGA Golgi associated g ear containing Arf binding protein 
gp      glycoprotein 
H 
HAc 
hour(s) 
acetic acid 
HCMV     human cytomegalovirus 
HEPES 2-[4-(2-Hydoxyethyl)-1-piperazinyl]-ethane sulfonic acid 
HIV  
HSV     
human immunodeficiency virus 
herpes simplex virus 
IF immunofluorescence 
IFN      interferon 
IgG      immunglobulin G 
i.p. intraperitoneal 
IPTG 
ISRE 
Jak 
isopropylthiogalactoside 
IFN-stimulated response element 
Janus kinase 
kb kilo base pair 
kDa      kilodaltons 
KLH keyhole limpet hemocyanin 
l liter 
L      late 
lamp lysosome-associated membran protein 
LB Luria-Bertani 
LE late endosomes 
limp      lysosomal integral membrane protein 
Lys lysosomes 
µ micro (10-6) 
m milli (10-3) 
m meter 
M mol/liter 
M mitochondrium 
MIIC MHC class II compartment 
mAb monoclonal antibody 
MCMV     murine cytomegalovirus 
MeOH  
mdm2    
methanol 
murine double minute 2 
MHC      major histocompatibility complex 
min minute(s) 
MLP 
MPR 
major late promoter 
mannose-6-phosphate receptor 
MOI     multiplicity of infection 
MOPS 3- (N-Morpholino)propanesulfonic acid 
mRNA 
MTOC 
messenger RNA 
microtubule organizing center 
n nano (10-9) 
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NFkB nuclear factor kB 
NK      natural killer 
o/n overnight 
OD optical density 
ORF     open reading frame 
p pico (10-12) 
p.i.      postinfection 
PAGE      polyacrylamide gel electrophoresis 
PBS phoshate buffered saline 
PCR polymerase chain reaction 
PFU  
PKR    
plaque forming units 
double stranded RNA-dependent protein kinase R 
PM plasma membrane 
PNGase F     peptide-N-glycosidase F 
Pwo Pyrococcus woesei 
R receptor 
RNA      ribonucleic acid 
rpm      revolutions per minute 
RT      room temperature 
s second(s) 
s.c. subcutaneous 
SDS      sodium dodecylsulfate 
SIV  
SPC  
SRP 
STAT   
simian immunodeficiency virus 
subtilisin-like proprotein convertase 
signal recognition particle 
signal transducer and activator of transcription 
t thymine 
Tab. table 
TAP      Transporter associated with antigen processing 
TEMED N, N, N’, N’-tetramethylendiamine 
TGN      trans-Golgi network 
TMD      transmembrane domain 
TNF      tumor necrosis factor 
TP 
TRAIL 
terminal protein 
tumor necrosis factor-related apoptosis-inducing ligand 
Tris Tris(hydroxymethyl)aminomethan 
VA virus-associated 
w/o     without 
U     Unit, enzyme activity 
UV ultraviolet 
V  
vCkBP     
Volt 
viral chemokine binding protein 
VSV G 
VZV 
vesicular stomatitis virus glycoprotein 
varicella zoster virus 
v/v      volumen/volumen 
w/v      weight/volumen 
wt      wild type 
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